U.S. patent application number 12/473112 was filed with the patent office on 2009-09-17 for acyloxyalkyl carbamate prodrugs, methods.
Invention is credited to Mark A. Gallop, Maria J. Ludwikow, Ge Peng, Thu Phan, Fenmei Yao.
Application Number | 20090234138 12/473112 |
Document ID | / |
Family ID | 34221430 |
Filed Date | 2009-09-17 |
United States Patent
Application |
20090234138 |
Kind Code |
A1 |
Gallop; Mark A. ; et
al. |
September 17, 2009 |
ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS
Abstract
The disclosures herein relate generally to acyloxyalkyl
carbamate prodrugs of (.+-.)-4-amino-3-(4-chlorophenyl)butanoic
acid and analogs thereof, pharmaceutical compositions thereof,
methods of making prodrugs of
(.+-.)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof,
methods of using prodrugs of
(.+-.)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof,
and pharmaceutical compositions thereof for treating or preventing
common diseases and/or disorders such as spasticity and/or acid
reflux disease. The disclosures herein also relate to acyloxyalkyl
carbamate prodrugs of (.+-.)-4-amino-3-(4-chlorophenyl)butanoic
acid and analogs thereof which are suitable for oral administration
and to sustained release oral dosage forms thereof.
Inventors: |
Gallop; Mark A.; (Los Altos,
CA) ; Yao; Fenmei; (Mountain View, CA) ;
Ludwikow; Maria J.; (Cupertino, CA) ; Phan; Thu;
(Fremont, CA) ; Peng; Ge; (Mountain View,
CA) |
Correspondence
Address: |
DORSEY & WHITNEY, LLP;INTELLECTUAL PROPERTY DEPARTMENT
370 SEVENTEENTH STREET, SUITE 4700
DENVER
CO
80202-5647
US
|
Family ID: |
34221430 |
Appl. No.: |
12/473112 |
Filed: |
May 27, 2009 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11923507 |
Oct 24, 2007 |
|
|
|
12473112 |
|
|
|
|
11508131 |
Aug 21, 2006 |
7300956 |
|
|
11923507 |
|
|
|
|
10932374 |
Aug 20, 2004 |
7109239 |
|
|
11508131 |
|
|
|
|
60606637 |
Aug 13, 2004 |
|
|
|
60496938 |
Aug 20, 2003 |
|
|
|
Current U.S.
Class: |
548/556 ;
560/160 |
Current CPC
Class: |
A61P 1/00 20180101; A61P
25/30 20180101; C07C 269/06 20130101; C07D 333/38 20130101; A61K
31/27 20130101; C07C 2601/08 20170501; A61P 1/08 20180101; C07D
213/79 20130101; C07D 307/30 20130101; A61P 25/14 20180101; A61P
25/32 20180101; C07C 271/22 20130101; A61P 39/02 20180101; C07D
307/68 20130101; C07C 2601/14 20170501; C07D 333/32 20130101; A61P
25/00 20180101; A61P 1/04 20180101 |
Class at
Publication: |
548/556 ;
560/160 |
International
Class: |
C07D 207/12 20060101
C07D207/12; C07C 271/22 20060101 C07C271/22 |
Claims
1-52. (canceled)
53. A compound of Formula (II): ##STR00023## or pharmaceutically
acceptable salts, hydrates or solvates thereof, wherein: X is
fluoro, chloro, bromo or iodo; R.sup.2 and R.sup.3 are
independently selected from the group consisting of hydrogen,
alkyl, substituted alkyl, alkoxycarbonyl, substituted
alkoxycarbonyl, aryl, substituted aryl, arylalkyl, substituted
arylalkyl, cycloalkyl, substituted cycloalkyl, heteroaryl,
substituted heteroaryl, heteroarylalkyl and substituted
heteroarylalkyl, or optionally, R.sup.2 and R.sup.3 together with
the carbon atom to which they are bonded form a cycloalkyl,
substituted cycloalkyl, cycloheteroalkyl or substituted
cycloheteroalkyl ring; R.sup.4 is selected from the group
consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted
aryl, arylalkyl, substituted arylalkyl, aryldialkylsilyl,
cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted
cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl,
substituted heteroaryl, heteroarylalkyl, substituted
heteroarylalkyl and trialkylsilyl; and R.sup.5 is selected from the
group consisting of substituted aryl, heteroaryl and substituted
heteroaryl.
54. The compound of claim 53, wherein X is chloro.
55. The compound of claim 53, wherein R.sup.5 is selected from the
group consisting of 4-chlorophenyl; R-(4-chlorophenyl),
2-chlorophenyl), 4-fluorophenyl, thien-2-yl, 5-chlorothien-2-yl,
5-bromothien-2-yl and 5-methylthien-2-yl.
56. The compound of claim 53, having Formula (VII):
##STR00024##
57. The compound of claim 53, having Formula (VIII):
##STR00025##
58. The compound of claim 53, wherein R.sup.2 and R.sup.3 are
independently selected from the group consisting of hydrogen,
alkyl, substituted alkyl, alkoxycarbonyl, substituted
alkoxycarbonyl, aryl, substituted aryl, arylalkyl, substituted
arylalkyl, carbamoyl, cycloalkyl, substituted cycloalkyl,
cycloalkoxycarbonyl, substituted cycloalkoxycarbonyl, heteroaryl,
substituted heteroaryl, heteroarylalkyl and substituted
heteroarylalkyl.
59. The compound of claim 53, wherein R.sup.2 and R.sup.3 are
independently selected from the group consisting of hydrogen,
C.sub.1-4 alkyl, substituted C.sub.1-4 alkyl, C.sub.1-4
alkoxycarbonyl, C.sub.3-6 cycloalkyl, C.sub.3-6
cycloalkoxycarbonyl, phenyl, substituted phenyl, C.sub.7-9
phenylalkyl and pyridyl.
60. The compound of claim 53, wherein R.sup.2 and R.sup.3 are
independently selected from the group consisting of hydrogen,
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl,
tert-butyl, cyclopentyl, cyclohexyl, methoxycarbonyl,
ethoxycarbonyl, isopropoxycarbonyl, cyclohexyloxycarbonyl, phenyl,
benzyl, phenethyl, 2-pyridyl, 3-pyridyl and 4-pyridyl.
61. The compound of claim 53, wherein: R.sup.2 is hydrogen, methyl,
ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, phenyl or
cyclohexyl; and R.sup.3 is hydrogen.
62. The compound of claim 53, wherein: R.sup.2 is methyl,
methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl or
cyclohexyloxycarbonyl; and R.sup.3 is methyl.
63. The compound of claim 53, wherein R.sup.2 and R.sup.3 together
with the carbon atom to which they are attached form a cycloalkyl,
substituted cycloalkyl, cycloheteroalkyl or substituted
cycloheteroalkyl ring.
64. The compound of claim 53, wherein R.sup.2 and R.sup.3 together
with the carbon atom to which they are attached form a cyclobutyl,
cyclopentyl or cyclohexyl ring.
65. The compound of claim 53, wherein R.sup.4 is hydrogen,
C.sub.1-6 alkyl, substituted C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl,
phenyl, substituted phenyl, C.sub.7-9 phenylalkyl, substituted
C.sub.7-9 phenylalkyl, trialkylsilyl or aryldialkylsilyl.
66. The compound of claim 53, wherein R.sup.4 is hydrogen, methyl,
ethyl, tert-butyl, allyl, benzyl, 4-methoxybenzyl, diphenylmethyl,
triphenylmethyl, trimethylsilyl, triethylsilyl, triisopropylsilyl,
tert-butyldimethylsilyl or phenyldimethylsilyl.
67. The compound of claim 53, wherein R.sup.4 is hydrogen, allyl,
benzyl or trimethylsilyl.
68. The compound of claim 53, wherein: R.sup.2 and R.sup.3 are
independently selected from the group consisting of hydrogen,
C.sub.1-4 alkyl, substituted C.sub.1-4 alkyl, C.sub.1-4
alkoxycarbonyl, C.sub.3-6 cycloalkyl, C.sub.3-6
cycloalkoxycarbonyl, phenyl, substituted phenyl, C.sub.7-9
phenylalkyl and pyridyl; and R.sup.4 is hydrogen, C.sub.1-6 alkyl,
substituted C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, phenyl,
substituted phenyl, C.sub.7-9 phenylalkyl, substituted C.sub.7-9
phenylalkyl, trialkylsilyl or aryldialkylsilyl.
69. The compound of claim 53, wherein: R.sup.2 is hydrogen, methyl,
ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl,
tert-butyl, cyclopentyl, cyclohexyl, methoxycarbonyl,
ethoxycarbonyl, isopropoxycarbonyl, cyclohexyloxycarbonyl, phenyl,
benzyl, phenethyl, 2-pyridyl, 3-pyridyl or 4-pyridyl; R.sup.3 is
hydrogen; and R.sup.4 is hydrogen, C.sub.1-6 alkyl, substituted
C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, phenyl, substituted phenyl,
C.sub.7-9 phenylalkyl, substituted C.sub.7-9 phenylalkyl,
trialkylsilyl or aryldialkylsilyl.
70. The compound of claim 53, wherein: R.sup.2 is hydrogen, methyl,
ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl,
cyclohexyl or phenyl; R.sup.3 is hydrogen; and R.sup.4 is hydrogen,
C.sub.1-6 alkyl, substituted C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl,
phenyl, substituted phenyl, C.sub.7-9 phenylalkyl, substituted
C.sub.7-9 phenylalkyl, trialkylsilyl or aryldialkylsilyl.
71. The compound of claim 53, wherein: R.sup.2 is methyl,
methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, or
cyclohexyloxycarbonyl; R.sup.3 is methyl; and R.sup.4 is hydrogen,
C.sub.1-6 alkyl, substituted C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl,
phenyl, substituted phenyl, C.sub.7-9 phenylalkyl, substituted
C.sub.7-9 phenylalkyl, trialkylsilyl or aryldialkylsilyl.
72. The compound of claim 53, wherein: R.sup.2 and R.sup.3 are
independently selected from the group consisting of hydrogen,
C.sub.1-4 alkyl, substituted C.sub.1-4 alkyl, C.sub.1-4
alkoxycarbonyl, C.sub.3-6 cycloalkyl, C.sub.3-6
cycloalkoxycarbonyl, phenyl, substituted phenyl, C.sub.7-9
phenylalkyl and pyridyl; and R.sup.4 is hydrogen, methyl, ethyl,
tert-butyl, allyl, benzyl, 4-methoxybenzyl, diphenylmethyl,
triphenylmethyl, trimethylsilyl, triethylsilyl, triisopropylsilyl,
tert-butyldimethylsilyl or phenyldimethylsilyl.
Description
[0001] This application claims the benefit under 35 U.S.C. .sctn.
119(e) from U.S. Provisional Application Ser. No. 60/496,938, filed
Aug. 20, 2003 and U.S. Provisional Application Ser. No. ______
filed Aug. 13, 2004 entitled "Methods for Synthesis of Acyloxyalkyl
Carbamate Prodrugs" which are herein incorporated by reference in
their entirety.
1. TECHNICAL FIELD
[0002] The disclosures herein relate generally to acyloxyalkyl
carbamate prodrugs of (.+-.)-4-amino-3-(4-chlorophenyl)butanoic
acid and analogs thereof, pharmaceutical compositions thereof,
methods of making prodrugs of
(.+-.)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof
and methods of using prodrugs of
(.+-.)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof
and pharmaceutical compositions thereof to treat various diseases
or disorders. The disclosures herein also relate to such prodrugs
suitable for oral administration and for oral administration using
sustained release dosage forms.
2. BACKGROUND
[0003] (.+-.)-4-Amino-3-(4-chlorophenyl)butanoic acid (baclofen),
(1), is an analog of gamma-aminobutyric acid (i.e., GABA) that
selectively activates GABA.sub.B receptors, resulting in neuronal
hyperpolarization. GABA.sub.B receptors are located in laminae I-IV
of the spinal cord, where primary sensory fibers end. These
G-protein coupled receptors activate conductance by
K.sup.+-selective ion channels and can reduce currents mediated by
Ca.sup.2+ channels in certain neurons. Baclofen has a presynaptic
inhibitory effect on the release of excitatory neurotransmitters
and also acts postsynaptically to decrease motor neuron firing (see
Bowery, Trends Pharmacol. Sci. 1989, 10, 401-407; Misgeld et al.,
Prog. Neurobiol. 1995, 46, 423-462).
##STR00001##
[0004] Many examples of compounds having agonistic or partially
agonistic affinity to GABA.sub.B receptors exist and include
certain amino acids, aminophosphonic acids, aminophosphinic acids,
aminophosphonous acids and aminosulfinic acids such as, for
example, [0005] 4-amino-3-(2-chlorophenyl)butanoic acid; [0006]
4-amino-3-(4-fluorophenyl)butanoic acid; [0007]
4-amino-3-hydroxybutanoic acid; [0008]
4-amino-3-(4-chlorophenyl)-3-hydroxyphenylbutanoic acid; [0009]
4-amino-3-(thien-2-yl)butanoic acid; [0010]
4-amino-3-(5-chlorothien-2-yl)butanoic acid; [0011]
4-amino-3-(5-bromothien-2-yl)butanoic acid; [0012]
4-amino-3-(5-methylthien-2-yl)butanoic acid; [0013]
4-amino-3-(2-imidazolyl)butanoic acid; [0014]
4-guanidino-3-(4-chlorophenyl)butanoic acid; [0015]
(3-aminopropyl)phosphonous acid; [0016]
(4-aminobut-2-yl)phosphonous acid; [0017]
(3-amino-2-methylpropyl)phosphonous acid; [0018]
(3-aminobutyl)phosphonous acid; [0019]
(3-amino-2-(4-chlorophenyl)propyl)phosphonous acid; [0020]
(3-amino-2-(4-chlorophenyl)-2-hydroxypropyl)phosphonous acid;
[0021] (3-amino-2-(4-fluorophenyl)propyl)phosphonous acid; [0022]
(3-amino-2-phenylpropyl)phosphonous acid; [0023]
(3-amino-2-hydroxypropyl)phosphonous acid; [0024]
(E)-(3-aminopropen-1-yl)phosphonous acid; [0025]
(3-amino-2-cyclohexylpropyl)phosphonous acid; [0026]
(3-amino-2-benzylpropyl)phosphonous acid; [0027]
[3-amino-2-(4-methylphenyl)propyl]phosphonous acid; [0028]
[3-amino-2-(4-trifluoromethylphenyl)propyl]phosphonous acid; [0029]
[3-amino-2-(4-methoxyphenyl)propyl]phosphonous acid; [0030]
[3-amino-2-(4-chlorophenyl)-2-hydroxypropyl]phosphonous acid;
[0031] (3-aminopropyl)methylphosphinic acid; [0032]
(3-amino-2-hydroxypropyl)methylphosphinic acid; [0033]
(3-aminopropyl)(difluoromethyl)phosphinic acid; [0034]
(4-aminobut-2-yl)methylphosphinic acid; [0035]
(3-amino-1-hydroxypropyl)methylphosphinic acid; [0036]
(3-amino-2-hydroxypropyl)(difluoromethyl)phosphinic acid; [0037]
(E)-(3-aminopropen-1-yl)methylphosphinic acid; [0038]
(3-amino-2-oxo-propyl)methyl phosphinic acid; [0039]
(3-aminopropyl)hydroxymethylphosphinic acid; [0040]
(5-aminopent-3-yl)methylphosphinic acid; [0041]
(4-amino-1,1,1-trifluorobut-2-yl)methylphosphinic acid; [0042]
3-aminopropylsulfinic acid; [0043]
(3-amino-2-(4-chlorophenyl)propyl)sulfinic acid; [0044]
(3-amino-2-hydroxypropyl)sulfinic acid; [0045]
(2S)-(3-amino-2-hydroxypropyl)sulfinic acid; [0046]
(2R)-(3-amino-2-hydroxypropyl)sulfinic acid; [0047]
(3-amino-2-fluoropropyl)sulfinic acid; [0048]
(2S)-(3-amino-2-fluoropropyl)sulfinic acid; [0049]
(2R)-(3-amino-2-fluoropropyl)sulfinic acid; and [0050]
(3-amino-2-oxopropyl)sulfinic acid.
[0051] A principal pharmacological effect of baclofen in mammals is
reduction of muscle tone and the drug is frequently used in the
treatment of spasticity. Spasticity is associated with damage to
the corticospinal tract and is a common complication of
neurological disease. Diseases and conditions in which spasticity
may be a prominent symptom include cerebral palsy, multiple
sclerosis, stroke, head and spinal cord injuries, traumatic brain
injury, anoxia and neurodegenerative diseases. Patients with
spasticity complain of stiffness, involuntary spasm and pain. These
painful spasms may be spontaneous or triggered by a minor sensory
stimulus, such as touching the patient.
[0052] Baclofen is useful in controlling gastro-esophageal reflux
disease (van Herwaarden et al., Aliment. Pharmacol. Ther. 2002, 16,
1655-1662; Ciccaglione et al., Gut 2003, 52, 464-470; Andrews et
al., U.S. Pat. No. 6,117,908; Fara et al., International
Publication No. WO02/096404); in promoting alcohol abstinence in
alcoholics (Gessa et al., International Publication No.
WO01/26638); in promoting smoking cessation (Gessa et al.,
International Publication No. WO01/08675); in reducing addiction
liability of narcotic agents (Robson et al., U.S. Pat. No.
4,126,684); in the treatment of emesis (Bountra et al., U.S. Pat.
No. 5,719,185) and as an anti-tussive for the treatment of cough
(Kreutner et al., U.S. Pat. No. 5,006,560).
[0053] Baclofen may be administered orally or by intrathecal
delivery through a surgically implanted programmable pump. The drug
is rapidly absorbed from the gastrointestinal tract and has an
climination half-life of approximately 3-4 hours. Baclofen is
partially metabolized in the liver but is largely excreted by the
kidneys unchanged. The short half-life of baclofen necessitates
frequent administration with typical oral dosing regimens ranging
from about 10 to about 80 mg of three or four divided doses daily.
Plasma baclofen concentrations of about 80 to about 400 ng/mL
result from these therapeutically effective doses in patients
(Katz, Am. J. Phys. Med. Rehabil. 1988, 2, 108-116; Krach, J. Child
Neurol. 2001, 16, 31-36). When baclofen is given orally, sedation
is a side effect, particularly at elevated doses. Impairment of
cognitive function, confusion, memory loss, dizziness, weakness,
ataxia and orthostatic hypotension are other commonly encountered
baclofen side-effects.
[0054] Intrathecal administration is often recommended for patients
who find the adverse effects of oral baclofen intolerable. The
intrathecal use of baclofen permits effective treatment of
spasticity with doses less than 1/100.sup.th of those required
orally, since administration directly into the spinal subarachnoid
space permits immediate access to the GABA.sub.B receptor sites in
the dorsal horn of the spinal cord. Surgical implantation of a pump
is, however, inconvenient and a variety of mechanical and medical
complications can arise (e.g., catheter displacement, kinking or
blockage, pump failure, sepsis and deep vein thrombosis). Acute
discontinuation of baclofen therapy (e.g., in cases of mechanical
failure) may cause serious withdrawal symptoms such as
hallucinations, confusion, agitation and seizures (Sampathkumar et
al., Anesth. Analg. 1998, 87, 562-563).
[0055] While the clinically prescribed baclofen product
(Lioresal.TM.) is available only as a racemate, the GABA.sub.B
receptor agonist activity resides entirely in one enantiomer,
R-(-)-baclofen (2) (also termed L-baclofen).
##STR00002##
[0056] The other isomer, S-baclofen, actually antagonizes the
action of R-baclofen at GABA.sub.B receptors and its
antinociceptive activity in the rat spinal cord (Terrence et al.,
Pharmacology 1983, 27, 85-94; Sawynok et al. Pharmacology 1985, 31,
248-259). Orally administered R-baclofen is reported to be about
5-fold more potent than orally administered racemic baclofen, with
an R-baclofen regimen of 2 mg t.i.d being equivalent to racemic
baclofen at 10 mg t.i.d. (Fromm et al., Neurology 1987, 37,
1725-1728). Moreover, the side effect profile, following
administration of R-baclofen, has been shown to be significantly
reduced, relative to equally efficacious dose of racemic
baclofen.
[0057] Baclofen, a zwitterionic amino acid, lacks the requisite
physicochemical characteristics for effective passive permeability
across cellular membranes. Passage of the drug across the
gastrointestinal tract and the blood-brain barrier (BBB) are
mediated primarily by active transport processes, rather than by
passive diffusion. Accordingly, baclofen is a substrate for active
transport mechanisms shared by neutral .alpha.-amino acids like
leucine, and .beta.-amino acids like .beta.-alanine and taurine
(van Bree et al., Pharm. Res. 1988, 5, 369-371; Cercos-Fortea et
al., Biopharm. Drug. Disp. 1995, 16, 563-577; Deguchi et al.,
Pharm. Res. 1995, 12, 1838-1844; Moll-Navarro et al., J. Pharm.
Sci. 1996, 85, 1248-1254). Transport across the BBB is
stereoselective, with preferential uptake of the active
R-enantiomer (2) being reported (van Bree et al., Pharm. Res. 1991,
8, 259-262). In addition, organic anion transporters localized in
capillary endothelial cells of the blood-brain barrier have been
implicated in efflux of baclofen from the brain (Deguchi et al.,
supra; Ohtsuki et al., J. Neurochem. 2002, 83, 57-66).
3-(p-Chlorophenyl)pyrrolidine has been described as a
CNS-penetrable prodrug of baclofen (Wall et al., J. Med. Chem.
1989, 32, 1340-1348). Prodrugs of other GABA analogs are described
in Bryans et al., International Publication No. WO01/90052; Bryans
et al., EP1178034; Cundy et al., U.S. Patent Application
Publication No. 2002/0151529; Gallop et al., U.S. Patent
Application Publication No. 2003/0176398; Gallop et al., U.S.
Patent Application Publication No. 2003/0171303; Gallop et al.,
U.S. Patent Application Publication No. 2004/0006132; and Raillard
et al., U.S. Patent Application Publication No. 2004/0014940.
[0058] Sustained released oral dosage formulations are a
conventional solution to the problem of rapid systemic drug
clearance, as is well known in the art (see, e.g., "Remington's
Pharmaceutical Sciences," Philadelphia College of Pharmacy and
Science, 19th Edition, 1995). Osmotic delivery systems are also
recognized methods for sustained drug delivery (See, e.g., Verma et
al., Drug Dev. Ind. Pharm. 2000, 26, 695-708). Successful
application of these technologies depends on the drug of interest
having an effective level of absorption from the large intestine
(also referred to herein as the colon), where the dosage form
spends a majority of its time during its passage down the
gastrointestinal tract. Baclofen is poorly absorbed following
administration into the colon in animal models (Merino et al.,
Biopharm. Drug. Disp. 1989, 10, 279-297), presumably, since the
transporter proteins mediating baclofen absorption in the upper
region of the small intestine are not expressed in the large
intestine. Development of an oral controlled release formulation
for baclofen should considerably improve the convenience, efficacy
and side effect profile of baclofen therapy. However, the rapid
passage of conventional dosage forms through the proximal
absorptive region of the small intestine has thus far prevented the
successful application of sustained release technologies to this
drug. A number of exploratory delivery technologies that rely on
either mucoadhesion or gastric retention have been suggested to
achieve sustained delivery of baclofen (Sinnreich, U.S. Pat. No.
4,996,058; Khanna, U.S. Pat. No. 5,091,184; Fara et al., supra;
Dudhara et al., International Publication No. WO03/011255) though
to date none of these appear to be able to achieve sustain blood
levels of baclofen in human subjects.
[0059] Thus, there is a significant need for new prodrugs of
baclofen and baclofen analogs which are well absorbed in the large
intestine/colon and hence suitable for oral sustained release
formulations, thus improving the convenience, efficacy and side
effect profile of baclofen therapy.
3. SUMMARY
[0060] These and other needs are satisfied by the disclosure herein
of acyloxyalkyl carbamate prodrugs of baclofen and baclofen
analogs, pharmaceutical compositions of acyloxyalkyl carbamate
prodrugs of baclofen and baclofen analogs, methods of making
acyloxyalkyl carbamate prodrugs of baclofen and baclofen analogs
and methods of using acyloxyalkyl carbamate prodrugs of baclofen
and baclofen analogs and/or pharmaceutical compositions thereof to
treat various medical disorders.
[0061] In a first aspect, a compound of Formula (I) is
provided,
##STR00003##
[0062] or pharmaceutically acceptable salts, hydrates or solvates
thereof, wherein:
[0063] R.sup.1 is selected from the group consisting of acyl,
substituted acyl, alkyl, substituted alkyl, aryl, substituted aryl,
arylalkyl, substituted arylalkyl, cycloalkyl, substituted
cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl,
heteroalkyl, substituted heteroalkyl, heteroaryl, substituted
heteroaryl, heteroarylalkyl and substituted heteroarylalkyl;
[0064] R.sup.2 and R.sup.3 are independently selected from the
group consisting of hydrogen, alkyl, substituted alkyl,
alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl,
arylalkyl, substituted arylalkyl, cycloalkyl, substituted
cycloalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl and
substituted heteroarylalkyl or optionally, R.sup.2 and R.sup.3
together with the carbon atom to which they are bonded form a
cycloalkyl, substituted cycloalkyl, cycloheteroalkyl or substituted
cycloheteroalkyl ring;
[0065] R.sup.4 is selected from the group consisting of hydrogen,
alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl,
substituted arylalkyl, aryldialkylsilyl, cycloalkyl, substituted
cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl,
heteroalkyl, substituted heteroalkyl, heteroaryl, substituted
heteroaryl, heteroarylalkyl, substituted heteroarylalkyl or
trialkylsilyl; and
[0066] R.sup.5 is selected from the group consisting of substituted
aryl, heteroaryl and substituted heteroaryl.
[0067] In a second aspect, a compound of Formula (II) is
provided,
##STR00004##
[0068] wherein:
[0069] X is fluoro, chloro, bromo or iodo; and
[0070] R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are as defined,
supra.
[0071] In a third aspect, a method of synthesizing a compound of
Formula (I) is provided, comprising:
##STR00005##
contacting a compound of Formula (II), a compound of Formula (III)
and at least one equivalent of a metal salt or an organic base or a
combination thereof wherein:
[0072] X is fluoro, chloro, bromo or iodo; and
[0073] R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5 are as
defined, supra.
[0074] In a fourth aspect, a method of synthesizing a compound of
Formula (I) is provided, comprising contacting a compound of
Formula (XVIII) with an oxidant, wherein:
##STR00006##
[0075] and R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5 are as
defined, supra.
[0076] In a fifth aspect, pharmaceutical compositions comprising a
compound of Formula (I), or pharmaceutically acceptable salts,
hydrates or solvates thereof, and a pharmaceutically acceptable
vehicle such as a diluent, carrier, excipient or adjuvant are
provided. The choice of diluent, carrier, excipient and adjuvant
will depend upon, among other factors, the desired mode of
administration.
[0077] In a sixth aspect, a sustained release oral dosage form,
comprising a baclofen prodrug or a baclofen analog prodrug of
Formula (I) is provided, the dosage form being adapted to be
swallowed by a patient in order to introduce the dosage form into
an intestinal lumen of the patient, the dosage form further being
adapted to release the baclofen prodrug or a baclofen analog
prodrug of Formula (I) gradually into the intestinal lumen of the
patient over a period of hours after said swallowing, said gradual
release causing baclofen or the baclofen analog to be cleaved from
the promoiety after said swallowing and providing a therapeutic
concentration of baclofen or the baclofen analog in the plasma of
the patient.
[0078] In a seventh aspect, a method of orally administering a
baclofen prodrug or a baclofen analog prodrug of Formula (I) is
provided, said method comprising:
[0079] placing a compound of Formula (I) in a sustained release
oral dosage form;
[0080] introducing the dosage form into the intestinal lumen of a
patient by having the patient swallow the dosage form;
[0081] releasing the prodrug gradually from the swallowed dosage
form into the intestinal lumen of the patient over a period of
hours; and
[0082] allowing baclofen or the baclofen analog to be cleaved from
the promoiety after said swallowing to provide a therapeutic
concentration of the baclofen or baclofen analog in the plasma of
the patient.
[0083] In an eighth aspect, methods are provided for treating or
preventing stiffness, involuntary movements and pain associated
with spasticity. Methods are also provided for treating or
preventing gastro-esophageal reflux disease, alcohol abuse or
addiction, nicotine abuse or addiction, narcotics abuse or
addiction, emesis and cough. The methods generally involve
administering to a patient in need of such treatment or prevention
a therapeutically effective amount of a compound of Formula (I)
and/or a pharmaceutical composition thereof.
4. DETAILED DESCRIPTION
4.1 Definitions
[0084] "1-Acyloxy-Alkyl Carbamate" refers to an
N-1-acyloxy-alkoxycarbonyl derivative of baclofen or a baclofen
analog as encompassed by compounds of Formulae (I), (V) and (VI)
disclosed herein.
[0085] "Alkyl" by itself or as part of another substituent refers
to a saturated or unsaturated, branched, straight-chain or cyclic
monovalent hydrocarbon radical derived by the removal of one
hydrogen atom from a single carbon atom of a parent alkane, alkene
or alkyne. Typical alkyl groups include, but are not limited to,
methyl; ethyls such as ethanyl, ethenyl, ethynyl; propyls such as
propan-1-yl, propan-2-yl, cyclopropan-1-yl, prop-1-en-1-yl,
prop-1-en-2-yl, prop-2-en-1-yl (allyl), cycloprop-1-en-1-yl;
cycloprop-2-en-1-yl, prop-1-yn-1-yl, prop-2-yn-1-yl, etc.; butyls
such as butan-1-yl, butan-2-yl, 2-methyl-propan-1-yl,
2-methyl-propan-2-yl, cyclobutan-1-yl, but-1-en-1-yl,
but-1-en-2-yl, 2-methyl-prop-1-en-1-yl, but-2-en-1-yl,
but-2-en-2-yl, buta-1,3-dien-1-yl, buta-1,3-dien-2-yl,
cyclobut-1-en-1-yl, cyclobut-1-en-3-yl, cyclobuta-1,3-dien-1-yl,
but-1-yn-1-yl, but-1-yn-3-yl, but-3-yn-1-yl, etc.; and the
like.
[0086] The term "alkyl" is specifically intended to include groups
having any degree or level of saturation, i.e., groups having
exclusively single carbon-carbon bonds, groups having one or more
double carbon-carbon bonds, groups having one or more triple
carbon-carbon bonds and groups having mixtures of single, double
and triple carbon-carbon bonds. Where a specific level of
saturation is intended, the expressions "alkanyl," "alkenyl," and
"alkynyl" are used. Preferably, an alkyl group comprises from 1 to
20 carbon atoms, more preferably, from 1 to 10 carbon atoms, most
preferably, from 1 to 6 carbon atoms.
[0087] "Alkanyl" by itself or as part of another substituent refers
to a saturated branched, straight-chain or cyclic alkyl radical
derived by the removal of one hydrogen atom from a single carbon
atom of a parent alkane. Typical alkanyl groups include, but are
not limited to, methanyl; ethanyl; propanyls such as propan-1-yl,
propan-2-yl (isopropyl), cyclopropan-1-yl, etc.; butanyls such as
butan-1-yl, butan-2-yl (sec-butyl), 2-methyl-propan-1-yl
(isobutyl), 2-methyl-propan-2-yl (t-butyl), cyclobutane-1-yl, etc.;
and the like.
[0088] "Alkenyl" by itself or as part of another substituent refers
to an unsaturated branched, straight-chain or cyclic alkyl radical
having at least one carbon-carbon double bond derived by the
removal of one hydrogen atom from a single carbon atom of a parent
alkene. The group may be in either the cis or trans conformation
about the double bond(s). Typical alkenyl groups include, but are
not limited to, ethenyl; propenyls such as prop-1-en-1-yl,
prop-1-en-2-yl, prop-2-en-1-yl (allyl), prop-2-en-2-yl,
cycloprop-1-en-1-yl; cycloprop-2-en-1-yl; butenyls such as
but-1-en-1-yl, but-1-en-2-yl, 2-methyl-prop-1-en-1-yl,
but-2-en-1-yl, but-2-en-1-yl, but-2-en-2-yl, buta-1,3-dien-1-yl,
buta-1,3-dien-2-yl, cyclobut-1-en-1-yl, cyclobut-1-en-3-yl,
cyclobuta-1,3-dien-1-yl, etc.; and the like.
[0089] "Alkynyl" by itself or as part of another substituent refers
to an unsaturated branched, straight-chain or cyclic alkyl radical
having at least one carbon-carbon triple bond derived by the
removal of one hydrogen atom from a single carbon atom of a parent
alkyne. Typical alkynyl groups include, but are not limited to,
ethynyl; propynyls such as prop-1-yn-1-yl, prop-2-yn-1-yl, etc.;
butynyls such as but-1-yn-1-yl, but-1-yn-3-yl, but-3-yn-1-yl, etc.;
and the like.
[0090] "Acyl" by itself or as part of another substituent refers to
a radical --C(O)R.sup.30, where R.sup.30 is hydrogen, alkyl,
cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl,
heteroaryl, heteroarylalkyl as defined herein. Representative
examples include, but are not limited to formyl, acetyl,
cyclohexylcarbonyl, cyclohexylmethylcarbonyl, benzoyl,
benzylcarbonyl and the like.
[0091] "Alkoxy" by itself or as part of another substituent refers
to a radical --OR.sup.31 where R.sup.31 represents an alkyl or
cycloalkyl group as defined herein. Representative examples
include, but are not limited to, methoxy, ethoxy, propoxy, butoxy,
cyclohexyloxy and the like.
[0092] "Alkoxycarbonyl" by itself or as part of another substituent
refers to a radical --C(O)OR.sup.31 where R.sup.31 represents an
alkyl or cycloalkyl group as defined herein. Representative
examples include, but are not limited to, methoxycarbonyl,
ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl,
cyclohexyloxycarbonyl and the like.
[0093] "Aryl" by itself or as part of another substituent refers to
a monovalent aromatic hydrocarbon radical derived by the removal of
one hydrogen atom from a single carbon atom of a parent aromatic
ring system. Typical aryl groups include, but are not limited to,
groups derived from aceanthrylene, acenaphthylene,
acephenanthrylene, anthracene, azulene, benzene, chrysene,
coronene, fluoranthene, fluorene, hexacene, hexaphene, hexylene,
as-indacene, s-indacene, indane, indene, naphthalene, octacene,
octaphene, octalene, ovalene, penta-2,4-diene, pentacene,
pentalene, pentaphene, perylene, phenalene, phenanthrene, picene,
pleiadene, pyrene, pyranthrene, rubicene, triphenylene,
trinaphthalene and the like. Preferably, an aryl group comprises
from 6 to 20 carbon atoms, more preferably, from 6 to 12 carbon
atoms.
[0094] "Arylalkyl" by itself or as part of another substituent
refers to an acyclic alkyl radical in which one of the hydrogen
atoms bonded to a carbon atom, typically a terminal or sp.sup.3
carbon atom, is replaced with an aryl group. Typical arylalkyl
groups include, but are not limited to, benzyl, 2-phenylethan-1-yl,
2-phenylethen-1-yl, naphthylmethyl, 2-naphthylethan-1-yl,
2-naphthylethen-1-yl, naphthobenzyl, 2-naphthophenylethan-1-yl and
the like. Where specific alkyl moieties are intended, the
nomenclature arylalkanyl, arylalkenyl and/or arylalkynyl is used.
Preferably, an arylalkyl group is (C.sub.7-C.sub.30) arylalkyl,
e.g., the alkanyl, alkenyl or alkynyl moiety of the arylalkyl group
is (C.sub.1-C.sub.10) and the aryl moiety is (C.sub.6-C.sub.20),
more preferably, an arylalkyl group is (C.sub.7-C.sub.20)
arylalkyl, e.g., the alkanyl, alkenyl or alkynyl moiety of the
arylalkyl group is (C.sub.1-C.sub.8) and the aryl moiety is
(C.sub.6-C.sub.12).
[0095] "Aryldialkylsilyl" by itself or as part of another
substituent refers to the radical --SiR.sup.32R.sup.33R.sup.34
where one of R.sup.32, R.sup.33 or R.sup.34 is aryl as defined
herein and the other two of R.sup.32, R.sup.33 or R.sup.34 are
alkyl as defined herein.
[0096] "AUC" is the area under the plasma drug
concentration-versus-time curve extrapolated from zero time to
infinity.
[0097] "C.sub.max" is the highest drug concentration observed in
plasma following an extravascular dose of drug.
[0098] "Compounds" refers to compounds encompassed by structural
formulae (I)-(XXIII) disclosed herein and includes any specific
compounds within these formulae whose structure is disclosed
herein. Compounds may be identified either by their chemical
structure and/or chemical name. When the chemical structure and
chemical name conflict, the chemical structure is determinative of
the identity of the compound. The compounds described herein may
contain one or more chiral centers and/or double bonds and
therefore, may exist as stereoisomers, such as double-bond isomers
(i.e., geometric isomers), enantiomers or diastereomers.
Accordingly, the chemical structures depicted herein encompass all
possible enantiomers and stereoisomers of the illustrated compounds
including the stereoisomerically pure form (e.g., geometrically
pure, enantiomerically pure or diastereomerically pure) and
enantiomeric and stereoisomeric mixtures. Enantiomeric and
stereoisomeric mixtures can be resolved into their component
enantiomers or stereoisomers using separation techniques or chiral
synthesis techniques well known to the skilled artisan. The
compounds may also exist in several tautomeric forms including the
enol form, the keto form and mixtures thereof. Accordingly, the
chemical structures depicted herein encompass all possible
tautomeric forms of the illustrated compounds. The compounds
described also include isotopically labeled compounds where one or
more atoms have an atomic mass different from the atomic mass
conventionally found in nature. Examples of isotopes that may be
incorporated into the compounds disclosed herein include, but are
not limited to, .sup.2H, .sup.3H, .sup.11C, .sup.13C, .sup.14C,
.sup.15N, .sup.18O, .sup.17O, etc. Compounds may exist in
unsolvated forms as well as solvated forms, including hydrated
forms and as N-oxides. In general, compounds may be hydrated,
solvated or N-oxides. Certain compounds may exist in multiple
crystalline or amorphous forms. In general, all physical forms are
equivalent for the uses contemplated herein and are intended to be
within the scope of the present disclosure. Further, it should be
understood, when partial structures of the compounds are
illustrated, that brackets indicate the point of attachment of the
partial structure to the rest of the molecule.
[0099] "Cycloalkoxycarbonyl" by itself or as part of another
substituent refers to a radical --C(O)OR.sup.36 where R.sup.36
represents an cycloalkyl group as defined herein. Representative
examples include, but are not limited to, cyclobutyloxycarbonyl,
cyclohexyloxycarbonyl and the like.
[0100] "Cycloalkyl" by itself or as part of another substituent
refers to a saturated or unsaturated cyclic alkyl radical. Where a
specific level of saturation is intended, the nomenclature
"cycloalkanyl" or "cycloalkenyl" is used. Typical cycloalkyl groups
include, but are not limited to, groups derived from cyclopropane,
cyclobutane, cyclopentane, cyclohexane and the like. Preferably,
the cycloalkyl group is (C.sub.3-C.sub.10) cycloalkyl, more
preferably (C.sub.3-C.sub.7) cycloalkyl.
[0101] "Cycloheteroalkyl" by itself or as part of another
substituent refers to a saturated or unsaturated cyclic alkyl
radical in which one or more carbon atoms (and any associated
hydrogen atoms) are independently replaced with the same or
different heteroatom. Typical heteroatoms to replace the carbon
atom(s) include, but are not limited to, N, P, O, S, Si, etc. Where
a specific level of saturation is intended, the nomenclature
"cycloheteroalkanyl" or "cycloheteroalkenyl" is used. Typical
cycloheteroalkyl groups include, but are not limited to, groups
derived from epoxides, azirines, thiiranes, imidazolidine,
morpholine, piperazine, piperidine, pyrazolidine, pyrrolidine,
quinuclidine and the like.
[0102] "1-Haloalkyl Carbamate" refers to an N-1-haloalkoxycarbonyl
derivative of baclofen or a baclofen analog as encompassed by
compounds of Formulae (II), (VII) and (VIII) disclosed herein.
[0103] "Heteroalkyl. Heteroalkanyl Heteroalkenyl and Heteroalkynyl"
by themselves or as part of another substituent refer to alkyl,
alkanyl, alkenyl and alkynyl groups, respectively, in which one or
more of the carbon atoms (and any associated hydrogen atoms) are
independently replaced with the same or different heteroatomic
groups. Typical heteroatomic groups which can be included in these
groups include, but are not limited to, --O--, --S--, --O--O--,
--S--S--, --O--S--, --NR.sup.37R.sup.38--, .dbd.N--N.dbd.,
--N.dbd.N--, --N.dbd.N--NR.sup.39R.sup.40, --PR.sup.41--,
--P(O).sub.2--, --POR.sup.42--, --O--P(O).sub.2--, --SO--,
--SO.sub.2--, --SnR.sup.43R.sup.44-- and the like, where R.sup.37,
R.sup.38, R.sup.39, R.sup.40, R.sup.41, R.sup.42, R.sup.43 and
R.sup.44 are independently hydrogen, alkyl, substituted alkyl,
aryl, substituted aryl, arylalkyl, substituted arylalkyl,
cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted
cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl,
substituted heteroaryl, heteroarylalkyl or substituted
heteroarylalkyl.
[0104] "Heteroaryl" by itself or as part of another substituent,
refers to a monovalent heteroaromatic radical derived by the
removal of one hydrogen atom from a single atom of a parent
heteroaromatic ring system. Typical heteroaryl groups include, but
are not limited to, groups derived from acridine, arsindole,
carbazole, .beta.-carboline, chromane, chromene, cinnoline, furan,
imidazole, indazole, indole, indoline, indolizine, isobenzofuran,
isochromene, isoindole, isoindoline, isoquinoline, isothiazole,
isoxazole, naphthyridine, oxadiazole, oxazole, perimidine,
phenanthridine, phenanthroline, phenazine, phthalazine, pteridine,
purine, pyran, pyrazine, pyrazole, pyridazine, pyridine,
pyrimidine, pyrrole, pyrrolizine, quinazoline, quinoline,
quinolizine, quinoxaline, tetrazole, thiadiazole, thiazole,
thiophene, triazole, xanthene, and the like. Preferably, the
heteroaryl group is from 5-20 membered heteroaryl, more preferably
from 5-10 membered heteroaryl. Preferred heteroaryl groups are
those derived from thiophene, pyrrole, benzothiophene, benzofuran,
indole, pyridine, quinoline, imidazole, oxazole and pyrazine.
[0105] "Heteroarylalkyl" by itself or as part of another
substituent refers to an acyclic alkyl radical in which one of the
hydrogen atoms bonded to a carbon atom, typically a terminal or
sp.sup.3 carbon atom, is replaced with a heteroaryl group. Where
specific alkyl moieties are intended, the nomenclature
heteroarylalkanyl, heteroarylalkenyl and/or heterorylalkynyl is
used. In preferred embodiments, the heteroarylalkyl group is a 6-30
membered heteroarylalkyl, e.g., the alkanyl, alkenyl or alkynyl
moiety of the heteroarylalkyl is 1-10 membered and the heteroaryl
moiety is a 5-20-membered heteroaryl, more preferably, 6-20
membered heteroarylalkyl, e.g., the alkanyl, alkenyl or alkynyl
moiety of the heteroarylalkyl is 1-8 membered and the heteroaryl
moiety is a 5-12-membered heteroaryl.
[0106] "Parent Aromatic Ring System" refers to an unsaturated
cyclic or polycyclic ring system having a conjugated .pi. electron
system. Specifically included within the definition of "parent
aromatic ring system" are fused ring systems in which one or more
of the rings are aromatic and one or more of the rings are
saturated or unsaturated, such as, for example, fluorene, indane,
indene, phenalene, etc. Typical parent aromatic ring systems
include, but are not limited to, aceanthrylene, acenaphthylene,
acephenanthrylene, anthracene, azulene, benzene, chrysene,
coronene, fluoranthene, fluorene, hexacene, hexaphene, hexylene,
as-indacene, s-indacene, indane, indene, naphthalene, octacene,
octaphene, octalene, ovalene, penta-2,4-diene, pentacene,
pentalene, pentaphene, perylene, phenalene, phenanthrene, picene,
pleiadene, pyrene, pyranthrene, rubicene, triphenylene,
trinaphthalene and the like.
[0107] "Parent Heteroaromatic Ring System" refers to a parent
aromatic ring system in which one or more carbon atoms (and any
associated hydrogen atoms) are independently replaced with the same
or different heteroatom. Typical heteroatoms to replace the carbon
atoms include, but are not limited to, N, P, O, S, Si, etc.
Specifically included within the definition of "parent
heteroaromatic ring systems" are fused ring systems in which one or
more of the rings are aromatic and one or more of the rings are
saturated or unsaturated, such as, for example, arsindole,
benzodioxan, benzofuran, chromane, chromene, indole, indoline,
xanthene, etc. Typical parent heteroaromatic ring systems include,
but are not limited to, arsindole, carbazole, .beta.-carboline,
chromane, chromene, cinnoline, furan, imidazole, indazole, indole,
indoline, indolizine, isobenzofuran, isochromene, isoindole,
isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine,
oxadiazole, oxazole, perimidine, phenanthridine, phenanthroline,
phenazine, phthalazine, pteridine, purine, pyran, pyrazine,
pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine,
quinazoline, quinoline, quinolizine, quinoxaline, tetrazole,
thiadiazole, thiazole, thiophene, triazole, xanthene, and the
like.
[0108] "Pharmaceutical composition" refers to at least one compound
and a pharmaceutically acceptable vehicle, with which the compound
is administered to a patient.
[0109] "Pharmaceutically acceptable salt" refers to a salt of a
compound, which possesses the desired pharmacological activity of
the parent compound. Such salts include: (1) acid addition salts,
formed with inorganic acids such as hydrochloric acid, hydrobromic
acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or
formed with organic acids such as acetic acid, propionic acid,
hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic
acid, lactic acid, malonic acid, succinic acid, malic acid, maleic
acid, fumaric acid, tartaric acid, citric acid, benzoic acid,
3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid,
methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic
acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid,
4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid,
4-toluenesulfonic acid, camphorsulfonic acid,
4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic acid, glucoheptonic
acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary
butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic
acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic
acid, and the like; or (2) salts formed when an acidic proton
present in the parent compound is replaced by a metal ion, e.g., an
alkali metal ion, an alkaline earth ion, or an aluminum ion; or
coordinates with an organic base such as ethanolamine,
diethanolamine, triethanolamine, N-methylglucamine and the
like.
[0110] "Pharmaceutically acceptable vehicle" refers to a diluent,
adjuvant, excipient or carrier with which a compound sis
administered.
[0111] "Patient" includes humans. The terms "human" and "patient"
are used interchangeably herein.
[0112] "Preventing" or "prevention" refers to a reduction in risk
of acquiring a disease or disorder (i.e., causing at least one of
the clinical symptoms of the disease not to develop in a patient
that may be exposed to or predisposed to the disease but does not
yet experience or display symptoms of the disease).
[0113] "Prodrug" refers to a derivative of a drug molecule that
requires a transformation within the body to release the active
drug. Prodrugs are frequently, although not necessarily,
pharmacologically inactive until converted to the parent drug.
[0114] "Promoiety" refers to a form of protecting group that when
used to mask a functional group within a drug molecule converts the
drug into a prodrug. Typically, the promoiety will be attached to
the drug via bond(s) that are cleaved by enzymatic or non-enzymatic
means in vivo.
[0115] "Protecting group" refers to a grouping of atoms that when
attached to a reactive functional group in a molecule masks,
reduces or prevents reactivity of the functional group. Examples of
protecting groups can be found in Green et al., "Protective Groups
in Organic Chemistry", (Wiley, 2.sup.nd ed. 1991) and Harrison et
al., "Compendium of Synthetic Organic Methods", Vols. 1-8 (John
Wiley and Sons, 1971-1996). Representative amino protecting groups
include, but are not limited to, formyl, acetyl, trifluoroacetyl,
benzyl, benzyloxycarbonyl ("CBZ"), tert-butoxycarbonyl ("Boc"),
trimethyl silyl ("TMS"), 2-trimethylsilyl-ethanesulfonyl ("SES"),
trityl and substituted trityl groups, allyloxycarbonyl,
9-fluorenylmethyloxycarbonyl ("FMOC"), nitro-veratryloxycarbonyl
("NVOC") and the like. Representative hydroxy protecting groups
include, but are not limited to, those where the hydroxy group is
either acylated or alkylated such as benzyl, and trityl ethers as
well as alkyl ethers, tetrahydropyranyl ethers, trialkylsilyl
ethers and allyl ethers.
[0116] "Substantially one diastereomer" refers to a compound
containing 2 or more stereogenic centers such that the
diastereomeric excess (d.e.) of the compound is greater than or at
least 90%. In some embodiments, the d.e. is, for example, greater
than or at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.
[0117] "Substituted" refers to a group in which one or more
hydrogen atoms are independently replaced with the same or
different substituent(s). Typical substituents include, but are not
limited to, -M, --R.sup.60, --O.sup.-, .dbd.O, --OR.sup.60,
--SR.sup.60, --S.sup.-, .dbd.S, --NR.sup.60R.sup.61,
.dbd.NR.sup.60, --CF.sub.3, --CN, --OCN, --SCN, --NO, --NO.sub.2,
.dbd.N.sub.2, --N.sub.3, --S(O).sub.2O.sup.-, --S(O).sub.2OH,
--S(O).sub.2R.sup.60, --OS(O.sub.2)O.sup.-, --OS(O).sub.2R.sup.60,
--P(O)(O.sup.-).sub.2, --P(O)(OR.sup.60)(O.sup.-),
--OP(O)(OR.sup.60)(OR.sup.61), --C(O)R.sup.60, --C(S)R.sup.60,
--C(O)OR.sup.60, --C(O)NR.sup.60R.sup.61, --C(O)O.sup.-,
--C(S)OR.sup.60, --NR.sup.62C(O)NR.sup.60R.sup.61,
--NR.sup.62C(S)NR.sup.60R.sup.61,
--NR.sup.62C(NR.sup.63)NR.sup.60R.sup.61 and
--C(NR.sup.62)NR.sup.60R.sup.61 where M is independently a halogen;
R.sup.60, R.sup.61, R.sup.62 and R.sup.63 are independently
hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy,
cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted
cycloheteroalkyl, aryl, substituted aryl, heteroaryl or substituted
heteroaryl, or optionally R.sup.60 and R.sup.61 together with the
nitrogen atom to which they are bonded form a cycloheteroalkyl or
substituted cycloheteroalkyl ring; and R.sup.64 and R.sup.65 are
independently hydrogen, alkyl, substituted alkyl, aryl, cycloalkyl,
substituted cycloalkyl, cycloheteroalkyl, substituted
cycloheteroalkyl, aryl, substituted aryl, heteroaryl or substituted
heteroaryl, or optionally R.sup.64 and R.sup.65 together with the
nitrogen atom to which they are bonded form a cycloheteroalkyl or
substituted cycloheteroalkyl ring. Preferably, substituents include
-M, --R.sup.60, .dbd.O, --OR.sup.60, --SR.sup.60, --S.sup.-,
.dbd.S, --NR.sup.60R.sup.61, .dbd.NR.sup.60, --CF.sub.3, --CN,
--OCN, --SCN, --NO, --NO.sub.2, .dbd.N.sub.2, --N.sub.3,
--S(O).sub.2R.sup.60, --OS(O.sub.2)O.sup.-, --OS(O).sub.2R.sup.60,
--P(O)(O.sup.-).sub.2, --P(O)(OR.sup.60)(O.sup.-),
--OP(O)(OR.sup.60)(OR.sup.61), --C(O)R.sup.60, --C(S)R.sup.60,
--C(O)OR.sup.60, --C(O)NR.sup.60R.sup.61, --C(O)O.sup.-,
--NR.sup.62C(O)NR.sup.60R.sup.61, more preferably, -M, --R.sup.60,
.dbd.O, --OR.sup.60, --SR.sup.60, --NR.sup.60R.sup.61, --CF.sub.3,
--CN, --NO.sub.2, --S(O).sub.2R.sup.60, --P(O)(OR.sup.60)(O--),
--OP(O)(OR.sup.60)(OR.sup.61), --C(O)R.sup.60, --C(O)OR.sup.60,
--C(O)NR.sup.60R.sup.61, --C(O)O.sup.-, most preferably, -M,
--R.sup.60, .dbd.O, --OR.sup.60, --SR.sup.60, --NR.sup.60R.sup.61,
--CF.sub.3, --CN, --NO.sub.2, --S(O).sub.2R.sup.60,
--OP(O)(OR.sup.60)(OR.sup.61), --C(O)R.sup.60, --C(O)OR.sup.60,
--C(O)O.sup.-, where R.sup.60, R.sup.61 and R.sup.62 are as defined
above.
[0118] "Treating" or "treatment" of any disease or disorder refers,
in some embodiments, to ameliorating the disease or disorder (i.e.,
arresting or reducing the development of the disease or at least
one of the clinical symptoms thereof). In other embodiments
"treating" or "treatment" refers to ameliorating at least one
physical parameter, which may not be discernible by the patient. In
yet other embodiments, "treating" or "treatment" refers to
inhibiting the disease or disorder, either physically, (e.g.,
stabilization of a discernible symptom), physiologically, (e.g.,
stabilization of a physical parameter), or both. In still other
embodiments, "treating" or "treatment" refers to delaying the onset
of the disease or disorder.
[0119] "Therapeutically effective amount" means the amount of a
compound that, when administered to a patient for treating a
disease, is sufficient to effect such treatment for the disease.
The "therapeutically effective amount" will vary depending on the
compound, the disease and its severity and the age, weight, etc.,
of the patient to be treated.
[0120] "Trialkylsilyl" by itself or as part of another substituent
refers to a radical SiR.sup.50R.sup.51R.sup.52 where R.sup.50,
R.sup.51 and R.sup.52 are alkyl as defined herein.
[0121] Reference will now be made in detail to particular
embodiments of compounds and methods. The disclosed embodiments are
not intended to be limiting of the claims. To the contrary, is the
claims are intended to cover all alternatives, modifications and
equivalents.
4.2 Compounds
[0122] In a first aspect, a compound of Formula (I) is
provided,
##STR00007##
[0123] or pharmaceutically acceptable salts, hydrates or solvates
thereof, wherein:
[0124] R.sup.1 is selected from the group consisting of acyl,
substituted acyl, alkyl, substituted alkyl, aryl, substituted aryl,
arylalkyl, substituted arylalkyl, cycloalkyl, substituted
cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl,
heteroalkyl, substituted heteroalkyl, heteroaryl, substituted
heteroaryl, heteroarylalkyl and substituted heteroarylalkyl;
[0125] R.sup.2 and R.sup.3 are independently selected from the
group consisting of hydrogen, alkyl, substituted alkyl,
alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl,
arylalkyl, substituted arylalkyl, cycloalkyl, substituted
cycloalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl and
substituted heteroarylalkyl or optionally, R.sup.2 and R.sup.3
together with the carbon atom to which they are bonded form a
cycloalkyl, substituted cycloalkyl, cycloheteroalkyl or substituted
cycloheteroalkyl ring;
[0126] R.sup.4 is selected from the group consisting of hydrogen,
alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl,
substituted arylalkyl, aryldialkylsilyl, cycloalkyl, substituted
cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl,
heteroalkyl, substituted heteroalkyl, heteroaryl, substituted
heteroaryl, heteroarylalkyl, substituted heteroarylalkyl or
trialkylsilyl; and
[0127] R.sup.5 is selected from the group consisting of substituted
aryl, heteroaryl and substituted heteroaryl.
[0128] In some embodiments, R.sup.5 is selected from the group
consisting of 4-chlorophenyl, (3R)-4-chlorophenyl, 2-chlorophenyl,
4-fluorophenyl, thien-2-yl; 5-chlorothien-2-yl, 5-bromothien-2-yl,
5-methylthien-2-yl and 2-imidazolyl. In other embodiments, R.sup.5
is selected from the group consisting of -chlorophenyl,
(3R)-4-chlorophenyl, 2-chlorophenyl, 4-fluorophenyl.
[0129] In still other embodiments, the compound of Formula (I) has
the structure of Formula (V):
##STR00008##
[0130] or pharmaceutically acceptable salts, hydrates or solvates
thereof;
[0131] wherein:
[0132] R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined,
supra.
[0133] In still other embodiments, a compound of Formula (I), has
the structure of Formula (VI):
##STR00009##
[0134] or pharmaceutically acceptable salts, hydrates or solvates
thereof;
[0135] wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as
defined, supra.
[0136] In some embodiments of compounds of Formulae (I), (V) or
(VI), R.sup.1 is selected from the group consisting of C.sub.1-6
alkyl, substituted C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, phenyl,
substituted phenyl, C.sub.7-9 phenylalkyl and pyridyl. In other
embodiments of compounds of Formulae (I), (V) or (VI), R.sup.1 is
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl,
tert-butyl, n-pentyl, isopentyl, sec-pentyl, neopentyl,
1,1-dimethoxyethyl, 1,1-diethoxyethyl, phenyl, 4-methoxyphenyl,
benzyl, phenethyl, styryl, cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, 2-pyridyl, 3-pyridyl or 4-pyridyl. In still other
embodiments of compounds of Formulae (I), (V) or (VI), R.sup.1 is
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl,
tert-butyl, n-pentyl, isopentyl, sec-pentyl, neopentyl,
1,1-diethoxyethyl, phenyl, cyclohexyl or 3-pyridyl.
[0137] In still other embodiments of compounds of Formulae (I), (V)
or (VI), R.sup.2 and R.sup.3 are independently selected from the
group consisting of hydrogen, alkyl, substituted alkyl,
alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl,
arylalkyl, substituted arylalkyl, carbamoyl, cycloalkyl,
substituted cycloalkyl, cycloalkoxycarbonyl, substituted
cycloalkoxycarbonyl, heteroaryl, substituted heteroaryl,
heteroarylalkyl and substituted heteroarylalkyl. In still other
embodiments of compounds of Formulae (I), (V) or (VI), R.sup.2 and
R.sup.3 are independently selected from the group consisting of
hydrogen, C.sub.1-4 alkyl, substituted C.sub.1-4 alkyl, C.sub.1-4
alkoxycarbonyl, C.sub.3-6 cycloalkyl, C.sub.3-6
cycloalkoxycarbonyl, phenyl, substituted phenyl, C.sub.7-9
phenylalkyl and pyridyl. In still other embodiments of compounds of
Formulae (I), (V) or (VI), R.sup.2 and R.sup.3 are independently
selected from the group consisting of hydrogen, methyl, ethyl,
n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl,
cyclopentyl, cyclohexyl, methoxycarbonyl, ethoxycarbonyl,
isopropoxycarbonyl, cyclohexyloxycarbonyl, phenyl, benzyl,
phenethyl, 2-pyridyl, 3-pyridyl and 4-pyridyl. In still other
embodiments of compounds of Formulae (I), (V) or (VI), R.sup.2 is
hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl,
sec-butyl, tert-butyl, cyclopentyl, cyclohexyl, methoxycarbonyl,
ethoxycarbonyl, isopropoxycarbonyl, cyclohexyloxycarbonyl, phenyl,
benzyl, phenethyl, 2-pyridyl, 3-pyridyl or 4-pyridyl and R.sup.3 is
hydrogen. In still other embodiments of compounds of Formulae (I),
(V) or (VI), R.sup.2 is hydrogen, methyl, ethyl, n-propyl,
isopropyl, n-butyl, isobutyl, sec-butyl, phenyl or cyclohexyl and
R.sup.3 is hydrogen. In still other embodiments of a compound of
Formulae (I), (V) or (VI), R.sup.2 is methyl, methoxycarbonyl,
ethoxycarbonyl, isopropoxycarbonyl or cyclohexyloxycarbonyl, and
R.sup.3 is methyl.
[0138] In still other embodiments of a compound of Formulae (I),
(V) or (VI), R.sup.2 and R.sup.3 together with the carbon atom to
which they are attached form a cycloalkyl, substituted cycloalkyl,
cycloheteroalkyl or substituted cycloheteroalkyl ring. In still
other embodiments of compounds of Formulae (I), (V) or (VI),
R.sup.2 and R.sup.3 together with the carbon atom to which they are
attached form a cyclobutyl, cyclopentyl or cyclohexyl ring.
[0139] In still other embodiments of a compound of Formulae (I),
(V) or (VI), R.sup.4 is selected from the group consisting of
hydrogen, C.sub.1-6 alkyl, substituted C.sub.1-6 alkyl, C.sub.3-6
cycloalkyl, phenyl, substituted phenyl, C.sub.7-9 phenylalkyl,
substituted C.sub.7-9 phenylalkyl, trialkylsilyl and
aryldialkylsilyl. In still other embodiments of a compound of
Formulae (I), (V) or (VI), R.sup.4 is hydrogen, methyl, ethyl,
tert-butyl, allyl, benzyl, 4-methoxybenzyl, diphenylmethyl,
triphenylmethyl, trimethylsilyl, triethylsilyl, triisopropylsilyl,
tert-butyldimethylsilyl or phenyldimethylsilyl. In still other
embodiments of a compound of Formulae (I), (V) or (VI), R.sup.4 is
hydrogen, allyl, benzyl or trimethylsilyl. In still other
embodiments of a compound of Formulae (I), (V) or (VI), R.sup.4 is
hydrogen.
[0140] In some embodiments of a compound of Formula (I), R.sup.5 is
substituted aryl. In other embodiments of a compound of Formula
(I), R.sup.5 is substituted phenyl. In still other embodiments,
R.sup.5 is phenyl substituted with one or more halogen atoms.
[0141] In some embodiments of a compound of Formulae (I), (V) or
(VI), R.sup.1 is selected from the group consisting of C.sub.1-6
alkyl, substituted C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, phenyl,
substituted phenyl, C.sub.7-9 phenylalkyl and pyridyl, R.sup.2 and
R.sup.3 are independently selected from the group consisting of
hydrogen, C.sub.1-4 alkyl, substituted C.sub.1-4 alkyl, C.sub.1-4
alkoxycarbonyl, C.sub.3-6 cycloalkyl, C.sub.3-6
cycloalkoxycarbonyl, phenyl, substituted phenyl, C.sub.7-9
phenylalkyl and pyridyl and R.sup.4 is selected from the group
consisting of hydrogen, C.sub.1-6 alkyl, substituted C.sub.1-6
alkyl, C.sub.3-6 cycloalkyl, phenyl, substituted phenyl, C.sub.7-9
phenylalkyl, substituted C.sub.7-9 phenylalkyl, trialkylsilyl and
aryldialkylsilyl. Preferably, in the above embodiments, R.sup.1 is
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl,
tert-butyl, n-pentyl, isopentyl, sec-pentyl, neopentyl,
1,1-dimethoxyethyl, 1,1-diethoxyethyl, phenyl, 4-methoxyphenyl,
benzyl, phenethyl, styryl, cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, 2-pyridyl, 3-pyridyl or 4-pyridyl, more preferably,
R.sup.1 is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl,
sec-butyl, tert-butyl, n-pentyl, isopentyl, sec-pentyl, neopentyl,
1,1-diethoxyethyl, phenyl, cyclohexyl or 3-pyridyl. In the above
embodiments of a compound of Formula (I), R.sup.5 is preferably
substituted aryl, more preferably, substituted phenyl, most
preferably, phenyl substituted with one or more halogen atoms.
[0142] In some embodiments of a compound of Formulae (I), (V) or
(VI), R.sup.1 is selected from the group consisting of C.sub.1-6
alkyl, substituted C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, phenyl,
substituted phenyl, C.sub.7-9 phenylalkyl and pyridyl, R.sup.2 and
R.sup.3 are independently selected from the group consisting of
hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl,
sec-butyl, tert-butyl, cyclopentyl, cyclohexyl, methoxycarbonyl,
ethoxycarbonyl, isopropoxycarbonyl, cyclohexyloxycarbonyl, phenyl,
benzyl, phenethyl, 2-pyridyl, 3-pyridyl and 4-pyridyl and R.sup.4
is selected from the group consisting of hydrogen, C.sub.1-6 alkyl,
substituted C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, phenyl,
substituted phenyl, C.sub.7-9 phenylalkyl, substituted C.sub.7-9
phenylalkyl, trialkylsilyl and aryldialkylsilyl. Preferably, in the
above embodiments, R.sup.1 is methyl, ethyl, n-propyl, isopropyl,
n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl,
sec-pentyl, neopentyl, 1,1-dimethoxyethyl, 1,1-diethoxyethyl,
phenyl, 4-methoxyphenyl, benzyl, phenethyl, styryl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, 2-pyridyl, 3-pyridyl or
4-pyridyl, more preferably, R.sup.1 is methyl, ethyl, n-propyl,
isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl,
isopentyl, sec-pentyl, neopentyl, 1,1-diethoxyethyl, phenyl,
cyclohexyl or 3-pyridyl. In the above embodiments of a compound of
Formula (I), R.sup.5 is preferably substituted aryl, more
preferably, substituted phenyl, most preferably, phenyl substituted
with one or more halogen atoms.
[0143] In some embodiments of a compound of Formulae (I), (V) or
(VI), R.sup.1 is selected from the group consisting of C.sub.1-6
alkyl, substituted C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, phenyl,
substituted phenyl, C.sub.7-9 phenylalkyl and pyridyl, R.sup.2 is
hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl,
sec-butyl, phenyl or cyclohexyl, R.sup.3 is hydrogen and R.sup.4 is
selected from the group consisting of hydrogen, C.sub.1-6 alkyl,
substituted C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, phenyl,
substituted phenyl, C.sub.7-9 phenylalkyl, substituted C.sub.7-9
phenylalkyl, trialkylsilyl and aryldialkylsilyl. Preferably, in the
above embodiments, R.sup.1 is methyl, ethyl, n-propyl, isopropyl,
n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl,
sec-pentyl, neopentyl, 1,1-dimethoxyethyl, 1,1-diethoxyethyl,
phenyl, 4-methoxyphenyl, benzyl, phenethyl, styryl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, 2-pyridyl, 3-pyridyl or
4-pyridyl, more preferably, R.sup.1 is methyl, ethyl, n-propyl,
isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl,
isopentyl, sec-pentyl, neopentyl, 1,1-diethoxyethyl, phenyl,
cyclohexyl or 3-pyridyl. In the above embodiments of a compound of
Formula (I), R.sup.5 is preferably substituted aryl, more
preferably, substituted phenyl, most preferably, phenyl substituted
with one or more halogen atoms.
[0144] In some embodiments of a compound of Formulae (I), (V) or
(VI), R.sup.1 is selected from the group consisting of C.sub.1-6
alkyl, substituted C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, phenyl,
substituted phenyl, C.sub.7-9 phenylalkyl and pyridyl, R.sup.2 is
methyl, methoxycarbonyl, ethoxycarbonyl, isopropoxy carbonyl or
cyclohexyloxycarbonyl, R.sup.3 is methyl and R.sup.4 is selected
from the group consisting of hydrogen, C.sub.1-6 alkyl, substituted
C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, phenyl, substituted phenyl,
C.sub.7-9 phenylalkyl, substituted C.sub.7-9 phenylalkyl,
trialkylsilyl and aryldialkylsilyl. Preferably, in the above
embodiments, R.sup.1 is methyl, ethyl, n-propyl, isopropyl,
n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl,
sec-pentyl, neopentyl, 1,1-dimethoxyethyl, 1,1-diethoxyethyl,
phenyl, 4-methoxyphenyl, benzyl, phenethyl, styryl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, 2-pyridyl, 3-pyridyl or
4-pyridyl, more preferably, R.sup.1 is methyl, ethyl, n-propyl,
isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl,
isopentyl, sec-pentyl, neopentyl, 1,1-diethoxyethyl, phenyl,
cyclohexyl or 3-pyridyl. In the above embodiments of a compound of
Formula (I), R.sup.5 is preferably substituted aryl, more
preferably, substituted phenyl, most preferably, phenyl substituted
with one or more halogen atoms.
[0145] In some embodiments of a compound of Formulae (I), (V) or
(VI), R.sup.1 is selected from the group consisting of C.sub.1-6
alkyl, substituted C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, phenyl,
substituted phenyl, C.sub.7-9 phenylalkyl and pyridyl, R.sup.2 and
R.sup.3 are independently selected from the group consisting of
hydrogen, C.sub.1-4 alkyl, substituted C.sub.1-4 alkyl, C.sub.1-4
alkoxycarbonyl, C.sub.3-6 cycloalkyl, C.sub.3-6
cycloalkoxycarbonyl, phenyl, substituted phenyl, C.sub.7-9
phenylalkyl and pyridyl and R.sup.4 is hydrogen, methyl, ethyl,
tert-butyl, allyl, benzyl, 4-methoxybenzyl, diphenylmethyl,
triphenylmethyl, trimethylsilyl, triisopropylsilyl,
tert-butyldimethylsilyl or phenyldimethylsilyl. Preferably, in the
above embodiments, R.sup.1 is methyl, ethyl, n-propyl, isopropyl,
n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl,
sec-pentyl, neopentyl, 1,1-dimethoxyethyl, 1,1-diethoxyethyl,
phenyl, 4-methoxyphenyl, benzyl, phenethyl, styryl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, 2-pyridyl, 3-pyridyl or
4-pyridyl, more preferably, R.sup.1 is methyl, ethyl, n-propyl,
isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl,
isopentyl, sec-pentyl, neopentyl, 1,1-diethoxyethyl, phenyl,
cyclohexyl or 3-pyridyl. In the above embodiments of a compound of
Formula (I), R.sup.5 is preferably substituted aryl, more
preferably, substituted phenyl, most preferably, phenyl substituted
with one or more halogen atoms.
[0146] In some embodiments of a compound of Formulae (I), (V) or
(VI), R.sup.1 is selected from the group consisting of C.sub.1-6
alkyl, substituted C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, phenyl,
substituted phenyl, C.sub.7-9 phenylalkyl and pyridyl, R.sup.2 and
R.sup.3 are independently selected from the group consisting of
hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl,
sec-butyl, tert-butyl, cyclopentyl, cyclohexyl, methoxycarbonyl,
ethoxycarbonyl, isopropoxycarbonyl, cyclohexyloxycarbonyl, phenyl,
benzyl, phenethyl, 2-pyridyl, 3-pyridyl and 4-pyridyl and R.sup.4
is hydrogen, methyl, ethyl, tert-butyl, allyl, benzyl,
4-methoxybenzyl, diphenylmethyl, triphenylmethyl, trimethylsilyl,
triisopropylsilyl, tert-butyldimethylsilyl or phenyldimethylsilyl.
Preferably, in the above embodiments, R.sup.1 is methyl, ethyl,
n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl,
n-pentyl, isopentyl, sec-pentyl, neopentyl, 1,1-dimethoxyethyl,
1,1-diethoxyethyl, phenyl, 4-methoxyphenyl, benzyl, phenethyl,
styryl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
2-pyridyl, 3-pyridyl or 4-pyridyl, more preferably, R.sup.1 is
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl,
tert-butyl, n-pentyl, isopentyl, sec-pentyl, neopentyl,
1,1-diethoxyethyl, phenyl, cyclohexyl or 3-pyridyl. In the above
embodiments of a compound of Formula (I), R.sup.5 is preferably
substituted aryl, more preferably, substituted phenyl, most
preferably, phenyl substituted with one or more halogen atoms.
[0147] In some embodiments of a compound of Formulae (I), (V) or
(VI), R.sup.1 is selected from the group consisting of C.sub.1-6
alkyl, substituted C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, phenyl,
substituted phenyl, C.sub.7-9 phenylalkyl and pyridyl, R.sup.2 is
hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl,
sec-butyl, phenyl or cyclohexyl, R.sup.3 is hydrogen and R.sup.4 is
hydrogen, methyl, ethyl, tert-butyl, allyl, benzyl,
4-methoxybenzyl, diphenylmethyl, triphenylmethyl, trimethylsilyl,
triisopropylsilyl, tert-butyldimethylsilyl or phenyldimethylsilyl.
Preferably, in the above embodiments, R.sup.1 is methyl, ethyl,
n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl,
n-pentyl, isopentyl, sec-pentyl, neopentyl, 1,1-dimethoxyethyl,
1,1-diethoxyethyl, phenyl, 4-methoxyphenyl, benzyl, phenethyl,
styryl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
2-pyridyl, 3-pyridyl or 4-pyridyl, more preferably, R.sup.1 is
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl,
tert-butyl, n-pentyl, isopentyl, sec-pentyl, neopentyl,
1,1-diethoxyethyl, phenyl, cyclohexyl or 3-pyridyl. In the above
embodiments of a compound of Formula (I), R.sup.5 is preferably
substituted aryl, more preferably, substituted phenyl, most
preferably, phenyl substituted with one or more halogen atoms.
[0148] In some embodiments of a compound of Formulae (I), (V) or
(VI), R.sup.1 is selected from the group consisting of C.sub.1-6
alkyl, substituted C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, phenyl,
substituted phenyl, C.sub.7-9 phenylalkyl and pyridyl, R.sup.2 is
methyl, methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl or
cyclohexyloxycarbonyl, R.sup.3 is methyl and R.sup.4 is hydrogen,
methyl, ethyl, tert-butyl, allyl, benzyl, 4-methoxybenzyl,
diphenylmethyl, triphenylmethyl, trimethylsilyl, triisopropylsilyl,
tert-butyldimethylsilyl or phenyldimethylsilyl. Preferably, in the
above embodiments, R.sup.1 is methyl, ethyl, n-propyl, isopropyl,
n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl,
sec-pentyl, neopentyl, 1,1-dimethoxyethyl, 1,1-diethoxyethyl,
phenyl, 4-methoxyphenyl, benzyl, phenethyl, styryl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, 2-pyridyl, 3-pyridyl or
4-pyridyl, more preferably, R.sup.1 is methyl, ethyl, n-propyl,
isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl,
isopentyl, sec-pentyl, neopentyl, 1,1-diethoxyethyl, phenyl,
cyclohexyl or 3-pyridyl. In the above embodiments of a compound of
Formula (I), R.sup.5 is preferably substituted aryl, more
preferably, substituted phenyl, most preferably, phenyl substituted
with one or more halogen atoms.
[0149] In some embodiments of a compound of Formulae (I), (V) or
(VI), R.sup.1 is selected from the group consisting of C.sub.1-6
alkyl, substituted C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, phenyl,
substituted phenyl, C.sub.7-9 phenylalkyl and pyridyl, R.sup.2 and
R.sup.3 are independently selected from the group consisting of
hydrogen, C.sub.1-4 alkyl, substituted C.sub.1-4 alkyl, C.sub.1-4
alkoxycarbonyl, C.sub.3-6 cycloalkyl, C.sub.3-6
cycloalkoxycarbonyl, phenyl, substituted phenyl, C.sub.7-9
phenylalkyl and pyridyl and R.sup.4 is hydrogen, allyl, benzyl or
trimethylsilyl. Preferably, in the above embodiments, R.sup.1 is
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl,
tert-butyl, n-pentyl, isopentyl, sec-pentyl, neopentyl,
1,1-dimethoxyethyl, 1,1-diethoxyethyl, phenyl, 4-methoxyphenyl,
benzyl, phenethyl, styryl, cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, 2-pyridyl, 3-pyridyl or 4-pyridyl, more preferably,
R.sup.1 is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl,
sec-butyl, tert-butyl, n-pentyl, isopentyl, sec-pentyl, neopentyl,
1,1-diethoxyethyl, phenyl, cyclohexyl or 3-pyridyl. In the above
embodiments of a compound of Formula (I), R.sup.5 is preferably
substituted aryl, more preferably, substituted phenyl, most
preferably, phenyl substituted with one or more halogen atoms.
[0150] In some embodiments of a compound of Formulae (I), (V) or
(VI), R.sup.1 is selected from the group consisting of C.sub.1-6
alkyl, substituted C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, phenyl,
substituted phenyl, C.sub.7-9 phenylalkyl and pyridyl, R.sup.2 and
R.sup.3 are independently selected from the group consisting of
hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl,
sec-butyl, tert-butyl, cyclopentyl, cyclohexyl, methoxycarbonyl,
ethoxycarbonyl, isopropoxycarbonyl, cyclohexyloxycarbonyl, phenyl,
benzyl, phenethyl, 2-pyridyl, 3-pyridyl and 4-pyridyl and R.sup.4
is hydrogen, allyl, benzyl or trimethylsilyl. Preferably, in the
above embodiments, R.sup.1 is methyl, ethyl, n-propyl, isopropyl,
n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl,
sec-pentyl, neopentyl, 1,1-dimethoxyethyl, 1,1-diethoxyethyl,
phenyl, 4-methoxyphenyl, benzyl, phenethyl, styryl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, 2-pyridyl, 3-pyridyl or
4-pyridyl, more preferably, R.sup.1 is methyl, ethyl, n-propyl,
isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl,
isopentyl, sec-pentyl, neopentyl, 1,1-diethoxyethyl, phenyl,
cyclohexyl or 3-pyridyl. In the above embodiments of a compound of
Formula (I), R.sup.5 is preferably substituted aryl, more
preferably, substituted phenyl, most preferably, phenyl substituted
with one or more halogen atoms.
[0151] In some embodiments of a compound of Formulae (I), (V) or
(VI), R.sup.1 is selected from the group consisting of C.sub.1-6
alkyl, substituted C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, phenyl,
substituted phenyl, C.sub.7-9 phenylalkyl and pyridyl, R.sup.2 is
hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl,
sec-butyl, phenyl or cyclohexyl, R.sup.3 is hydrogen and R.sup.4 is
hydrogen, allyl, benzyl or trimethylsilyl. Preferably, in the above
embodiments, R.sup.1 is methyl, ethyl, n-propyl, isopropyl,
n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl,
sec-pentyl, neopentyl, 1,1-dimethoxyethyl, 1,1-diethoxyethyl,
phenyl, 4-methoxyphenyl, benzyl, phenethyl, styryl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, 2-pyridyl, 3-pyridyl or
4-pyridyl, more preferably, R.sup.1 is methyl, ethyl, n-propyl,
isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl,
isopentyl, sec-pentyl, neopentyl, 1,1-diethoxyethyl, phenyl,
cyclohexyl or 3-pyridyl. In the above embodiments of a compound of
Formula (I), R.sup.5 is preferably substituted aryl, more
preferably, substituted phenyl, most preferably, phenyl substituted
with one or more halogen atoms.
[0152] In some embodiments of a compound of Formulae (I), (V) or
(VI), R.sup.1 is selected from the group consisting of C.sub.1-6
alkyl, substituted C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, phenyl,
substituted phenyl, C.sub.7-9 phenylalkyl and pyridyl, R.sup.2 is
methyl, methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl or
cyclohexyloxycarbonyl, R.sup.3 is methyl and R.sup.4 is hydrogen,
allyl, benzyl or trimethylsilyl. Preferably, in the above
embodiments, R.sup.1 is methyl, ethyl, n-propyl, isopropyl,
n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl,
sec-pentyl, neopentyl, 1,1-dimethoxyethyl, 1,1-diethoxyethyl,
phenyl, 4-methoxyphenyl, benzyl, phenethyl, styryl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, 2-pyridyl, 3-pyridyl or
4-pyridyl, more preferably, R.sup.1 is methyl, ethyl, n-propyl,
isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl,
isopentyl, sec-pentyl, neopentyl, 1,1-diethoxyethyl, phenyl,
cyclohexyl or 3-pyridyl. In the above embodiments of a compound of
Formula (I), R.sup.5 is preferably substituted aryl, more
preferably, substituted phenyl, most preferably, phenyl substituted
with one or more halogen atoms.
[0153] In some embodiments of a compound of Formulae (I), (V) or
(VI), R.sup.1 is selected from the group consisting of C.sub.1-6
alkyl, substituted C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, phenyl,
substituted phenyl, C.sub.7-9 phenylalkyl and pyridyl, R.sup.2 and
R.sup.3 are independently selected from the group consisting of
hydrogen, C.sub.1-4 alkyl, substituted C.sub.1-4 alkyl, C.sub.1-4
alkoxycarbonyl, C.sub.3-6 cycloalkyl, C.sub.3-6
cycloalkoxycarbonyl, phenyl, substituted phenyl, C.sub.7-9
phenylalkyl and pyridyl and R.sup.4 is hydrogen. Preferably, in the
above embodiments, R.sup.1 is methyl, ethyl, n-propyl, isopropyl,
n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl,
sec-pentyl, neopentyl, 1,1-dimethoxyethyl, 1,1-diethoxyethyl,
phenyl, 4-methoxyphenyl, benzyl, phenethyl, styryl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, 2-pyridyl, 3-pyridyl or
4-pyridyl, more preferably, R.sup.1 is methyl, ethyl, n-propyl,
isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl,
isopentyl, sec-pentyl, neopentyl, 1,1-diethoxyethyl, phenyl,
cyclohexyl or 3-pyridyl. In the above embodiments of a compound of
Formula (I), R.sup.5 is preferably substituted aryl, more
preferably, substituted phenyl, most preferably, phenyl substituted
with one or more halogen atoms.
[0154] In some embodiments of a compound of Formulae (I), (V) or
(VI), R.sup.1 is selected from the group consisting of C.sub.1-6
alkyl, substituted C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, phenyl,
substituted phenyl, C.sub.7-9 phenylalkyl and pyridyl, R.sup.2 and
R.sup.3 are independently selected from the group consisting of
hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl,
sec-butyl, tert-butyl, cyclopentyl, cyclohexyl, methoxycarbonyl,
ethoxycarbonyl, isopropoxycarbonyl, cyclohexyloxycarbonyl, phenyl,
benzyl, phenethyl, 2-pyridyl, 3-pyridyl and 4-pyridyl and R.sup.4
is hydrogen. Preferably, in the above embodiments, R.sup.1 is
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl,
tert-butyl, n-pentyl, isopentyl, sec-pentyl, neopentyl,
1,1-dimethoxyethyl, 1,1-diethoxyethyl, phenyl, 4-methoxyphenyl,
benzyl, phenethyl, styryl, cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, 2-pyridyl, 3-pyridyl or 4-pyridyl, more preferably,
R.sup.1 is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl,
sec-butyl, tert-butyl, n-pentyl, isopentyl, sec-pentyl, neopentyl,
1,1-diethoxyethyl, phenyl, cyclohexyl or 3-pyridyl. In the above
embodiments of a compound of Formula (I), R.sup.1 is preferably
substituted aryl, more preferably, substituted phenyl, most
preferably, phenyl substituted with one or more halogen atoms.
[0155] In some embodiments of a compound of Formulae (I), (V) or
(VI), R.sup.1 is selected from the group consisting of C.sub.1-6
alkyl, substituted C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, phenyl,
substituted phenyl, C.sub.7-9 phenylalkyl and pyridyl, R.sup.2 is
hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl,
sec-butyl, phenyl or cyclohexyl, R.sup.3 is hydrogen and R.sup.4 is
hydrogen. Preferably, in the above embodiments, R.sup.1 is methyl,
ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl,
tert-butyl, n-pentyl, isopentyl, sec-pentyl, neopentyl,
1,1-dimethoxyethyl, 1,1-diethoxyethyl, phenyl, 4-methoxyphenyl,
benzyl, phenethyl, styryl, cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, 2-pyridyl, 3-pyridyl or 4-pyridyl, more preferably,
R.sup.1 is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl,
sec-butyl, tert-butyl, n-pentyl, isopentyl, sec-pentyl, neopentyl,
1,1-diethoxyethyl, phenyl, cyclohexyl or 3-pyridyl. In the above
embodiments of a compound of Formula (I), R.sup.5 is preferably
substituted aryl, more preferably, substituted phenyl, most
preferably, phenyl substituted with one or more halogen atoms.
[0156] In some embodiments of a compound of Formulae (I), (V) or
(VI), R.sup.1 is selected from the group consisting of C.sub.1-6
alkyl, substituted C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, phenyl,
substituted phenyl, C.sub.7-9 phenylalkyl and pyridyl, R.sup.2 is
methyl, methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl or
cyclohexyloxycarbonyl, R.sup.3 is methyl and R.sup.4 is hydrogen.
Preferably, in the above embodiments, R.sup.1 is methyl, ethyl,
n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl,
n-pentyl, isopentyl, sec-pentyl, neopentyl, 1,1-dimethoxyethyl,
1,1-diethoxyethyl, phenyl, 4-methoxyphenyl, benzyl, phenethyl,
styryl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
2-pyridyl, 3-pyridyl or 4-pyridyl, more preferably, R.sup.1 is
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl,
tert-butyl, n-pentyl, isopentyl, sec-pentyl, neopentyl,
1,1-diethoxyethyl, phenyl, cyclohexyl or 3-pyridyl. In the above
embodiments of a compound of Formula (I), R.sup.5 is preferably
substituted aryl, more preferably, substituted phenyl, most
preferably, phenyl substituted with one or more halogen atoms.
[0157] In some embodiments of a compound of Formulae (I), (V) or
(VI), R.sup.1 is methyl, ethyl, n-propyl, isopropyl, n-butyl,
isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, sec-pentyl,
neopentyl, 1,1-diethoxyethyl, phenyl, cyclohexyl, 2-pyridyl,
3-pyridyl or 4-pyridyl, R.sup.2 is hydrogen, methyl, ethyl,
n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, phenyl or
cyclohexyl, R.sup.3 is hydrogen and R.sup.4 is hydrogen. In other
embodiments of compounds of Formulae (I), (V) or (VI), R.sup.1 is
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl,
tert-butyl, n-pentyl, isopentyl, sec-pentyl, neopentyl,
1,1-diethoxyethyl, phenyl, cyclohexyl, 2-pyridyl, 3-pyridyl or
4-pyridyl, R.sup.2 is hydrogen, methyl, n-propyl, or isopropyl,
R.sup.3 is hydrogen and R.sup.4 is hydrogen. In still other
embodiments of compounds of Formulae (I), (V) or (VI), R.sup.1 is
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl,
tert-butyl, phenyl, cyclohexyl or 3-pyridyl, R.sup.2 is hydrogen,
methyl, n-propyl, or isopropyl, R.sup.3 is hydrogen and R.sup.4 is
hydrogen.
[0158] In still other embodiments of compounds of Formulae (I), (V)
or (VI), R.sup.1 is methyl, ethyl, n-propyl, isopropyl, n-butyl,
isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, sec-pentyl,
neopentyl, 1,1-diethoxyethyl, phenyl, cyclohexyl, 2-pyridyl,
3-pyridyl or 4-pyridyl, R.sup.2 is methyl, methoxycarbonyl,
ethoxycarbonyl, isopropoxycarbonyl or cyclohexyloxycarbonyl,
R.sup.3 is methyl and R.sup.4 is hydrogen.
[0159] In some embodiments of a compound of Formulae (I), (V) or
(VI), R.sup.1 is methyl, ethyl, n-propyl, isopropyl, n-butyl,
isobutyl, sec-butyl, tert-butyl, phenyl, cyclohexyl or 3-pyridyl,
R.sup.2 is hydrogen, R.sup.3 is hydrogen and R.sup.4 is hydrogen.
In other embodiments of a compound of Formulae (I), (V) or (VI),
R.sup.1 is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl,
sec-butyl, lert-butyl, phenyl, cyclohexyl or 3-pyridyl, R.sup.2 is
methyl, R.sup.3 is hydrogen and R.sup.4 is hydrogen. In yet other
embodiments of a compound of Formulae (I), (V) or (VI), R.sup.1 is
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl,
tert-butyl, phenyl, cyclohexyl or 3-pyridyl, R.sup.2 is n-propyl,
R.sup.3 is hydrogen and R.sup.4 is hydrogen. In still other
embodiments of a compound of Formulae (I), (V) or (VI), R.sup.1 is
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl,
tert-butyl, phenyl, cyclohexyl or 3-pyridyl, R.sup.2 is isopropyl,
R.sup.3 is hydrogen and R.sup.4 is hydrogen.
[0160] In some embodiments of a compound of Formula (I), R.sup.2
and R.sup.3 are different and the compound of Formula (I) is
substantially one diastereomer. In other embodiments of a compound
of Formula (I), the stereochemistry at the carbon to which R.sup.2
and R.sup.3 are attached is of the S-configuration and the compound
of Formula (I) is substantially one diastereomer. In still other
embodiments of a compound of Formula (I), the stereochemistry at
the carbon to which R.sup.2 and R.sup.3 are attached is of the
R-configuration, and the compound of Formula (I) is substantially
one diastereomer. In some embodiments of a compound of Formula (I),
R.sup.2 is C.sub.1-4 alkyl, R.sup.3 is hydrogen and the compound of
Formula (I) is substantially one diastereomer. In other embodiments
of a compound of Formula (I), R.sup.2 is C.sub.1-4 alkyl, R.sup.3
is hydrogen, the stereochemistry at the carbon to which R.sup.2 and
R.sup.3 are attached is of the S-configuration and the compound of
Formula (I) is substantially one diastereomer. In other embodiments
of a compound of Formula (I), R.sup.2 is C.sub.1-4 alkyl, R.sup.3
is hydrogen, the stereochemistry at the carbon to which R.sup.2 and
R.sup.3 are attached is of the R-configuration, and the compound of
Formula (I) is substantially one diastereomer.
[0161] In some embodiments of a compound of Formula (VI), R.sup.2
and R.sup.3 in the compound of Formula (VI) are different and the
compound of Formula (VI) is substantially one diastereomer. In
other embodiments of a compound of Formula (VI), the
stereochemistry at the carbon to which R.sup.2 and R.sup.3 are
attached is of the S-configuration and the compound of Formula (VI)
is substantially one diastereomer. In other embodiments of a
compound of Formula (VI), the stereochemistry at the carbon to
which R.sup.2 and R.sup.3 are attached is of the R-configuration
and the compound of Formula (VI) is substantially one diastereomer.
In still other embodiments of a compound of Formula (VI), R.sup.2
is C.sub.1-4 alkyl, R.sup.3 is hydrogen, and the compound of
Formula (VI) is substantially one diastereomer. In still other
embodiments of a compound of Formula (VI), R.sup.2 is C.sub.1-4
alkyl, R.sup.3 is hydrogen, the stereochemistry at the carbon to
which R.sup.2 and R.sup.3 are attached is of the S-configuration,
and the compound of Formula (VI) is substantially one diastereomer.
In still other embodiments of a compound of Formula (VI), R.sup.2
is C.sub.1-4 alkyl, R.sup.3 is hydrogen, the stereochemistry at the
carbon to which R.sup.2 and R.sup.3 are attached is of the
R-configuration, and the compound of Formula (VI) is substantially
one diastereomer.
[0162] In some embodiments of a compound of Formulae (I), (V) or
(VI), R.sup.1 is methyl, ethyl, n-propyl, isopropyl, n-butyl,
isobutyl, sec-butyl, tert-butyl, phenyl, cyclohexyl or 3-pyridyl,
R.sup.2 is methyl, R.sup.3 is hydrogen, R.sup.4 is hydrogen, the
stereochemistry at the carbon to which R.sup.2 and R.sup.3 are
attached is of the S-configuration and the compound of Formulae
(I), (V) or (VI) is substantially one diastereomer. In other
embodiments of a compound of Formulae (I), (V) or (VI), R.sup.1 is
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl,
teri-butyl, phenyl, cyclohexyl or 3-pyridyl, R.sup.2 is methyl,
R.sup.3 is hydrogen, R.sup.4 is hydrogen, the stereochemistry at
the carbon to which R.sup.2 and R.sup.3 are attached is of the
R-configuration and the compound of Formulae (I), (V) or (VI), is
substantially one diastereomer. In still other embodiments of a
compound of Formulae (I), (V) or (VI), R.sup.1 is methyl, ethyl,
n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl,
phenyl, cyclohexyl or 3-pyridyl, R.sup.2 is n-propyl, R.sup.3 is
hydrogen, R.sup.4 is hydrogen, the stereochemistry at the carbon to
which R.sup.2 and R.sup.3 are attached is of the S-configuration,
and the compound of Formulae (I), (V) or (VI), is substantially one
diastereomer. In still other embodiments of a compound of Formulae
(I), (V) or (VI), R.sup.1 is methyl, ethyl, n-propyl, isopropyl,
n-butyl, isobutyl, sec-butyl, tert-butyl, phenyl, cyclohexyl or
3-pyridyl, R.sup.2 is n-propyl, R.sup.3 is hydrogen, R.sup.4 is
hydrogen, the stereochemistry at the carbon to which R.sup.2 and
R.sup.3 are attached is of the R-configuration, and the compound of
Formulae (I), (V) or (VI) is substantially one diastereomer. In
still other embodiments of a compound of Formulae (I), (V) or (VI),
R.sup.1 is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl,
sec-butyl, tert-butyl, phenyl, cyclohexyl or 3-pyridyl, R.sup.2 is
isopropyl, R.sup.3 is hydrogen, R.sup.4 is hydrogen, the
stereochemistry at the carbon to which R.sup.2 and R.sup.3 are
attached is of the S-configuration and the compound of Formulae
(I), (V) or (VI) is substantially one diastereomer. In other
embodiments of a compound of Formulae (I), (V) or (VI), R.sup.1 is
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl,
tert-butyl, phenyl, cyclohexyl or 3-pyridyl, R.sup.2 is isopropyl,
R.sup.3 is hydrogen, R.sup.4 is hydrogen, the stereochemistry at
the carbon to which R.sup.2 and R.sup.3 are attached is of the
R-configuration and the compound of Formulae (I), (V) or (VI), is
substantially one diastereomer. In still other embodiments of a
compound of Formulae (I), (V) or (VI), R.sup.1 is isopropyl,
R.sup.2 is isopropyl, R.sup.3 is hydrogen, R.sup.4 is hydrogen, the
stereochemistry at the carbon to which R.sup.2 and R.sup.3 are
attached is of the S-configuration, and the compound of Formulae
(I), (V) or (VI) is substantially one diastereomer. In still other
embodiments of a compound of Formulae (I), (V) or (VI), R.sup.1 is
isopropyl, R.sup.2 is isopropyl, R.sup.3 is hydrogen, R.sup.4 is
hydrogen, the stereochemistry at the carbon to which R.sup.2 and
R.sup.3 are attached is of the R-configuration, and the compound of
Formulae (I), (V) or (VI) is substantially one diastereomer.
[0163] In another aspect, a compound of Formula (II) is
provided,
##STR00010##
[0164] wherein:
[0165] X is fluoro, chloro, bromo or iodo;
[0166] R.sup.2 and R.sup.3 are independently selected from the
group consisting of hydrogen, alkyl, substituted alkyl,
alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl,
arylalkyl, substituted arylalkyl, cycloalkyl, substituted
cycloalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl and
substituted heteroarylalkyl or optionally, R.sup.2 and R.sup.3
together with the carbon atom to which they are bonded form a
cycloalkyl, substituted cycloalkyl, cycloheteroalkyl or substituted
cycloheteroalkyl ring;
[0167] R.sup.4 is selected from the group consisting of hydrogen,
alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl,
substituted arylalkyl, aryldialkylsilyl, cycloalkyl, substituted
cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl,
heteroalkyl, substituted heteroalkyl, heteroaryl, substituted
heteroaryl, heteroarylalkyl, substituted heteroarylalkyl or
trialkylsilyl; and
[0168] R.sup.5 is selected from the group consisting of substituted
aryl, heteroaryl and substituted heteroaryl.
[0169] In some embodiments, R.sup.5 is selected from the group
consisting of [0170] 4-chlorophenyl; [0171] R-(4-chlorophenyl),
2-chlorophenyl), 4-fluorophenyl, thien-2-yl, 5-chlorothien-2-yl,
5-bromothien-2-yl and 5-methylthien-2-yl.
[0172] In other embodiments, the compound of Formula (II) has the
structure of Formula (VII):
##STR00011##
[0173] or pharmaceutically acceptable salts, hydrates or solvates
thereof;
[0174] wherein:
[0175] X, R.sup.2, R.sup.3 and R.sup.4 are as previously defined,
supra.
[0176] In still other embodiments, the compound of Formula (II) has
the structure of Formula (VIII):
##STR00012##
[0177] or pharmaceutically acceptable salts, hydrates or solvates
thereof;
[0178] wherein:
[0179] X, R.sup.2, R.sup.3 and R.sup.4 are as previously defined,
supra.
[0180] In some embodiments of a compound of Formulae (II), (VII) or
(VIII), X is chloro, bromo or iodo. In other embodiments of a
compound of Formulae (II), (VII) or (VIII), X is chloro.
[0181] In still other embodiments of a compound of Formulae (II),
(VII) or (VIII), R.sup.2 and R.sup.3 are independently selected
from the group consisting of hydrogen, alkyl, substituted alkyl,
alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl,
arylalkyl, substituted arylalkyl, carbamoyl, cycloalkyl,
substituted cycloalkyl, cycloalkoxycarbonyl, substituted
cycloalkoxycarbonyl, heteroaryl, substituted heteroaryl,
heteroarylalkyl and substituted heteroarylalkyl. In still other
embodiments of a compound of Formulae (II), (VII) or (VIII),
R.sup.2 and R.sup.3 are independently selected from the group
consisting of hydrogen, C.sub.1-4 alkyl, substituted C.sub.1-4
alkyl, C.sub.1-4 alkoxycarbonyl, C.sub.3-6 cycloalkyl, C.sub.3-6
cycloalkoxycarbonyl, phenyl, substituted phenyl, C.sub.7-9
phenylalkyl and pyridyl. In still other embodiments of a compound
of Formulae (II), (VII) or (VIII), R.sup.2 and R.sup.3 are
independently selected from the group consisting of hydrogen,
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl,
tert-butyl, cyclopentyl, cyclohexyl, methoxycarbonyl,
ethoxycarbonyl, isopropoxycarbonyl, cyclohexyloxycarbonyl, phenyl,
benzyl, phenethyl, 2-pyridyl, 3-pyridyl and 4-pyridyl. In still
other embodiments of a compound of Formulae (II), (VII) or (VIII),
R.sup.2 is hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl,
isobutyl, sec-butyl, phenyl or cyclohexyl and R.sup.3 is hydrogen.
In still other embodiments of a compound of Formulae (II), (VII) or
(VIII), R.sup.2 is methyl, methoxycarbonyl, ethoxycarbonyl,
isopropoxycarbonyl or cyclohexyloxycarbonyl and R.sup.3 is
methyl.
[0182] In still other embodiments of a compound of Formulae (II),
(VII) or (VIII), R.sup.2 and R.sup.3 together with the carbon atom
to which they are attached form a cycloalkyl, substituted
cycloalkyl, cycloheteroalkyl or substituted cycloheteroalkyl ring.
In still other embodiments of a compound of Formulae (II), (VII) or
(VIII), R.sup.2 and R.sup.3 together with the carbon atom to which
they are attached form a cyclobutyl, cyclopentyl or cyclohexyl
ring.
[0183] In still other embodiments of a compound of Formulae (II),
(VII) or (VIII), R.sup.4 is selected from the group consisting of
hydrogen, C.sub.1-6 alkyl, substituted C.sub.1-6 alkyl, C.sub.3-6
cycloalkyl, phenyl, substituted phenyl, C.sub.7-9 phenylalkyl,
substituted C.sub.7-9 phenylalkyl, trialkylsilyl and
aryldialkylsilyl. In still other embodiments of a compound of
Formulae (II), (VII) or (VIII), R.sup.4 is hydrogen, methyl, ethyl,
tert-butyl, allyl, benzyl, 4-methoxybenzyl, diphenylmethyl,
triphenylmethyl, trimethylsilyl, triethylsilyl, triisopropylsilyl,
tert-butyldimethylsilyl or phenyldimethylsilyl. In still other
embodiments of a compound of Formulae (II), (VII) or (VIII),
R.sup.4 is hydrogen, allyl, benzyl or trimethylsilyl.
[0184] In still other embodiments, of a compound of Formulae (II),
(VII) or (VIII), X is chloro, bromo or iodo, R.sup.2 and R.sup.3
are independently selected from the group consisting of hydrogen,
C.sub.1-4 alkyl, substituted C.sub.1-4 alkyl, C.sub.1-4
alkoxycarbonyl, C.sub.3-6 cycloalkyl, C.sub.3-6
cycloalkoxycarbonyl, phenyl, substituted phenyl, C.sub.7-9
phenylalkyl and pyridyl and R.sup.4 is selected from the group
consisting of hydrogen, C.sub.1-6 alkyl, substituted C.sub.1-6
alkyl, C.sub.3-6 cycloalkyl, phenyl, substituted phenyl, C.sub.7-9
phenylalkyl, substituted C.sub.7-9 phenylalkyl, trialkylsilyl and
aryldialkylsilyl.
[0185] In still other embodiments, of a compound of Formulae (II),
(VII) or (VIII), X is chloro, bromo or iodo, R.sup.2 is hydrogen,
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl,
tert-butyl, cyclopentyl, cyclohexyl, methoxycarbonyl,
ethoxycarbonyl, isopropoxycarbonyl, cyclohexyloxycarbonyl, phenyl,
benzyl, phenethyl, 2-pyridyl, 3-pyridyl or 4-pyridyl, R.sup.3 is
hydrogen and R.sup.4 is selected from the group consisting of
hydrogen, C.sub.1-6 alkyl, substituted C.sub.1-6 alkyl, C.sub.3-6
cycloalkyl, phenyl, substituted phenyl, C.sub.7-9 phenylalkyl,
substituted C.sub.7-9 phenylalkyl, trialkylsilyl and
aryldialkylsilyl.
[0186] In still other embodiments, of a compound of Formulae (II),
(VII) or (VIII), X is chloro, bromo or iodo, R.sup.2 is hydrogen,
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl,
cyclohexyl or phenyl, R.sup.3 is hydrogen and R.sup.4 is selected
from the group consisting of hydrogen, C.sub.1-6 alkyl, substituted
C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, phenyl, substituted phenyl,
C.sub.7-9 phenylalkyl, substituted C.sub.7-9 phenylalkyl,
trialkylsilyl and aryldialkylsilyl.
[0187] In still other embodiments, of a compound of Formulae (II),
(VII) or (VIII), X is chloro, bromo or iodo, R.sup.2 is methyl,
methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, or
cyclohexyloxycarbonyl, R.sup.3 is methyl and R.sup.4 is selected
from the group consisting of hydrogen, C.sub.1-6 alkyl, substituted
C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, phenyl, substituted phenyl,
C.sub.7-9 phenylalkyl, substituted C.sub.7-9 phenylalkyl,
trialkylsilyl and aryldialkylsilyl.
[0188] In still other embodiments, of a compound of Formulae (II),
(VII) or (VIII), X is chloro, bromo or iodo, R.sup.2 and R.sup.3
are independently selected from the group consisting of hydrogen,
C.sub.1-4 alkyl, substituted C.sub.1-4 alkyl, C.sub.1-4
alkoxycarbonyl, C.sub.3-6 cycloalkyl, C.sub.3-6
cycloalkoxycarbonyl, phenyl, substituted phenyl, C.sub.7-9
phenylalkyl and pyridyl and R.sup.4 is hydrogen, methyl, ethyl,
tert-butyl, allyl, benzyl, 4-methoxybenzyl, diphenylmethyl,
triphenylmethyl, trimethylsilyl, triethylsilyl, triisopropylsilyl,
tert-butyldimethylsilyl or phenyldimethylsilyl.
[0189] In still other embodiments, of a compound of Formulae (II),
(VII) or (VIII), X is chloro, bromo or iodo, R.sup.2 is hydrogen,
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl,
tert-butyl, cyclopentyl, cyclohexyl, methoxycarbonyl,
ethoxycarbonyl, isopropoxycarbonyl, cyclohexyloxycarbonyl, phenyl,
benzyl, phenethyl, 2-pyridyl, 3-pyridyl or 4-pyridyl, R.sup.3 is
hydrogen and R.sup.4 is hydrogen, methyl, ethyl, tert-butyl, allyl,
benzyl, 4-methoxybenzyl, diphenylmethyl, triphenylmethyl, trimethyl
silyl, triethylsilyl, triisopropylsilyl, tert-butyldimethylsilyl or
phenyldimethylsilyl.
[0190] In still other embodiments, of a compound of Formulae (II),
(VII) or (VIII), X is chloro, bromo or iodo, R.sup.2 is hydrogen,
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl,
cyclohexyl or phenyl, R.sup.3 is hydrogen and R.sup.4 is hydrogen,
methyl, ethyl, tert-butyl, allyl, benzyl, 4-methoxybenzyl,
diphenylmethyl, triphenylmethyl, trimethylsilyl, triethylsilyl,
triisopropylsilyl, tert-butyldimethylsilyl or
phenyldimethylsilyl.
[0191] In still other embodiments, of a compound of Formulae (II),
(VII) or (VIII), X is chloro, bromo or iodo, R.sup.2 is methyl,
methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, or
cyclohexyloxycarbonyl, R.sup.3 is methyl and R.sup.4 is hydrogen,
methyl, ethyl, tert-butyl, allyl, benzyl, 4-methoxybenzyl,
diphenylmethyl, triphenylmethyl, trimethylsilyl, triethylsilyl,
triisopropylsilyl, tert-butyldimethylsilyl or
phenyldimethylsilyl.
[0192] In still other embodiments, of a compound of Formulae (II),
(VII) or (VIII), X is chloro, bromo or iodo, R.sup.2 and R.sup.3
are independently selected from the group consisting of hydrogen,
C.sub.1-4 alkyl, substituted C.sub.1-4 alkyl, C.sub.1-4
alkoxycarbonyl, C.sub.3-6 cycloalkyl, C.sub.3-6
cycloalkoxycarbonyl, phenyl, substituted phenyl, C.sub.7-9
phenylalkyl and pyridyl and R.sup.4 is hydrogen, allyl, benzyl or
trimethylsilyl.
[0193] In still other embodiments, of a compound of Formulae (II),
(VII) or (VIII), X is chloro, bromo or iodo, R.sup.2 is hydrogen,
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl,
tert-butyl, cyclopentyl, cyclohexyl, methoxycarbonyl,
ethoxycarbonyl, isopropoxycarbonyl, cyclohexyloxycarbonyl, phenyl,
benzyl, phenethyl, 2-pyridyl, 3-pyridyl or 4-pyridyl, R.sup.3 is
hydrogen and R.sup.4 is hydrogen, allyl, benzyl or
trimethylsilyl.
[0194] In still other embodiments, of a compound of Formulae (II),
(VII) or (VIII), X is chloro, bromo or iodo, R.sup.2 is hydrogen,
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl,
cyclohexyl or phenyl, R.sup.3 is hydrogen and R.sup.4 is hydrogen,
allyl, benzyl or trimethyl silyl.
[0195] In still other embodiments, of a compound of Formulae (II),
(VII) or (VIII), X is chloro, bromo or iodo, R.sup.2 is methyl,
methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, or
cyclohexyloxycarbonyl, R.sup.3 is methyl and R.sup.4 is hydrogen,
allyl, benzyl or trimethylsilyl.
[0196] In still other embodiments, of a compound of Formulae (II),
(VII) or (VIII), X is chloro, bromo or iodo, R.sup.2 and R.sup.3
are independently selected from the group consisting of hydrogen,
C.sub.1-4 alkyl, substituted C.sub.1-4 alkyl, C.sub.1-4
alkoxycarbonyl, C.sub.3-6 cycloalkyl, C.sub.3-6
cycloalkoxycarbonyl, phenyl, substituted phenyl, C.sub.7-9
phenylalkyl and pyridyl and R.sup.4 is hydrogen.
[0197] In still other embodiments, of a compound of Formulae (II),
(VII) or (VIII), X is chloro, bromo or iodo, R.sup.2 is hydrogen,
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl,
tert-butyl, cyclopentyl, cyclohexyl, methoxycarbonyl,
ethoxycarbonyl, isopropoxycarbonyl, cyclohexyloxycarbonyl, phenyl,
benzyl, phenethyl, 2-pyridyl, 3-pyridyl or 4-pyridyl, R.sup.3 is
hydrogen and R.sup.4 is hydrogen.
[0198] In still other embodiments, of a compound of Formulae (II),
(VII) or (VIII), X is chloro, bromo or iodo, R.sup.2 is hydrogen,
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl,
cyclohexyl or phenyl, R.sup.3 is hydrogen and R.sup.4 is
hydrogen.
[0199] In still other embodiments, of a compound of Formulae (II),
(VII) or (VIII), X is chloro, bromo or iodo, R.sup.2 is methyl,
methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, or
cyclohexyloxycarbonyl, R.sup.3 is methyl and R.sup.4 is
hydrogen.
[0200] In still other embodiments of a compound of Formulae (II),
(VII) or (VIII), X is chloro, bromo or iodo, R.sup.2 is hydrogen,
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl,
phenyl or cyclohexyl, R.sup.3 is hydrogen and R.sup.4 is hydrogen,
allyl, benzyl or trimethylsilyl. In other embodiments of a compound
of Formulae (II), (VII) or (VIII), X is chloro, bromo or iodo,
R.sup.2 is hydrogen, methyl, n-propyl, or isopropyl, R.sup.3 is
hydrogen and R.sup.4 is hydrogen, allyl, benzyl or trimethylsilyl.
In still other embodiments of a compound of Formulae (II), (VII) or
(VIII), X is chloro, R.sup.2 is hydrogen, methyl, n-propyl, or
isopropyl, R.sup.3 is hydrogen and R.sup.4 is hydrogen, allyl,
benzyl or trimethylsilyl.
[0201] In still other embodiments of a compound of Formulae (II),
(VII) or (VIII), X is chloro, bromo or iodo, R.sup.2 is methyl,
methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl or
cyclohexyloxycarbonyl R.sup.3 is methyl and R.sup.4 is hydrogen,
allyl, benzyl or trimethylsilyl.
[0202] Compounds of Formulae (II), (VII) and (VIII) are useful
intermediates in the synthesis of compounds of Formulae (I), (VI)
and (VII), as described in detail in Section 4.3 below.
4.3 Synthesis
[0203] The compounds disclosed herein may be obtained via the
synthetic methods illustrated in Schemes 1-10. Those of ordinary
skill in the art will appreciate that a preferred synthetic route
to the disclosed compounds consists of attaching promoieties to
baclofen or baclofen analogs. Numerous methods have been described
in the art for the synthesis of baclofen and baclofen analogs
(e.g., Keberle et al., U.S. Pat. No. 3,471,548; Keberle et al.,
U.S. Pat. No. 3,634,428; Krogsgaard-Larsen, Med. Res. Rev. 1988, 8,
27-56; Berthelot et al., J. Med. Chem. 1987, 30, 743-746; Berthelot
et al., J. Med. Chem. 1991, 34, 2557-2560; Debaert et al., European
Patent No. EP 0463969 B1). Methods for preparation of R-baclofen
have also been described in the art (e.g., Witczuk et al., Pol. J.
Pharmacol. Pharm. 1980, 32, 187-196; Chenevert et al., Tetrahedron
Lett. 1991, 32, 4249-4250; Herdeis et al., Tetrahedron Asymmetry
1992, 3, 1213-1221; Hubmann et al., German Patent Application No.
DE 422-4342 A1; Yoshifuji et al., Chem. Pharm. Bull. 1995, 43,
1302-1306; Wildervanck et al., U.S. Pat. No. 6,051,734; Thakur et
al., Tetrahedron Asymmetry 2003, 14, 581-586). Other prodrug (or
related) derivatives of baclofen have been described in the art
(e.g., Kaplan et al., U.S. Pat. No. 4,094,992; Mazaki et al., Jpn.
Kokai Tokkyo Koho JP 01319466 A2; Castagnoli et al., International
Publication No. WO98/22110; Guillon et al. Pharm. Pharmacol.
Commun. 1999, 5, 243-247; Leisen et al., Pharm. Res. 2003, 20,
772-778; Mills, U.S. Pat. No. 5,773,592; Mills, U.S. Patent Appl.
Publ. 2003/0228644). General synthetic methods useful in the
synthesis of the compounds described herein are available in the
art (e.g., Green et al., "Protective Groups in Organic Chemistry",
(Wiley, 2.sup.nd ed. 1991); Harrison et al., "Compendium of
Synthetic Organic Methods", Vols. 1-8 (John Wiley and Sons,
1971-1996; Larock "Comprehensive Organic Transformations," VCH
Publishers, 1989; and Paquette, "Encyclopedia of Reagents for
Organic Synthesis," John Wiley & Sons, 1995).
[0204] Accordingly, starting materials useful for preparing
compounds and intermediates thereof, and/or practicing methods
described herein are commercially available or can be prepared by
well-known synthetic methods. Other methods for synthesis of the
prodrugs described herein are either described in the art or will
be readily apparent to the skilled artisan in view of the
references provided above and may be used to synthesize the
compounds described herein. Accordingly, the methods presented in
the Schemes herein are illustrative rather than comprehensive.
[0205] Intermediate (XI) useful in the preparation of 1-haloalkyl
carbamates of Formula (II) may be generated according to reactions
detailed in Scheme 1.
##STR00013##
[0206] The amino group of (IV) is protected under standard
conditions with a protecting group (Pg) to afford compound (IX).
The carboxylic acid moiety in (IX) is esterified to yield compound
(X), either via alkylation with R.sup.4--Y, where Y is halide,
--OSO.sub.2R' (R' is alkyl, substituted alkyl, aryl or substituted
aryl) or any other suitable leaving group or via condensation with
alcohol R.sup.4--OH under standard acylation conditions (e.g., in
the presence of a coupling agent such as a carbodiimide, via an
acyl halide, acid anhydride or other activated ester intermediate).
Removal of the protecting group from (X) under standard
deprotection conditions affords compound (XI). Preferably, the
protecting group Pg is removable under acidic conditions and
compound (XI) is isolated as a salt, which is stabilized against
lactam formation relative to the corresponding free base.
tert-Butoxycarbonyl (i.e., Boc) is one preferred protecting group,
and may be removed with HCl to afford (XI) as a hydrochloride
salt.
[0207] In some embodiments, the hydrochloride salt of (XI) is
prepared directly from (IV) by treatment with an excess of thionyl
chloride or hydrogen chloride gas and alcohol R.sup.4--OH (Scheme
2). Typical ratios of (IV) to thionyl chloride from between about
1:1 and about 1:20, and ratios of (IV) to alcohol from between
about 1:1 and about 1:20 may be used. The reaction may be performed
at temperatures between about -20.degree. C. and about 25.degree.
C. The alcohol may be used as a solvent for the reaction under
conditions where R.sup.4--OH is a liquid. Alternatively, the
reaction may be performed in a suitable solvent, such as
dichloromethane, dichloroethane, chloroform, toluene,
dimethylformamide, dimethylacetamide, N-methylpyrrolidinone,
pyridine or combinations thereof. Preferred alcohols R.sup.4--OH
for this reaction include arylalkyl, substituted arylalkyl and
allylic alcohols. Allyl alcohol and benzyl alcohol are particularly
preferred.
##STR00014##
[0208] In some embodiments, a compound of Formula (II) is prepared
by acylation of (XI) with compound (XII) (see Scheme 3), where X is
halide and Z is a leaving group (e.g., halide, p-nitrophenolate,
imidazolyl, etc.). In other embodiments, X is Cl, Br or I and Z is
Cl. In yet other embodiments, X and Z are both Cl. The acylation
reaction may be performed in the presence of a inorganic base or an
organic base (e.g., tertiary amine bases, such as triethylamine,
tributylamine, diisopropylethylamine, dimethylisopropylamine,
N-methylmorpholine, N-methylpyrrolidine, N-methylpiperidine,
pyridine, 2-methylpyridine, 2,6-dimethylpyridine,
4-dimethylaminopyridine, 1,4-diazabicyclo[2.2.2]octane,
1,8-diazabicyclo[5.4.0]undec-7-ene or
1,5-diazabicyclo[4.3.0]undec-7-ene or combinations thereof) or
combinations thereof. Suitable solvents for acylation include, but
are not limited to, dichloromethane, dichloroethane, chloroform,
toluene, dimethylformamide, dimethylacetamide,
N-methylpyrrolidinone, dimethyl sulfoxide, pyridine, ethyl acetate,
isopropyl acetate, acetonitrile, acetone, 2-butanone, methyl
tert-butyl ether or combinations thereof. Alternatively, biphasic
solvent mixtures comprising water and including one or more of
dichloromethane, dichloroethane, chloroform, toluene, ethyl
acetate, isopropyl acetate or methyl tert-butyl ether, may be
utilized. Typical temperatures for performing this reaction are
between about -20.degree. C. and about 50.degree. C., more
preferably between about -20.degree. C. and about 25.degree. C.
##STR00015##
[0209] In other embodiments, a compound of Formula (II), where
R.sup.4 is trialkylsilyl or aryldialkylsilyl, may be prepared
directly from compound (IV) by silylation (e.g., using a silyl
halide or silylamide reagent) followed by acylation of the
resulting intermediate with compound (XII) (see Scheme 4). Suitable
solvents for performing this reaction include, but are not limited
to, dichloromethane, dichloroethane, chloroform, toluene, pyridine,
acetonitrile or combinations thereof. Suitable bases for performing
this reaction include but are not limited to, triethylamine,
tributylamine, diisopropylethylamine, dimethylisopropylamine,
N-methylmorpholine, N-methylpyrrolidine, N-methylpiperidine,
pyridine, 2-methylpyridine, 2,6-dimethylpyridine,
4-dimethylaminopyridine, 1,4-diazabicyclo[2.2.2]octane,
1,8-diazabicyclo[5.4.0]undec-7-ene,
1,5-diazabicyclo[4.3.0]undec-7-ene or combinations thereof. Typical
temperatures for performing this reaction are between about
-78.degree. C. and about 50.degree. C., more preferably between
about -20.degree. C. and about 25.degree. C.
##STR00016##
[0210] In still other embodiments, 1-acyloxylalkyl carbamates of
Formula (I) are prepared from compounds of Formula (II) by
treatment with carboxylic acids of Formula (III) in the presence of
an organic or inorganic base, or other metal salt, as illustrated
in Scheme 5.
##STR00017##
[0211] Those of skill in the art will appreciate that the following
embodiments, infra, refer to compounds of Formulae (I), (II) and
(III). In some embodiments, the ratio of the compound of Formula
(II) to the compound of Formula (III) is between about 1:1 and
1:20. In other embodiments, the ratio of the compound of Formula
(II) to the compound of Formula (III) is between about 1:1 and 1:5.
In still other embodiments, the ratio of the compound of Formula
(II) to the compound of Formula (III) is about 1:1.
[0212] In some embodiments, the compounds of Formulae (II) and
(III) and the metal salt are contacted with a solvent. In other
embodiments, the ratio of the compound of Formula (II) to the
compound of Formula (III) is between about 1:1 and 1:20. In still
other embodiments, the ratio of the compound of Formula (II) to the
compound of Formula (III) is between about 1:1 and 1:5. In still
other embodiments, the ratio of the compound of Formula (II) to the
compound of Formula (III) is about 1:1. In some embodiments, the
solvent is dichloromethane, dichloroethane, chloroform, toluene,
dimethylformamide, dimethylacetamide, N-methylpyrrolidinone,
dimethyl sulfoxide, pyridine, ethyl acetate, acetonitrile, acetone,
2-butanone, methyl tert-butyl ether, methanol, ethanol,
isopropanol, tert-butanol, water, hexamethylphosphoramide or
combinations thereof. In other embodiments, the metal is Ag, Hg,
Na, K, Li, Cs, Ca, Mg or Zn.
[0213] In some embodiments, the compounds of Formulae (II) and
(III) and the organic base are contacted with a solvent. In other
embodiments, the ratio of the compound of Formula (II) to the
compound of Formula (III) is between about 1:1 and 1:20. In still
other embodiments, the ratio of the compound of Formula (II) to the
compound of Formula (III) is between about 1:15 and 1:20. In still
other embodiments, the ratio of the compound of Formula (II) to the
compound of Formula (III) is about 1:10. In still other
embodiments, the ratio of the compound of Formula (II) to the
compound of Formula (III) is between about 1:1 and 1:5. In still
other embodiments, the ratio of the compound of Formula (II) to the
compound of Formula (III) is about 1:1. In some embodiments, the
solvent is dichloromethane, dichloroethane, chloroform, toluene,
dimethylformamide, dimethylacetamide, N-methylpyrrolidinone,
dimethyl sulfoxide, pyridine, ethyl acetate, acetonitrile, acetone,
2-butanone, methyl tert-butyl ether, methanol, ethanol,
isopropanol, tert-butanol, water, hexamethylphosphoramide or
combinations thereof. In other embodiments, the organic base is
triethylamine, tributylamine, diisopropylethylamine,
dimethylisopropylamine, N-methylmorpholine, N-methylpyrrolidine,
N-methylpiperidine, pyridine, 2-methylpyridine,
2,6-dimethylpyridine, 4-dimethylaminopyridine,
1,4-diazabicyclo[2.2.2]octane, 1,8-diazabicyclo[5.4.0]undec-7-ene,
1,5-diazabicyclo[4.3.0]undec-7-ene or combinations thereof.
[0214] In some embodiments, the compound of Formula (III) is a
liquid under the conditions of said contacting, the compound of
Formula (III) further serving as a solvent for the reaction with
the compound of Formula (II). In other embodiments, the compound of
Formula (III) is acetic acid, methoxyacetic acid, ethoxyacetic
acid, propionic acid, butyric acid, isobutyric acid, pivalic acid,
valeric acid, isovaleric acid, 2-methylbutyric acid,
cyclobutanecarboxylic acid, cyclopentanecarboxylic acid or
cyclohexanecarboxylic acid.
[0215] In some embodiments, the compound of Formula (II), the
compound of Formula (III) and the metal salt are contacted at a
temperature between about -25.degree. C. and about 120.degree. C.
In other embodiments, the temperature is between about 0.degree. C.
and about 25.degree. C.
[0216] In still some other embodiments, the compound of Formula
(II), the compound of Formula (III) and the organic base are
contacted at a temperature between about -25.degree. C. and about
120.degree. C. In other embodiments, the temperature is between
about 0.degree. C. and about 25.degree. C.
[0217] In some embodiments, the compound of Formula (II), the
compound of Formula (III) and the organic base are contacted with a
catalytic amount of an iodide salt. In still other embodiments, the
iodide salt is sodium iodide, potassium iodide, tetramethylammonium
iodide, tetraethylammonium iodide or tetrabutylammonium iodide.
[0218] In some embodiments, R.sup.4 is a carboxylic acid protecting
group that can be removed under mild conditions to provide a
compound of Formula (I) where R.sup.4 is hydrogen. Carboxylic acid
protecting groups removable via mild acidic hydrolysis, fluoride
ion-promoted hydrolysis, catalytic hydrogenolysis, transfer
hydrogenolysis, or other transition metal-mediated deprotection
reactions are preferred. In some embodiments, R.sup.4 is
trimethylsilyl, allyl or benzyl.
[0219] In still other embodiments compounds of Formula (I) are
prepared as illustrated in Scheme 6.
##STR00018##
[0220] Chloroformate (XIII) is treated with an aromatic leaving
group such as p-nitrophenol in the presence of base to provide
p-nitrophenylcarbonate (XIV). Halide interchange provides iodide
(XV), which is reacted with a metal or tetraalkylammonium salt of a
carboxylic acid to afford compound (XVI). Treatment of (XVI) with
baclofen analog derivative (XI), optionally, in the presence of
trimethylsilyl chloride, affords a compound of Formula (I). Methods
for making related acyloxyalkyl carbamate compounds have been
described in the art (Alexander, U.S. Pat. No. 4,760,057;
Alexander, U.S. Pat. No. 4,916,230; Alexander, U.S. Pat. No.
5,466,811; Alexander, U.S. Pat. No. 5,684,018).
[0221] Another method for synthesis of compounds of Formula (I)
proceeds via carbonylation of baclofen analog derivative (XI) to an
intermediate carbamic acid species, which is captured by an in situ
alkylation reaction in an adaptation of methods disclosed in the
art (Butcher, Synlett 1994, 825-6; Ferres et al., U.S. Pat. No.
4,036,829). Carbon dioxide gas is bubbled into a solution
containing (XI) and a base (e.g., Cs.sub.2CO.sub.3,
Ag.sub.2CO.sub.3 or AgO) in a solvent such as DMF or NMP. The
activated halide is added, optionally, in the presence of iodide
ion as a catalyst, and the carbonylation continued until the
reaction is completed. This method is illustrated in Scheme 7 for
the preparation of compounds of Formula (I) from halide (XVII).
##STR00019##
[0222] Yet another method for synthesis of compounds of Formula (I)
relies upon oxidation of ketocarbamate derivatives of baclofen and
baclofen analogs (e.g., Gallop et al., U.S. Patent Appl. Publ.
2003/0171303; and Bhat et al., U.S. patent application Ser. No.
______ entitled "Methods for Synthesis of Acyloxyalkyl Compounds").
As illustrated in Scheme 8, oxidation of ketocarbamate (XVIII)
affords a compound of Formula (I). Methods for synthesis of
compounds of Formula (XVIII) are disclosed in the pending
applications, supra. Typical oxidants include those, which have
been successfully used in Baeyer-Villager oxidations of ketones to
esters or lactones (Strukul, Angnew. Chem. Int. Ed. 1998, 37, 1198;
Renz et al., Eur. J. Org. Chem. 1999, 737; Beller et al., in
"Transition Metals in Organic Synthesis" Chapter 2, Wiley VCH;
Stewart, Current Organic Chemistry, 1998, 2, 195; Kayser et al.,
Synlett 1999, 1, 153). The use of anhydrous oxidants may be
beneficial since prodrugs (I) may be labile. Thus, performing the
oxidation under anhydrous reaction conditions may avoid hydrolysis
of the reactive products.
##STR00020##
[0223] Preferably, the oxidation is performed in the liquid phase,
more preferably, in the presence of a solvent. Choosing a solvent
for oxidation of a compound of Formula (XVIII) is well within the
ambit of one of skill in the art. Generally, a useful solvent will
dissolve, at least partially, both the oxidant and the compound of
Formula (XVIII) and will be inert to the reaction conditions.
Preferred solvents are anhydrous and include, but are not limited
to, dichloromethane, dichloroethane, chloroform, ethyl acetate,
isopropyl acetate, toluene, chlorobenzene, xylene, acetonitrile,
diethyl ether, methyl tert-butyl ether, acetic acid, cyclohexane
and hexanes. Mixtures of the above solvents may also be used in the
oxidation of a compound of Formula (XVIII) to a compound of Formula
(I).
[0224] In some embodiments, the anhydrous oxidant is an anhydrous
peroxyacid generated in situ by reaction of the urea-hydrogen
peroxide complex (4) ("UHP") with a carboxylic acid anhydride. In
other embodiments, the anhydrous oxidant is an anhydrous
peroxysulfonic acid generated in situ by reaction of the
urea-hydrogen peroxide complex (4) with a sulfonic acid anhydride.
The UHP complex serves as a source of anhydrous hydrogen peroxide
and has been used in a variety of oxidative transformations in
anhydrous organic solvents (Cooper et al., Synlett. 1990, 533-535;
Balicki et al., Synth. Commun. 1993, 23, 3149; Astudillo et al.,
Heterocycles 1993, 36, 1075-1080; Varma et al., Organic Lett. 1999,
1, 189-191). However, other suitable sources of anhydrous hydrogen
peroxide may also be used in the reaction instead of the
UHP-complex (e.g., the 1,4-diazabicyclo[2.2.2]octane-hydrogen
peroxide complex).
[0225] A useful oxidant is anhydrous peroxytrifluoroacetic acid,
generated in situ by reacting the UHP-complex with trifluoroacetic
anhydride (Cooper et al., Synlett. 1990, 533-535; Benjamin, et al.,
J. Am. Chem. Soc. 2002, 124, 827-833). Anhydrous peroxycarboxylic
acids (XX) may generally be prepared by treating carboxylic acid
anhydrides with anhydrous hydrogen peroxide, more preferably, with
the UHP-complex (4). Similarly, anhydrous peroxysulfonic acids
(XXII) may be prepared by reacting sulfonic acid anhydrides (XXI)
with anhydrous hydrogen peroxide, preferably, with the UHP-complex
(4). The preparation of anhydrous peroxycarboxylic acids (XX) and
the peroxysulfonic acids (XXII) is illustrated in Scheme 9.
##STR00021##
[0226] The UHP-complex (4) and a carboxylic acid anhydride (XIX) or
a sulfonic acid anhydride (XXI) are reacted in dichloromethane or
other suitable solvent at temperatures ranging from about
-25.degree. C. to about 100.degree. C. to generate the anhydrous
peroxyacids. The peroxyacids may be generated first and
subsequently reacted with the ketocarbamate (XVIII). In some
embodiments, a carboxylic acid anhydride is added to a stirred
suspension or solution containing the UHP-complex and (XVIII) to
generate the peroxycarboxylic acid, which reacts in situ with
(XVIII) to give compound (I). In other embodiments, the molar ratio
of UHP-complex and the acid anhydride is about 6:1. In still other
embodiments, the molar ratio of UHP-complex and acid anhydride
(XIX) is between about 5:1 and about 1:1. In yet other embodiments,
the molar ratio of UHP-complex and acid anhydride (XIX) is between
about 2:1 and about 1:1.
[0227] In some embodiments, the molar ratio of the peroxyacid
oxidant to the compound of Formula (XVIII) is between about 8:1 and
about 1:1. In other embodiments, the molar ratio of the peroxyacid
oxidant to the compound of Formula (XVIII) is between about 4:1 and
about 1:1. In yet other embodiments, the molar ratio of the
peroxyacid oxidant to the compound of Formula (XVIII) is between
about 2:1 and about 1:1. Preferably, when the oxidant is
peroxytrifluoroacetic acid or another substituted peroxyacetic
acid, the molar ratio of the peroxyacid oxidant to the compound of
Formula (XVIII) is about 2:1.
[0228] Further, the use of additives in the oxidation of a compound
of Formula (XVIII) to a compound of Formula (I) is also
contemplated. While not wishing to be bound by theory, additives
may either catalyze the reaction or stabilize the final product or
both. In some embodiments, a Lewis acid or a protic acid or any
combination of Lewis acid or protic acid may be used in the
oxidation of a compound of Formula (XVIII) (preferably, in the
presence of a solvent). Lewis acids include, but are not limited
to, BF.sub.3, SeO.sub.2, MeReO.sub.3, MnO.sub.2, SnCl.sub.4,
Sc(OTf).sub.3, Ti(O-iPr).sub.4, Al.sub.2O.sub.3 and
Fe.sub.2O.sub.3. Protic acids include, but are not limited to,
trifluoroacetic acid, acetic acid, p-toluenesulfonic acid,
methanesulfonic acid, trifluoromethanesulfonic acid, hydrochloric
acid and sulfuric acid. While not wishing to be bound by theory,
the Lewis acid and/or protic acid may catalyze oxidation by
increasing the electrophilicity of the carbonyl group in Formula
(XVIII).
[0229] In other embodiments, the oxidation may be conducted in the
presence of an anhydrous base. While not wishing to be bound by
theory, the base may stabilize acid sensitive products by reacting
with acidic by-products formed during oxidation.
[0230] Generally, the temperature of the reaction may be readily
optimized by methods known to those of ordinary skill in the art.
Preferably, the oxidation of a compound of Formula (XVIII) is
carried out at a temperature between about -25.degree. C. and about
100.degree. C. (more preferably, between about 0.degree. C. and
about 25.degree. C.).
[0231] An advantageous feature of this method of synthesis of
compounds of Formula (I) is that oxidation of ketocarbamate
derivatives (XVIII) proceeds stereospecifically, with retention of
configuration at the carbon atom initially adjacent to the carbonyl
group in ketone (XVIII). This may be exploited in a stereoselective
synthesis of prodrug derivatives. For example, the chiral
R-baclofen prodrug
4-{[(1S)-isobutanoyloxyethoxy]carbonylamino}-(3R)-(4-chlorophenyl)-butano-
ic acid (34) may be synthesized as a single diastereomer by
stereoselective oxidation of
4-{[(1S)-isobutanoylethoxy]carbonylamino}-(3R)-(4-chlorophenyl)-butanoic
acid (35) as described in Example 30 of Section 5 below.
Acyloxyalkyl prodrugs of other baclofen analogs may be amenable to
synthesis from the appropriate ketocarbamate derivatives via
Baeyer-Villiger type oxidation, provided that they do not contain
chemical functionality susceptible to decomposition or other
transformation under conditions of the reaction.
[0232] Another method for synthesis of compounds of Formula (I),
illustrated in Scheme 10, relies upon reaction of compounds of
Formulae (IV) or (XI) with a 1-(acyloxy)-alkyl
N-hydroxysuccinimidyl carbonate compound of Formula (XXIII), as
described in the co-pending application Gallop et al., U.S.
Provisional Patent Application Ser. No. ______ entitled "Methods
for Synthesis of Acyloxyalkyl Carbamate Prodrugs," filed Aug. 13,
2004).
##STR00022##
wherein R.sup.9 and R.sup.10 are independently hydrogen, acylamino,
acyloxy, alkoxycarbonylamino, alkoxycarbonyloxy, alkyl, substituted
alkyl, alkoxy, substituted alkoxy, aryl, substituted aryl,
arylalkyl, carbamoyloxy, dialkylamino, heteroaryl, hydroxy,
sulfonamido, or optionally, R.sup.9 and R.sup.10 together with the
atoms to which they are attached form a substituted cycloalkyl,
substituted cycloheteroalkyl or substituted aryl ring and R.sup.1
to R.sup.5 are as described in Section 4.2.
[0233] In some embodiments of the method described in Scheme 10 for
synthesizing a compound of Formula (I), R.sup.2 and R.sup.3 in the
compound of Formula (XXIII) are different, such that the carbon
atom to which these substituents are attached is a stereogenic
center.
[0234] In some embodiments of the method described in Scheme 10 for
synthesizing a compound of Formula (I), R.sup.9 and R.sup.10 in the
compound of Formula (XXIII) are each benzoyloxy, the
stereochemistry at the carbon to which R.sup.9 is attached is of
the Reconfiguration, and the stereochemistry at the carbon to which
R.sup.10 is attached is of the R-configuration. In other
embodiments of the method described in Scheme 10 for synthesizing a
compound of Formula (I), R.sup.9 and R.sup.10 in the compound of
Formula (XXIII) are each benzoyloxy, the stereochemistry at the
carbon to which R.sup.9 is attached is of the S-configuration and
the stereochemistry at the carbon to which R.sup.10 is attached is
of the S-configuration.
[0235] In some embodiments of the methods for synthesizing a
compound of Formula (I), R.sup.2 and R.sup.3 in the compound of
Formula (I) are different and the compound of Formula (I) is
substantially one diastereomer. In some embodiments of the method
described in Scheme 10 for synthesizing a compound of Formula (I),
R.sup.1 is isopropyl, R.sup.2 is isopropyl, R.sup.3 is hydrogen,
the stereochemistry at the carbon to which R.sup.2 and R.sup.3 are
attached is of the S-configuration and the compound of Formula (I)
is substantially one diastereomer. In still other embodiments of
the method of Scheme 10 for synthesizing a compound of Formula (I),
R.sup.1 is isopropyl, R.sup.2 is isopropyl, R.sup.3 is hydrogen,
the stereochemistry at the carbon to which R.sup.2 and R.sup.3 are
attached is of the R-configuration, and the compound of Formula (I)
is substantially one diastereomer.
[0236] In some embodiments of the method of Scheme 10 for
synthesizing a compound of Formula (I), R.sup.1 is C.sub.1-6 alkyl,
R.sup.2 is hydrogen or C.sub.1-4 alkyl, R.sup.3 is hydrogen,
R.sup.4 is hydrogen, R.sup.5 is 4-chlorophenyl, R.sup.9 and
R.sup.10 are each benzoyloxy, and the stereochemistry at the carbon
to which R.sup.5 is attached is of the R-configuration. In still
other embodiments of the method of Scheme 10 for synthesizing a
compound of Formula (I), R.sup.1 is isopropyl, R.sup.2 is
isopropyl, R.sup.3 is hydrogen, R.sup.4 is hydrogen, R.sup.5 is
4-chlorophenyl, R.sup.9 and R.sup.10 are each benzoyloxy, and the
stereochemistry at the carbon to which R.sup.5 is attached is of
the R-configuration.
[0237] In still other embodiments of the method of Scheme 10 for
synthesizing a compound of Formula (I), R.sup.1 is isopropyl,
R.sup.2 is isopropyl, R.sup.3 is hydrogen, R.sup.4 is hydrogen,
R.sup.5 is 4-chlorophenyl, R.sup.9 and R.sup.10 are each
benzoyloxy, the stereochemistry at the carbon to which R.sup.2 and
R.sup.3 are attached is of the S-configuration, the stereochemistry
at the carbon to which R.sup.5 is attached is of the
R-configuration, the stereochemistry at the carbon to which R.sup.9
is attached is of the R-configuration, and the stereochemistry at
the carbon to which R.sup.10 is attached is of the R-configuration.
In still other embodiments of the method of Scheme 10 for
synthesizing a compound of Formula (I), R.sup.1 is isopropyl,
R.sup.2 is isopropyl, R.sup.3 is hydrogen, R.sup.4 is hydrogen,
R.sup.5 is 4-chlorophenyl, R.sup.9 and R.sup.10 are each
benzoyloxy, the stereochemistry at the carbon to which R.sup.2 and
R.sup.3 are attached is of the R-configuration, the stereochemistry
at the carbon to which R.sup.5 is attached is of the
R-configuration, the stereochemistry at the carbon to which R.sup.9
is attached is of the S-configuration and the stereochemistry at
the carbon to which R.sup.10 is attached is of the
S-configuration.
[0238] In some embodiments, the method of Scheme 10 is carried out
in a solvent. Useful solvent include, but are not limited to,
acetone, acetonitrile, dichloromethane, dichloroethane, chloroform,
toluene, tetrahydrofuran, dioxane, dimethylformamide,
dimethylacetamide, N-methylpyrrolidinone, dimethyl sulfoxide,
pyridine, ethyl acetate, methyl tert-butyl ether, methanol,
ethanol, isopropanol, tert-butanol, water or combinations thereof.
Preferably, the solvent is acetone, acetonitrile, dichloromethane,
toluene, tetrahydrofuran, pyridine, methyl tert-butyl ether,
methanol, ethanol, isopropanol, water, or combinations thereof. In
some embodiments, the solvent is a mixture of acetonitrile and
water. In other embodiments, the solvent is a mixture of
acetonitrile and water, with a volume ratio of acetonitrile to
water from about 1:5 to about 5:1. In still other embodiments, the
solvent is a mixture of methyl tert-butyl ether and water. In still
other embodiments, the solvent is a mixture of methyl tert-butyl
ether and water, with a volume ratio of methyl tert-butyl ether to
water from about 20:1 to about 2:1. In still other embodiments, the
solvent is a mixture of methyl tert-butyl ether and water, wherein
the methyl tert-butyl ether contains from about 10% to about 50%
acetone by volume. In still other embodiments, the solvent is
dichloromethane, water or a combination thereof. In still other
embodiments, the solvent is a biphasic mixture of dichloromethane
and water. In still other embodiments, the solvent is a biphasic
mixture of dichloromethane and water containing from about 0.001
equivalents to about 0.1 equivalents of a phase transfer catalyst.
Preferably, the phase transfer catalyst is a tetraalkylammonium
salt, more preferably, the phase transfer catalyst is a
tetrabutylammonium salt.
[0239] The method of Scheme 10 is preferably carried out a
temperature between about -20.degree. C. and about 40.degree. C. In
some embodiments, the temperature is between about -20.degree. C.
and about 25.degree. C. In other embodiments, the temperature is
between about 0.degree. C. and about 25.degree. C. In still other
embodiments, the temperature is between about 25.degree. C. and
about 40.degree. C.
[0240] In some embodiments of the method of Scheme 10, the reaction
is performed in the absence of a base.
[0241] In other embodiments of the method of Scheme 10, the
reaction is performed in the presence of an inorganic base. In some
embodiments, the reaction is performed in the presence of an alkali
metal bicarbonate or alkali metal carbonate salt. In other
embodiments, the reaction is performed in the presence of sodium
bicarbonate.
[0242] In still other embodiments of the method of Scheme 10, the
reaction is performed in the presence of an organic base.
Preferably, the reaction is performed in the presence of
triethylamine, tributylamine, diisopropylethylamine,
dimethylisopropylamine, N-methylmorpholine, N-methylpyrrolidine,
N-methylpiperidine, pyridine, 2-methylpyridine,
2,6-dimethylpyridine, 4-dimethylaminopyridine,
1,4-diazabicyclo[2.2.2]octane, 1,8-diazabicyclo[5.4.0]undec-7-ene
or 1,5-diazabicyclo[4.3.0]undec-7-ene, more preferably, the
reaction is performed in the presence of triethylamine,
diisopropylethylamine, N-methylmorpholine, or pyridine.
4.4 Pharmaceutical Compositions
[0243] Pharmaceutical compositions comprising a therapeutically
effective amount of one or more baclofen or baclofen analog prodrug
compounds of Formulae (I), (V) or (VI), preferably in purified
form, together with a suitable amount of a pharmaceutically
acceptable vehicle, so as to provide a form for proper
administration to a patient are provided herein. Suitable
pharmaceutical vehicles include excipients such as starch, glucose,
lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel,
sodium stearate, glycerol monostearate, talc, sodium chloride,
dried skim milk, glycerol, propylene, glycol, water, ethanol and
the like. The present compositions, if desired, can also contain
minor amounts of wetting or emulsifying agents, or pH buffering
agents. In addition, auxiliary, stabilizing, thickening,
lubricating and coloring agents may be used.
[0244] Pharmaceutical compositions may be manufactured by means of
conventional mixing, dissolving, granulating, dragee-making,
levigating, emulsifying, encapsulating, entrapping or lyophilizing
processes. Pharmaceutical compositions may be formulated in
conventional manner using one or more physiologically acceptable
carriers, diluents, excipients or auxiliaries, which facilitate
processing of compounds disclosed herein into preparations which
can be used pharmaceutically. Proper formulation is dependent upon
the route of administration chosen.
[0245] The present pharmaceutical compositions can take the form of
solutions, suspensions, emulsion, tablets, pills, pellets,
capsules, capsules containing liquids, powders, sustained-release
formulations, suppositories, emulsions, aerosols, sprays,
suspensions, or any other form suitable for use. In some
embodiments, the pharmaceutically acceptable vehicle is a capsule
(see e.g., Grosswald et al., U.S. Pat. No. 5,698,155). Other
examples of suitable pharmaceutical vehicles have been described in
the art (see Remington's Pharmaceutical Sciences, Philadelphia
College of Pharmacy and Science, 19th Edition, 1995). In some
embodiments, compositions are formulated for oral delivery,
particularly for oral sustained release administration.
[0246] Pharmaceutical compositions for oral delivery may be in the
form of tablets, lozenges, aqueous or oily suspensions, granules,
powders, emulsions, capsules, syrups, or elixirs, for example.
Orally administered compositions may contain one or more optional
agents, for example, sweetening agents such as fructose, aspartame
or saccharin, flavoring agents such as peppermint, oil of
wintergreen, or cherry coloring agents and preserving agents, to
provide a pharmaceutically palatable preparation. Moreover, when in
tablet or pill form, the compositions may be coated to delay
disintegration and absorption in the gastrointestinal tract,
thereby providing a sustained action over an extended period of
time. Oral compositions can include standard vehicles such as
mannitol, lactose, starch, magnesium stearate, sodium saccharine,
cellulose, magnesium carbonate, etc. Such vehicles are preferably
of pharmaceutical grade.
[0247] For oral liquid preparations such as, for example,
suspensions, elixirs and solutions, suitable carriers, excipients
or diluents include water, saline, alkyleneglycols (e.g., propylene
glycol), polyalkylene glycols (e.g., polyethylene glycol) oils,
alcohols, slightly acidic buffers between pH 4 and pH 6 (e.g.,
acetate, citrate, ascorbate at between about 5 mM to about 50 mM),
etc. Additionally, flavoring agents, preservatives, coloring
agents, bile salts, acylcamitines and the like may be added.
[0248] When a compound of Formulae (I), (V) or (VI) is acidic, it
may be included in any of the above-described formulations as the
free acid, a pharmaceutically acceptable salt, a solvate or
hydrate. Pharmaceutically acceptable salts substantially retain the
activity of the free acid, may be prepared by reaction with bases,
and tend to be more soluble in aqueous and other protic solvents
than the corresponding free acid form. In some embodiments, sodium
salts of a compound of Formulae (I), (V) or (VI) are used in the
above described formulations.
[0249] 4.5 Sustained Release Oral Dosage Forms
[0250] The disclosed compounds can be used with a number of
different dosage forms, which may be adapted to provide sustained
release of a compound of Formulae (I), (V) or (VI) upon oral
administration.
[0251] In some embodiments, the dosage form comprises beads that on
dissolution or diffusion release a compound disclosed herein over
an extended period of hours, preferably, over a period of at least
6 hours, more preferably, over a period of at least 8 hours and
most preferably, over a period of at least 12 hours. The beads may
have a central composition or core comprising a compound disclosed
herein and pharmaceutically acceptable vehicles, including an
optional lubricant, antioxidant and buffer. The beads may be
medical preparations with a diameter of about 0.05 mm to about 2
mm. Individual beads may comprise doses of a compound disclosed
herein, for example, doses of up to about 40 mg of compound. The
beads, in some embodiments, are formed of non-cross-linked
materials to enhance their discharge from the gastrointestinal
tract. The beads may be coated with a release rate-controlling
polymer that gives a timed release profile.
[0252] The time-release beads may be manufactured into a tablet for
therapeutically effective administration. The beads can be made
into matrix tablets by the direct compression of a plurality of
beads coated with, for example, an acrylic resin and blended with
excipients such as hydroxypropylmethyl cellulose. The manufacture
of beads has been disclosed in the art (Lu, Int. J. Pharm., 1994,
112, 117-124; Pharmaceutical Sciences by Remington, 14.sup.th ed,
pp 1626-1628 (1970); Fincher, J. Pharm. Sci. 1968, 57, 1825-1835;
and U.S. Pat. No. 4,083,949) as has the manufacture of tablets
(Pharmaceutical Sciences, by Remington, 17.sup.th Ed, Ch. 90, pp
1603-1625 (1985).
[0253] One type of sustained release oral dosage formulation that
may be used with the disclosed compounds comprises an inert core,
such as a sugar sphere, coated with an inner drug-containing layer
and an outer membrane layer controlling drug release from the inner
layer. A "sealcoat" may be provided between the inert core and the
layer containing the active ingredient. When the core is of a
water-soluble or water-swellable inert material, the sealcoat is
preferably in the form of a relatively thick layer of a
water-insoluble polymer. Such a controlled release bead may thus
comprise: (i) a core unit of a substantially water-soluble or
water-swellable inert material; (ii) a first layer on the core unit
of a substantially water-insoluble polymer; (iii) a second layer
covering the first layer and containing an active ingredient; and
(iv) a third layer on the second layer of polymer effective for
controlled release of the active ingredient, wherein the first
layer is adapted to control water penetration into the core.
[0254] Usually, the first layer (ii) above constitutes more than
about 2% (w/w) of the final bead composition, preferably, more than
about 3% (w/w), e.g., from about 3% to about 80% (w/w). The amount
of the second layer (ii) above usually constitutes from about 0.05%
to about 60% (w/w), preferably from about 0.1% to about 30% (w/w)
of the final bead composition. The amount of the third layer (iv)
above usually constitutes from about 1% to about 50% (w/w),
preferably, from about 2% to about 25% (w/w) of the final bead
composition. The core unit typically has a size in the range of
from about 0.05 to about 2 mm. The controlled release beads may be
provided in a multiple unit formulation, such as a capsule or a
tablet.
[0255] The cores are preferably of a water-soluble or swellable
material and may be any such material that is conventionally used
as cores or any other pharmaceutically acceptable water-soluble or
water-swellable material made into beads or pellets. The cores may
be spheres of materials such as sucrose/starch (Sugar Spheres NF),
sucrose crystals, or extruded and dried spheres typically comprised
of excipients such as microcrystalline cellulose and lactose. The
substantially water-insoluble material in the first, or sealcoat
layer is generally a "GI insoluble" or "GI partially insoluble"
film forming polymer (dispersed or dissolved in a solvent).
Examples include, but are not limited to, ethyl cellulose,
cellulose acetate, cellulose acetate butyrate, polymethacrylates
such as ethyl acrylate/methyl methacrylate copolymer (Eudragit
NE-30-D) and ammonia methacrylate copolymer types A and B (Eudragit
RL30D and RS30D) and silicone elastomers. Usually, a plasticizer is
used together with the polymer. Exemplary plasticizers include, but
are not limited to, dibutylsebacate, propylene glycol,
triethylcitrate, tributylcitrate, castor oil, acetylated
monoglycerides, acetyl triethylcitrate, acetyl butylcitrate,
diethyl phthalate, dibutyl phthalate, triacetin, fractionated
coconut oil (medium-chain triglycerides). The second layer
containing the active ingredient may be comprised of the active
ingredient with or without a polymer as a binder. The binder, when
used, is usually hydrophilic but may be water-soluble or
water-insoluble. Exemplary polymers that may be used in the second
layer containing the active drug are hydrophilic polymers such as,
for example, polyvinylpyrrolidone (PVP), polyalkylene glycol such
as polyethylene glycol, gelatine, polyvinyl alcohol, starch and
derivatives thereof, cellulose derivatives, such as
hydroxypropylmethyl cellulose (HPMC), hydroxypropyl cellulose,
carboxymethyl cellulose, methyl cellulose, ethyl cellulose,
hydroxyethyl cellulose, carboxyethyl cellulose,
carboxymethylhydroxyethyl cellulose, acrylic acid polymers,
polymethacrylates, or any other pharmaceutically acceptable
polymer. The ratio of drug to hydrophilic polymer in the second
layer is usually in the range of from 1:100 to 100:1 (w/w).
Suitable polymers for use in the third layer, or membrane, for
controlling the drug release may be selected from water-insoluble
polymers or polymers with pH-dependent solubility, such as, for
example, ethyl cellulose, hydroxypropylmethyl cellulose phthalate,
cellulose acetate phthalate, cellulose acetate trimellitate,
polymethacrylates, or mixtures thereof, optionally combined with
plasticizers, such as those mentioned above. Optionally, the
controlled release layer comprises, in addition to the polymers
above, other substance(s) with different solubility
characteristics, to adjust the permeability and thereby the release
rate, of the controlled release layer. Exemplary polymers that may
be used as a modifier together with, for example, ethyl cellulose
include, but are not limited to, HPMC, hydroxyethyl cellulose,
hydroxypropyl cellulose, methylcellulose, carboxymethylcellulose,
polyethylene glycol, polyvinylpyrrolidone (PVP), polyvinyl alcohol,
polymers with pH-dependent solubility, such as cellulose acetate
phthalate or ammonia methacrylate copolymer and methacrylic acid
copolymer, or mixtures thereof. Additives such as sucrose, lactose
and pharmaceutical grade surfactants may also be included in the
controlled release layer, if desired.
[0256] The preparation of the multiple unit formulation comprises
the additional step of transforming the prepared beads into a
pharmaceutical formulation, such as by filling a predetermined
amount of the beads into a capsule, or compressing the beads into
tablets. Examples of multi-particulate sustained release oral
dosage forms are described in, for example, U.S. Pat. Nos.
6,627,223 and 5,229,135.
[0257] In other embodiments, an oral sustained release pump may be
used (see Langer, supra; Sefton, 1987, CRC Crit Ref Biomed. Eng.
14:201; Saudek et al., 1989, N. Engl. J Med. 321:574).
[0258] In still other embodiments, polymeric materials can be used
(See "Medical Applications of Controlled Release," Langer and Wise
(eds.), CRC Press., Boca Raton, Fla. (1974); "Controlled Drug
Bioavailability," Drug Product Design and Performance, Smolen and
Ball (eds.), Wiley, New York (1984); Langer et al., 1983, J
Macromol. Sci. Rev. Macromol Chem. 23:61; see also Levy et al.,
1985, Science 228: 190; During et al., 1989, Ann. Neurol. 25:351;
Howard et al., 1989, J. Neurosurg. 71:105). In some embodiments,
polymeric materials are used for oral sustained release delivery.
Polymers include, but are not limited to, sodium
carboxymethylcellulose, hydroxypropylcellulose,
hydroxypropylmethylcellulose and hydroxyethylcellulose (especially,
hydroxypropylmethylcellulose). Other cellulose ethers have been
described (Alderman, Int. J. Pharm. Tech. & Prod. Mfr. 1984,
5(3) 1-9). Factors affecting drug release are well known to the
skilled artisan and have been described in the art (Bamba et al.,
Int. J. Pharm. 1979, 2, 307).
[0259] In other embodiments, enteric-coated preparations can be
used for oral sustained release administration. Preferred coating
materials include polymers with a pH-dependent solubility (i.e.,
pH-controlled release), polymers with a slow or pH-dependent rate
of swelling, dissolution or erosion (i.e., time-controlled
release), polymers that are degraded by enzymes (i.e.,
enzyme-controlled release) and polymers that form firm layers that
are destroyed by an increase in pressure (i.e., pressure-controlled
release).
[0260] In yet other embodiments, drug-releasing lipid matrices can
be used for oral sustained release administration. An example is
when solid microparticles of a compound disclosed herein are coated
with a thin controlled release layer of a lipid (e.g., glyceryl
behenate and/or glyceryl palmitostearate) as disclosed in Farah et
al., U.S. Pat. No. 6,375,987 and Joachim et al., U.S. Pat. No.
6,379,700. The lipid-coated particles can optionally be compressed
to form a tablet. Another controlled release lipid-based matrix
material which is suitable for sustained release oral
administration comprises polyglycolized glycerides as disclosed in
Roussin et al., U.S. Pat. No. 6,171,615.
[0261] In yet other embodiments, waxes can be used for oral
sustained release administration. Examples of suitable sustained
compound-releasing waxes are disclosed in Cain et al., U.S. Pat.
No. 3,402,240 (caranuba wax, candedilla wax, esparto wax and
ouricury wax); Shtohryn et al., U.S. Pat. No. 4,820,523
(hydrogenated vegetable oil, bees wax, caranuba wax, paraffin,
candelillia, ozokerite and mixtures thereof); and Walters, U.S.
Pat. No. 4,421,736 (mixture of paraffin and castor wax).
[0262] In still other embodiments, osmotic delivery systems are
used for oral sustained release administration (Verma et al., Drug
Dev. Ind. Pharm., 2000, 26:695-708). In some embodiments, OROS.RTM.
systems made by Alza Corporation, Mountain View, Calif. are used
for oral sustained release delivery devices (Theeuwes et al., U.S.
Pat. No. 3,845,770; Theeuwes et al., U.S. Pat. No. 3,916,899).
[0263] In other embodiments, a controlled-release system can be
placed in proximity of the target of a compound disclosed herein
(e.g., within the spinal cord), thus requiring only a fraction of
the systemic dose (See, e.g., Goodson, in "Medical Applications of
Controlled Release," supra, vol. 2, pp. 115-138 (1984)). Other
controlled-release systems discussed in Langer, 1990, Science
249.1527-1533 may also be used.
[0264] In other embodiments, the dosage form comprises a compound
disclosed herein coated on a polymer substrate. The polymer can be
an erodible, or a nonerodible polymer. The coated substrate may be
folded onto itself to provide a bilayer polymer drug dosage form.
For example, a compound disclosed herein can be coated onto a
polymer such as a polypeptide, collagen, gelatin, polyvinyl
alcohol, polyorthoester, polyacetyl, or a polyorthocarbonate and
the coated polymer folded onto itself to provide a bilaminated
dosage form. In operation, the bioerodible dosage form erodes at a
controlled rate to dispense a compound disclosed herein over a
sustained release period. Representative biodegradable polymers
comprise a member selected from the group consisting of
biodegradable poly(amides), poly(amino acids), poly(esters),
poly(lactic acid), poly(glycolic acid), poly(carbohydrate),
poly(orthoester), poly(orthocarbonate), poly(acetyl),
poly(anhydrides), biodegradable poly(dihydropyrans), and
poly(dioxinones) which are known in the art (Rosoff, Controlled
Release of Drugs Chap. 2, pp. 53-95 (1989); and in U.S. Pat. Nos.
3,811,444; 3,962,414; 4,066,747, 4,070,347; 4,079,038; and
4,093,709).
[0265] In other embodiments, the dosage form comprises a compound
disclosed herein loaded into a polymer that releases the compound
by diffusion through a polymer, or by flux through pores or by
rupture of a polymer matrix. The drug delivery polymeric dosage
form comprises between about 10 mg to 500 mg of compound
homogenously contained in or on a polymer. The dosage form
comprises at least one exposed surface at the beginning of dose
delivery. The non-exposed surface, when present, is coated with a
pharmaceutically acceptable material impermeable to the passage of
a compound. The dosage form may be manufactured by procedures known
in the art. An example of providing a dosage form comprises
blending a pharmaceutically acceptable carrier like polyethylene
glycol, with a known dose of a compound at an elevated temperature,
(e.g., 37.degree. C.), and adding it to a silastic medical grade
elastomer with a cross-linking agent, for example, octanoate,
followed by casting in a mold. The step is repeated for each
optional successive layer. The system is allowed to set for about 1
hour, to provide the dosage form. Representative polymers for
manufacturing the dosage form are selected from the group
consisting of olefinic polymers, vinyl polymers, addition polymers,
condensation polymers, carbohydrate polymer and silicone polymers
as represented by polyethylene, polypropylene, polyvinyl acetate,
polymethylacrylate, polyisobutylmethacrylate, poly alginate,
polyamide and polysilicone. The polymers and procedures for
manufacturing them have been described in the art (Coleman et al.,
Polymers 1990, 31, 1187-1231; Roerdink et al., Drug Carrier Systems
1989, 9, 57-10; Leong et al., Adv. Drug Delivery Rev. 1987, 1,
199-233; Roff et al., Handbook of Common Polymers 1971, CRC Press;
and U.S. Pat. No. 3,992,518).
[0266] In other embodiments, the dosage from comprises a plurality
of tiny pills. The tiny time-release pills provide a number of
individual doses for providing various time doses for achieving a
sustained-release prodrug delivery profile over an extended period
of time up to 24 hours. The matrix comprises a hydrophilic polymer
selected from the group consisting of a polysaccharide, agar,
agarose, natural gum, alkali alginate including sodium alginate,
carrageenan, fucoidan, furcellaran, laminaran, hypnea, gum arabic,
gum ghatti, gum karaya, grum tragacanth, locust bean gum, pectin,
amylopectin, gelatin, and a hydrophilic colloid. The hydrophilic
matrix comprises a plurality of 4 to 50 tiny pills, each tiny pill
comprise a dose population of from 10 ng, 0.5 mg, 1 mg, 1.2 mg, 1.4
mg, 1.6 mg, 5.0 mg, etc. The tiny pills comprise a release
rate-controlling wall of 0.001 mm up to 10 mm thickness to provide
for the timed release of a compound. Representative wall forming
materials include a triglyceryl ester selected from the group
consisting of glyceryl tristearate, glyceryl monostearate, glyceryl
dipalmitate, glyceryl laureate, glyceryl didecenoate and glyceryl
tridenoate. Other wall forming materials comprise polyvinyl
acetate, phthalate, methylcellulose phthalate and microporous
olefins. Procedures for manufacturing tiny pills are disclosed in
U.S. Pat. Nos. 4,434,153; 4,721,613; 4,853,229; 2,996,431;
3,139,383 and 4,752,470.
[0267] In still other embodiments, the dosage form comprises an
osmotic dosage form, which comprises a semipermeable wall that
surrounds a therapeutic composition comprising the compound. In use
within a patient, the osmotic dosage form comprising a homogenous
composition, imbibes fluid through the semipermeable wall into the
dosage form in response to the concentration gradient across the
semipermeable wall. The therapeutic composition in the dosage form
develops osmotic pressure differential that causes the therapeutic
composition to be administered through an exit from the dosage form
over a prolonged period of time up to 24 hours (or even in some
cases up to 30 hours) to provide controlled and sustained compound
release. These delivery platforms can provide an essentially zero
order delivery profile as opposed to the spiked profiles of
immediate release formulations.
[0268] In still other embodiments, the dosage form comprises
another osmotic dosage form comprising a wall surrounding a
compartment, the wall comprising a semipermeable polymeric
composition permeable to the passage of fluid and substantially
impermeable to the passage of compound present in the compartment,
a compound-containing layer composition in the compartment, a
hydrogel push layer composition in the compartment comprising an
osmotic formulation for imbibing and absorbing fluid for expanding
in size for pushing the compound composition layer from the dosage
form, and at least one passageway in the wall for releasing the
prodrug composition. The method delivers the compound by imbibing
fluid through the semipermeable wall at a fluid imbibing rate
determined by the permeability of the semipermeable wall and the
osmotic pressure across the semipermeable wall causing the push
layer to expand, thereby delivering the compound from the dosage
form through the exit passageway to a patient over a prolonged
period of time (up to 24 or even 30 hours). The hydrogel layer
composition may comprise 10 mg to 1000 mg of a hydrogel such as a
member selected from the group consisting of a polyalkylene oxide
of 1,000,000 to 8,000,000 weight-average molecular weight, which
are selected from the group consisting of a polyethylene oxide of
1,000,000 weight-average molecular weight, a polyethylene oxide of
2,000,000 molecular weight, a polyethylene oxide of 4,000,000
molecular weight, a polyethylene oxide of 5,000,000 molecular
weight, a polyethylene oxide of 7,000,000 molecular weight and a
polypropylene oxide of the 1,000,000 to 8,000,000 weight-average
molecular weight; or 10 mg to 1000 mg of an alkali
carboxymethylcellulose of 10,000 to 6,000,000 weight average
molecular weight, such as sodium carboxymethylcellulose or
potassium carboxymethylcellulose. The hydrogel expansion layer
comprises 0.0 mg to 350 mg, in present manufacture; 0.1 mg to 250
mg of a hydroxyalkylcellulose of 7,500 to 4,500,00 weight-average
molecular weight (e.g., hydroxymethylcellulose,
hydroxyethylcellulose, hydroxypropyl cellulose,
hydroxybutylcellulose or hydroxypentylcellulose) in present
manufacture; 1 mg to 50 mg of an agent selected from the group
consisting of sodium chloride, potassium chloride, potassium acid
phosphate, tartaric acid, citric acid, raffinose, magnesium
sulfate, magnesium chloride, urea, inositol, sucrose, glucose and
sorbitol; 0 to 5 mg of a colorant, such as ferric oxide; 0 mg to 30
mg, in a present manufacture, 0.1 mg to 30 mg of a
hydroxypropylalkylcellulose of 9,000 to 225,000 average-number
molecular weight, selected from the group consisting of
hydroxypropylethylcellulose, hydroxypropypentylcellulose,
hydroxypropylmethylcellulose, and hydropropylbutylcellulose; 0.00
to 1.5 mg of an antioxidant selected from the group consisting of
ascorbic acid, butylated hydroxyanisole, butylated hydroxyquinone,
butylhydroxyanisol, hydroxycoumarin, butylated hydroxytoluene,
cephalm, ethyl gallate, propyl gallate, octyl gallate, lauryl
gallate, propyl-hydroxybenzoate, trihydroxybutylrophenone,
dimethylphenol, dibutylphenol, vitamin E, lecithin and
ethanolamine; and 0.0 mg to 7 mg of a lubricant selected from the
group consisting of calcium stearate, magnesium stearate, zinc
stearate, magnesium oleate, calcium palmitate, sodium suberate,
potassium laurate, salts of fatty acids, salts of alicyclic acids,
salts of aromatic acids, stearic acid, oleic acid, palmitic acid, a
mixture of a salt of a fatty, alicyclic or aromatic acid, and a
fatty, alicyclic, or aromatic acid.
[0269] In the osmotic dosage forms, the semipermeable wall
comprises a composition that is permeable to the passage of fluid
and impermeable to the passage of prodrug. The wall is nontoxic and
comprises a polymer selected from the group consisting of a
cellulose acylate, cellulose diacylate, cellulose triacylate,
cellulose acetate, cellulose diacetate and cellulose triacetate.
The wall comprises 75 wt % (weight percent) to 100 wt % of the
cellulosic wall-forming polymer or, the wall can comprise
additionally 0.01 wt % to 80 wt % of polyethylene glycol, or 1 wt %
to 25 wt % of a cellulose ether selected from the group consisting
of hydroxypropylcellulose or a hydroxypropylalkycellulose such as
hydroxypropylmethylcellulose. The total weight percent of all
components comprising the wall is equal to 100 wt %. The internal
compartment comprises the compound-containing composition alone or
in layered position with an expandable hydrogel composition. The
expandable hydrogel composition in the compartment increases in
dimension by imbibing the fluid through the semipermeable wall,
causing the hydrogel to expand and occupy space in the compartment,
whereby the drug composition is pushed from the dosage form. The
therapeutic layer and the expandable layer act together during the
operation of the dosage form for the release of prodrug to a
patient over time. The dosage form comprises a passageway in the
wall that connects the exterior of the dosage form with the
internal compartment. The osmotic powered dosage form can be made
to deliver prodrug from the dosage form to the patient at a zero
order rate of release over a period of up to about 24 hours.
[0270] The expression "passageway" as used herein comprises means
and methods suitable for the metered release of the compound from
the compartment of the dosage form. The exit means comprises at
least one passageway, including orifice, bore, aperture, pore,
porous element, hollow fiber, capillary tube, channel, porous
overlay, or porous element that provides for the osmotic controlled
release of compound. The passageway includes a material that erodes
or is leached from the wall in a fluid environment of use to
produce at least one controlled-release dimensioned passageway.
Representative materials suitable for forming a passageway, or a
multiplicity of passageways comprise a leachable poly(glycolic)
acid or poly(lactic) acid polymer in the wall, a gelatinous
filament, poly(vinyl alcohol), leach-able polysaccharides, salts,
and oxides. A pore passageway, or more than one pore passageway,
can be formed by leaching a leachable compound, such as sorbitol,
from the wall. The passageway possesses controlled-release
dimensions, such as round, triangular, square and elliptical, for
the metered release of prodrug from the dosage form. The dosage
form can be constructed with one or more passageways in spaced
apart relationship on a single surface or on more than one surface
of the wall. The expression "fluid environment" denotes an aqueous
or biological fluid as in a human patient, including the
gastrointestinal tract. Passageways and equipment for forming
passageways are disclosed in U.S. Pat. Nos. 3,845,770; 3,916,899;
4,063,064; 4,088,864 and 4,816,263. Passageways formed by leaching
are disclosed in U.S. Pat. Nos. 4,200,098 and 4,285,987.
[0271] Regardless of the specific form of sustained release oral
dosage form used, compounds are preferably released from the dosage
form over a period of at least about 6 hours, more preferably, over
a period of at least about 8 hours, and most preferably, over a
period of at least about 12 hours. Further, the dosage form
preferably releases from 0 to 30% of the prodrug in 0 to 2 hours,
from 20 to 50% of the prodrug in 2 to 12 hours, from 50 to 85% of
the prodrug in 3 to 20 hours and greater than 75% of the prodrug in
5 to 18 hours. The sustained release oral dosage form further
provides a concentration of baclofen or baclofen analog in the
blood plasma of the patient over time, which curve has an area
under the curve (AUC) that is proportional to the dose of the
prodrug of baclofen or baclofen analog administered, and a maximum
concentration C.sub.max. The C.sub.max is less than 75%, and is
preferably, less than 60%, of the C.sub.max obtained from
administering an equivalent dose of the compound from an immediate
release oral dosage form and the AUC is substantially the same as
the AUC obtained from administering an equivalent dose of the
prodrug from an immediate release oral dosage form.
[0272] Preferred dosage forms are administered once or twice per
day, more preferably, once per day.
4.6 Therapeutic Uses of Compounds, Compositions and Dosage
Forms
[0273] In some embodiments, a therapeutically effective amount of
one or more compounds of Formulae (I), (V) or (VI) is administered
to a patient, preferably a human, suffering from stiffness,
involuntary movements and/or pain associated with spasticity. The
underlying etiology of the spasticity being so treated may have a
multiplicity of origins, including, e.g., cerebral palsy, multiple
sclerosis, stroke and head and spinal cord injuries. In other
embodiments, a therapeutically effective amount of one or more
compounds of Formulae (I), (V) or (VI) is administered to a
patient, preferably a human, suffering from gastro-esophageal
reflux disease. In still other embodiments, a therapeutically
effective amount of one or more compounds of Formulae (I), (V) or
(VI) is administered to a patient, preferably a human, suffering
from emesis. In still other embodiments, a therapeutically
effective amount of one or more compounds of Formulae (I), (V) or
(VI) is administered to a patient, preferably, a human, suffering
from cough. In still other embodiments, a therapeutically effective
amount of one or more compounds of Formulae (I), (V) or (VI) is
administered to a patient, preferably a human, suffering from drug
addiction. Addiction to stimulants such as cocaine or amphetamines,
or narcotics such as morphine or heroin may be effectively treated
by administration of one or more compounds of Formulae (I), (V) or
(VI). In yet other embodiments, a therapeutically effective amount
of one or more compounds of Formulae (I), (V) or (VI) is
administered to a patient, preferably a human, suffering from
alcohol abuse or addiction and nicotine abuse or addiction. In some
of the above embodiments, sustained release oral dosage forms are
administered to the patients.
[0274] Further, in certain embodiments, a therapeutically effective
amount of one or more compounds of Formulae (I), (V) or (VI) are
administered to a patient, preferably a human, as a preventative
measure against various diseases or disorders. Thus, the
therapeutically effective amount of one or more compounds of
Formulae (I), (V) or (VI) may be administered as a preventative
measure to a patient having a predisposition for spasticity,
gastro-esophageal reflux disease, emesis, cough, alcohol addiction
or abuse, nicotine abuse or addiction or other drug addiction or
abuse.
[0275] When used to treat or prevent the above diseases or
disorders the therapeutically effective amount of one or more
compounds of Formulae (I), (V) or (VI) may be administered or
applied singly, or in combination with other agents. The
therapeutically effective amount of one or more compounds of
Formulae (I), (V) or (VI) may also deliver a compound disclosed
herein in combination with another pharmaceutically active agent,
including another compound disclosed herein. For example, in the
treatment of a patient suffering from gastro-esophageal reflux
disease, a dosage form comprising a compound of Formulae (I), (V)
or (VI) may be administered in conjunction with a proton pump
inhibitor, such as omeprazole, esomeprazole, pantoprazole,
lansoprazole or rabeprazole sodium, or with an H.sub.2 antagonist
such as rantidine, cimetidine or famotidine.
[0276] Dosage forms, upon releasing the baclofen or baclofen analog
prodrug, preferably provide baclofen or baclofen analogs upon in
vivo administration to a patient. While not wishing to bound by
theory, the promoiety or promoieties of the prodrug may be cleaved
either chemically and/or enzymatically. One or more enzymes present
in the stomach, intestinal lumen, intestinal tissue, blood, liver,
brain or any other suitable tissue of a mammal may enzymatically
cleave the promoiety or promoieties of the prodrug. If the
promoiety or promoieties are cleaved after absorption by the
gastrointestinal tract, these baclofen or baclofen analog prodrugs
may have the opportunity to be absorbed into the systemic
circulation from the large intestine. It is preferred that the
promoiety or promoieties are cleaved after absorption by the
gastrointestinal tract.
4.7 Doses
[0277] Baclofen and baclofen analog prodrugs are administered to
treat or prevent diseases or disorders such as spasticity,
gastro-esophageal reflux disease, emesis, cough, alcohol, nicotine
or other drug addiction.
[0278] The amount of baclofen or baclofen analog prodrug that will
be effective in the treatment of a particular disorder or condition
disclosed herein will depend on the nature of the disorder or
condition, and can be determined by standard clinical techniques
known in the art. In addition, in vitro or in vivo assays may
optionally be employed to help identify optimal dosage ranges. The
amount of a compound administered will, of course, be dependent on,
among other factors, the subject being treated, the weight of the
subject, the severity of the affliction, the manner of
administration and the judgment of the prescribing physician.
[0279] Preferably, the dosage forms are adapted to be administered
to a patient no more than twice per day, more preferably, only once
per day. Dosing may be provided alone or in combination with other
drugs and may continue as long as required for effective treatment
of the disease state or disorder.
[0280] Suitable dosage ranges for oral administration are dependent
on the potency of the parent baclofen analog. For baclofen doses
are generally between about 0.15 mg to about 2.5 mg per kilogram
body weight. Other baclofen analogs may be more potent and lower
doses may be appropriate for both the parent drug and any prodrug
(measured on an equivalent molar basis). For example, doses of
R-baclofen prodrugs that are equivalent (on a molar basis) to
R-baclofen doses of between about 0.03 mg to about 1 mg per
kilogram body weight are appropriate. Dosage ranges may be readily
determined by methods known to the skilled artisan.
5. EXAMPLES
[0281] The following examples describe in detail preparation of
compounds and compositions disclosed herein and assays for using
compounds and compositions disclosed herein. It will be apparent to
those of ordinary skill in the art that many modifications, both to
materials and methods, may be practiced.
[0282] In the examples below, the following abbreviations have the
following meanings. If an abbreviation is not defined, it has its
generally accepted meaning. [0283] Boc=tert-butyloxycarbonyl [0284]
Cbz=carbobenzyloxy [0285] DCC=dicyclohexylcarbodiimide [0286]
DMAP=4-N,N-dimethylaminopyridine [0287] DMF=N,N-dimethylformamide
[0288] DMSO=dimethylsulfoxide [0289]
Fmoc=9-fluorenylmethyloxycarbonyl [0290] g=gram [0291] h=hour
[0292] HPLC=high pressure liquid chromatography [0293] L=liter
[0294] LC/MS=liquid chromatography/mass spectroscopy [0295] M=molar
[0296] min=minute [0297] mL=milliliter [0298] mmol=millimoles
[0299] THF=tetrahydrofuran [0300] TFA=trifluoroacetic acid [0301]
TLC=thin layer chromatography [0302] TMS=trimethylsilyl [0303]
.mu.L=microliter [0304] .mu.M=micromolar [0305] v/v=volume to
volume
Example 1
4-tert-Butoxycarbonylamino-(3R)-(4-chlorophenyl)-butanoic Acid
(5)
[0306] To a stirred solution containing (R)-baclofen hydrochloride
(2.34 g, 9.36 mmol) and NaOH (0.97 g, 24.34 mmol) in a mixture of
dioxane and water (1:1) was added a solution of di-tert-butyl
dicarbonate (2.65 g, 12.16 mmol) in dioxane (10 mL). The resulting
solution was stirred at ambient temperature for 40 min. Then the
reaction mixture was concentrated on a rotary evaporator to remove
most of dioxane, the residue was extracted with ether to remove
excess di-tert-butyl dicarbonate and the aqueous phase was
acidified to pH .about.3 with saturated citric acid solution to
precipitate a white solid. The precipitate was filtered, washed
with water, dried in a desiccator in vacuo to afford the title
compound (5) as a white fluffy powder (2.4 g, 82%). .sup.1H NMR
(CDCl.sub.3, 400 MHz): .delta. 1.40 (s, 9H), 2.56 (dd, 1H), 2.68
(dd, 1H), 3.26 (m, 2H), 3.40 (m, 1H), 7.14 (d, 2H), 7.27 (d,
2H).
Example 2
Benzyl 4-tert-Butoxycarbonylamino-(3R)-(4-chlorophenyl)-butanoate
(6)
[0307] To a stirred solution of compound (5) (1.41 g, 4.49 mmol)
and benzyl bromide (0.769 g, 4.49 mmol) in DMF was added
Cs.sub.2CO.sub.3 (1.46 g, 4.49 mmol) at ambient temperature. The
resulting suspension was stirred for 3 h, with the reaction
progress monitored by TLC and/or LC/MS. The reaction mixture was
poured into ice-water, extracted with ethyl acetate and the
combined organic phase was washed with water and brine, dried over
anhydrous Na.sub.2SO.sub.4 and concentrated in vacuo to afford the
title compound (6) as a white solid (1.69 g, 94%). .sup.1H NMR
(CDCl.sub.3, 400 MHz): .delta. 1.39 (s, 9H), 2.61 (dd, 1H), 2.74
(dd, 1H), 3.30 (m, 2H), 3.40 (m, 1H), 4.46 (br s, 1H), 4.99 (s,
2H), 7.07-7.35 (m, 9H).
Example 3
Benzyl 4-Amino-(3R)-(4-chlorophenyl)-butanoate Hydrochloride
(7)
[0308] Compound (6) (1.69 g, 4.19 mmol) was dissolved in a 4N
solution of HCl in dioxane and the resulting reaction mixture
stirred at room temperature for 40 min. The reaction mixture was
diluted with ether, the resulting precipitate was filtered off,
washed with ether and hexane, and dried in vacuo to afford the
title compound (7) (1.39 g, 98%). .sup.1H NMR (CD.sub.3OD, 400
MHz): .delta. 2.72 (dd, 1H), 2.86 (dd, 1H), 3.12 (m, 1H), 3.27 (m,
1H), 3.47 (m, 1H), 5.01 (s, 2H), 7.06-7.30 (m, 9H). MS (ESI) m/z
304.19 (M+H).sup.+.
Example 4
Benzyl
4-(Chloromethoxy)carbonylamino-(3R)-(4-chlorophenyl)-butanoate
(8)
[0309] To a stirred suspension of compound (7) (500 mg, 1.47 mmol)
in CH.sub.2Cl.sub.2 (20 mL) at 0.degree. C. was added
N-methylmorpholine (0.404 mL, 3.67 mmol). The resulting mixture was
stirred at 0.degree. C. until a clear solution was obtained. Then
1-chloromethyl chloroformate (199 mg, 1.544 mmol) in
CH.sub.2Cl.sub.2 (1 mL) was added and the reaction mixture was
stirred at 0.degree. C. with TLC monitoring. After 40 minutes, the
reaction was diluted with CH.sub.2Cl.sub.2, washed with citric acid
solution and brine and dried over anhydrous Na.sub.2SO.sub.4. The
solvent was removed in vacuo to afford the title compound (8) (430
mg, 74%). .sup.1H NMR (CDCl.sub.3, 400 MHz): .delta. 2.64 (dd, 1H),
2.74 (dd, 1H), 3.49 (m, 2H), 3.53 (m, 1H), 4.92 (br. s, 1H), 5.01
(s, 2H), 5.66 (AB q, 2H), 7.07-7.30 (m, 9H).
Example 5
Benzyl
4-[(Acetoxymethoxy)carbonylamino]-(3R)-(4-chlorophenyl)-butanoate
(9)
[0310] To a suspension of Ag.sub.2CO.sub.3 (417 mg, 1.514 mmol) and
acetic acid (0.170 mL, 3.028 mmol) in CHCl.sub.3 (2 mL) was added a
solution of compound (8) (300 mg, 0.757 mmol) in CHCl.sub.3 (1 mL).
The resulting suspension was stirred at room temperature for 24 h.
The reaction mixture was then diluted with CH.sub.2Cl.sub.2,
filtered through a pad of Celite, and the filtrate washed with 10%
aqueous NaHCO.sub.3 solution and brine, then dried over anhydrous
Na.sub.2SO.sub.4. After removal of the solvent in vacuo, the
residue was purified by flash chromatography on silica gel, eluting
with a gradient of 15%-30% ethyl acetate in hexane to afford the
title compound (9) (280 mg, 88%). .sup.1H NMR (CDCl.sub.3, 400
MHz): .delta. 2.05 (s, 3H), 2.62 (m, 1H), 2.70 (m, 1H), 3.33 (m,
2H), 3.47 (m, 1H), 4.99 (m, 3H), 5.62 (s, 2H), 7.08-7.28 (m,
9H).
Example 6
Sodium
4-[(Acetoxymethoxy)carbonylamino]-(3R)-(4-chlorophenyl)-butanoate
(10)
[0311] A solution of compound (9) (80 mg, 0.190 mmol) in ethanol
(20 mL) was stirred with 10% Pd on carbon (8 mg) in a 50 mL
round-bottomed flask under an atmosphere of hydrogen gas (balloon).
The reaction was judged complete in 30 min. (monitoring by LC/MS).
The mixture was filtered through a pad of Celite, and the solvent
removed in vacuo to afford the crude product, which was purified by
preparatory LC/MS to give the product in its protonated acid form
(46 mg, 73%). .sup.1H NMR (CD.sub.3OD, 400 MHz): .delta. 2.04 (s,
3H), 2.57 (m, 1H), 2.72 (m, 1H), 3.31 (m, 3H), 5.61 (s, 2H),
7.22-7.28 (m, 4H). MS (ESI) m/z 328.13 (M-H).sup.-.
[0312] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous
NaHCO.sub.3 (1 equiv.) with sonication for 10 min. The solvent was
removed by lyophilization to afford the title compound (10).
Example 7
Benzyl
4-[(Benzoyloxymethoxy)carbonylamino]-(3R)-(4-chlorophenyl)-butanoat-
e (11)
[0313] Following the procedure of Example 5 and replacing acetic
acid with benzoic acid, compound (11) was obtained in 72% yield.
.sup.1H NMR (CDCl.sub.3, 400 MHz): .delta. 2.62 (dd, 1H), 2.72 (dd,
1H), 3.33 (m, 2H), 3.50 (m, 1H), 4.98 (br. s, 3H), 5.90 (s, 2H),
7.05 (d, 2H), 7.12-7.28 (m, 7H), 7.56 (t, 1H), 7.41 (t, 2H), 8.03
(d, 2H).
Example 8
Sodium
4-[(Benzoyloxymethoxy)carbonylamino]-(3R)-(4-chlorophenyl)-butanoat-
e (12)
[0314] Following the procedure of Example 6 and replacing compound
(9) with compound (11) afforded the product in its protonated acid
form in 69% yield. .sup.1H NMR (CD.sub.3OD, 400 MHz): .delta. 2.57
(m, 1H), 2.71 (m, 1H), 3.33 (m, 3H), 5.89 (AB q, 2H), 7.20 (m, 4H),
7.50 (t, 2H), 7.63 (t, 1H), 8.00 (d, 2H). MS (ESI) m/z 390.15
(M-H).sup.-.
[0315] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous
NaHCO.sub.3 (1 equiv.) with sonication for 10 min. The solvent was
removed by lyophilization to afford the title compound (12).
Example 9
Benzyl
4-[(Cyclohexanecarboxymethoxy)carbonylamino]-(3R)-(4-chlorophenyl)--
butanoate (13)
[0316] Following the procedure of Example 5 and replacing acetic
acid with cyclohexane carboxylic acid, compound (13) was obtained
in 38% yield. .sup.1H NMR (CDCl.sub.3, 400 MHz): .delta. 1.20-1.42
(m, 5H), 1.62-1.87 (m, 5H), 2.29 (m, 1H), 2.61 (m, 1H), 2.71 (m,
1H), 3.32 (m, 2H), 3.48 (m, 1H), 4.99 (s, 2H), 5.12 (br. s, 1H),
5.64 (m, 2H), 7.06-7.28 (m, 9H).
Example 10
Sodium
4-[(Cylohexanecarboxymethoxy)carbonylamino]-(3R)-(4-chlorophenyl)-butanoat-
e (14)
[0317] Following the procedure of Example 6 and replacing compound
(9) with compound (13) afforded the product in its protonated acid
form in 40% yield. .sup.1H NMR (CDCl.sub.3, 400 MHz): .delta.
1.20-1.40 (m, 5H), 1.63-1.93 (m, 5H), 2.35 (m, 1H), 2.70 (m, 2H),
3.36 (m, 2H), 3.54 (m, 1H), 5.02 (br. m, 1H), 5.69 (m, 2H), 7.15
(d, 2H), 7.28 (d, 2H). MS (ESI) m/z 396.18 (M-H).sup.-.
[0318] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous
NaHCO.sub.3 (1 equiv.) with sonication for 10 min. The solvent was
removed by lyophilization to afford the title compound (14).
Example 11
Benzyl
4-[(Butanoyloxymethoxy)carbonylamino]-(3R)-(4-chlorophenyl)-butanoate
(15)
[0319] Following the procedure of Example 5 and replacing acetic
acid with n-butyric acid, compound (15) was obtained. .sup.1H NMR
(CDCl.sub.3, 400 MHz): .delta. 0.93 (t, 3H), 1.63 (m, 2H), 2.30 (t,
2H), 2.64 (m, 1H), 2.74 (m, 1H), 3.33 (m, 2H), 3.49 (m, 1H), 4.91
(br. s, 1H), 5.00 (s, 2H), 5.65 (m, 2H), 7.06-7.30 (m, 9H).
Example 12
Sodium
4-[(Butanoyloxymethoxy)carbonylamino]-(3R)-(4-chlorophenyl)-butanoa-
te (16)
[0320] Following the procedure of Example 6 and replacing compound
(9) with compound (15) afforded the product in its protonated acid
form in 40% yield. .sup.1H NMR (CDCl.sub.3, 400 MHz): .delta. 0.94
(t, 3H), 1.64 (m, 2H), 2.32 (t, 2H), 2.65 (m, 2H), 3.35 (m, 2H),
3.52 (m, 1H), 5.00 (br. s, 1H), 5.67 (s, 2H), 7.11-7.29 (m, 4H). MS
(ESI) m/z 356.19 (M-H).sup.-.
[0321] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous
NaHCO.sub.3 (1 equiv.) with sonication for 10 min. The solvent was
removed by lyophilization to afford the title compound (16).
Example 13
Benzyl
4-[(Isobutanoyloxymethoxy)carbonylamino]-(3R)-(4-chlorophenyl)-buta-
noate (17)
[0322] Following the procedure of Example 5 and replacing acetic
acid with isobutyric acid, compound (17) was obtained in 22% yield.
.sup.1H NMR (CDCl.sub.3, 400 MHz): .delta. 1.15 (m, 6H), 2.55 (m,
1H), 2.62 (dd, 1H), 2.72 (dd, J=1H), 3.33 (m, 2H), 3.48 (m, 1H),
4.83 (br. s, 1H), 4.99 (s, 2H), 5.65 (s, 2H), 7.06-7.30 (m,
9H).
Example 14
Sodium
4-[(Isobutanoyloxymethoxy)carbonylamino]-(3R)-(4-chlorophenyl)-buta-
noate (18)
[0323] Following the procedure of Example 6 and replacing compound
(9) with compound (17) afforded the product in its protonated acid
form in 80% yield. .sup.1H NMR (CDCl.sub.3, 400 MHz): .delta. 1.16
(m, 6H), 2.60 (m, 1H), 2.71 (m, 1H), 3.35 (m, 2H), 3.51 (m, 1H),
5.03 (br. t, 1H), 5.67 (s, 2H), 7.12 (d, 2H), 7.26 (d, 2H). MS
(ESI) m/z 356.15 (M-H).sup.-.
[0324] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous
NaHCO.sub.3 (1 equiv.) with sonication for 10 min. The solvent was
removed by lyophilization to afford the title compound (18).
Example 15
Benzyl
4-[(Pivaloyloxymethoxy)carbonylamino]-(3R)-(4-chlorophenyl)-butanoa-
te (19)
[0325] Following the procedure of Example 5 and replacing acetic
acid with pivalic acid, compound (19) was obtained in 36% yield.
.sup.1H NMR (CDCl.sub.3, 400 MHz): .delta. 1.17 (s, 9H), 2.62 (dd,
1H), 2.72 (dd, 1H), 3.33 (m, 2H), 3.48 (m, 1H), 4.84 (br. t, 1H),
5.00 (s, 2H), 5.65 (s, 2H), 7.06-7.30 (m, 9H).
Example 16
Sodium
4-[(Pivaloyloxymethoxy)carbonylamino]-(3R)-(4-chlorophenyl)-butanoa-
te (20)
[0326] Following the procedure of Example 6 and replacing compound
(9) with compound (19) afforded the product in its protonated acid
form in 75% yield. .sup.1H NMR (CDCl.sub.3, 400 MHz): .delta. 1.19
(s, 9H), 2.60 (dd, 1H), 2.68 (dd, 1H), 3.34 (m, 2H), 3.51 (m, 1H),
5.01 (br. t, 1H), 5.66 (s, 2H), 7.11 (m, 2H), 7.26 (m, 2H). MS
(ESI) m/z 370.22 (M-H).sup.-.
[0327] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous
NaHCO.sub.3 (1 equiv.) with sonication for 10 min. The solvent was
removed by lyophilization to afford the title compound (20).
Example 17
Benzyl
4-[(1-Chloroisobutoxy)carbonylamino]-(3R)-(4-chlorophenyl)-butanoat-
e (21)
[0328] To a stirred suspension of compound (7) (900 mg, 2.64 mmol)
in CH.sub.2Cl.sub.2 (50 mL) at 0.degree. C. was added
N-methylmorpholine (0.97 mL, 8.82 mmol). The resulting mixture was
stirred at 0.degree. C. until a clear solution was obtained. Then
1-chloro-2-methylpropyl chloroformate (474 mg, 2.77 mmol) in
CH.sub.2Cl.sub.2 (1 mL) was added and the solution stirred at
0.degree. C. for 3 h (TLC monitoring). The reaction mixture was
diluted with CH.sub.2Cl.sub.2, washed with citric acid solution and
brine, then dried over anhydrous Na.sub.2SO.sub.4. Removal of the
solvent in vacuo afforded the title compound (21) as a pair of
diastereomers (932 mg, 80%). .sup.1H NMR (CDCl.sub.3, 400 MHz):
.delta. 0.99 (d, 3H), 1.02 (d, 3H), 2.10 (m, 1H), 2.64 (dd, 1H),
2.74 (dd, 1H), 3.33 (m, 2H), 3.53 (m, 1H), 4.80 (br. s, 1H), 5.01
(s, 2H), 6.24 (d, 1H), 7.07-7.30 (m, 9H).
Example 18
Benzyl
4-[(1-Acetoxyisobutoxy)carbonylamino]-(3R)-(4-chlorophenyl)-butanoa-
te (22)
[0329] To a solution of compound (21) (246 mg, 0.561 mmol) in
CH.sub.2Cl.sub.2 (0.5 mL) was added acetic acid (0.32 mL, 5.61
mmol) and N-methylmorpholine (0.31 mL, 2.8 mmol). The resulting
mixture was stirred for 48 h at room temperature. The reaction then
was diluted with CH.sub.2Cl.sub.2, washed successively with water,
10% aqueous NaHCO.sub.3 solution, dilute citric acid solution and
brine, then dried over anhydrous Na.sub.2SO.sub.4. After removal of
the solvent in vacuo, the residue was purified by flash
chromatography on silica gel, eluting with a gradient of 10%-20%
ethyl acetate in hexane to afford the title compound (22) as a pair
of diastereomers (120 mg, 46%).
[0330] .sup.1H NMR (CDCl.sub.3, 400 MHz): .delta. 0.92 (m, 6H),
2.10 (m, 4H), 2.75 (m, 2H), 3.45 (m, 3H), 4.68 (br. s, 1H), 5.00
(s, 2H), 6.44 (m, 1H), 7.02-7.33 (m, 9H).
Example 19
Sodium
4-[(1-Acetoxyisobutoxy)carbonylamino]-(3R)-(4-chlorophenyl)-butanoa-
te (23)
[0331] Following the procedure of Example 6 and replacing compound
(9) with compound (22), the product in protonated acid form was
obtained as a pair of diastereomers. .sup.1H NMR (CDCl.sub.3, 400
MHz): .delta. 0.92 (m, 6H), 1.93 (m, 1H), 2.05 (s, 3H), 2.65 (m,
2H), 3.33 (m, 2H), 3.49 (m, 1H), 4.70 (br. s., 1H), 6.50 (m, 1H),
7.10 (m, 2H), 7.26 (m, 2H). MS (ESI) m/z 370.20 (M-H).sup.-.
[0332] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous
NaHCO.sub.3 (1 equiv.) with sonication for 10 min. The solvent was
removed by lyophilization to afford the title compound (23).
Example 20
Benzyl
4-[(1-Isobutanoyloxyisobutoxy)carbonylamino]-(3R)-(4-chlorophenyl)--
butanoate (24)
[0333] To a solution of compound (21) (50 mg, 0.114 mmol) in
isobutyric acid (0.5 mL, 5.39 mmol) was added N-methylmorpholine
(0.57 mmol). After stirring the mixture overnight at 50.degree. C.,
the reaction mixture was diluted with CH.sub.2Cl.sub.2, washed
successively with water, 10% aqueous NaHCO.sub.3 solution and brine
and then dried over anhydrous Na.sub.2SO.sub.4. After removal of
the solvent in vacuo, the title compound (24) was obtained as a
pair of diastereomers (40 mg, 72%). .sup.1H NMR (CDCl.sub.3, 400
MHz): .delta. 0.91 (m, 6H), 1.17 (m, 6H), 1.96 (m, 1H), 2.54 (m,
1H), 2.63 (m, 1H), 2.73 (m, 1H), 3.31 (m, 2H), 3.48 (m, 1H), 4.68
(br. s, 1H), 6.52 (m, 1H), 7.07-7.29 (m, 9H).
Example 21
Sodium
4-[(1-Isobutanoyloxyisobutoxy)carbonylamino]-(3R)-(4-chlorophenyl)--
butanoate (25)
[0334] Following the procedure of Example 6 and replacing compound
(9) with compound (24), the product in protonated acid form was
obtained as a pair of diastereomers in 50% yield. .sup.1H NMR
(CDCl.sub.3, 400 MHz): .delta. 0.92 (m, 6H), 1.16 (m, 6H), 1.97 (m,
1H), 2.51-2.74 (m, 3H), 3.33 (m, 3H), 6.50 (d, 1H), 7.10 (d, 2H),
7.27 (d, 2H). MS (ESI) m/z 398.18 (M-H).sup.-.
[0335] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous
NaHCO.sub.3 (1 equiv.) with sonication for 10 min. The solvent was
removed by lyophilization to afford the title compound (25).
Example 22
Benzyl
4-[(1-Butanoyloxyisobutoxy)carbonylamino]-(3R)-(4-chlorophenyl)-but-
anoate (26)
[0336] Following the procedure of Example 20 and replacing
isobutyric acid with n-butyric acid, the title compound (26) was
obtained as a pair of diastereomers (90 mg, 80%). .sup.1H NMR
(CDCl.sub.3, 400 MHz): .delta. 0.92 (m, 9H), 1.64 (m, 2H), 1.96 (m,
1H), 2.27 (m, 2H), 2.61 (m, 1H), 2.74 (m, 1H), 3.32 (m, 2H), 3.48
(m, 1H), 4.76 (br. s, 1H), 6.53 (m, 1H), 7.06-7.28 (m, 9H).
Example 23
Sodium
4-[(1-Butanoyloxyisobutoxy)carbonylamino]-(3R)-(4-chlorophenyl)-but-
anoate (27)
[0337] Following the procedure of Example 6 and replacing compound
(9) with compound (26), the product in protonated acid form was
obtained as a pair of diastereomers in 75% yield. .sup.1H NMR
(CDCl.sub.3, 400 MHz): .delta. 0.92 (m, 9H), 1.65 (m, 2H), 1.96 (m,
1H), 2.29 (t, 2H), 2.66 (m, 2H), 3.25-3.59 (m, 3H), 4.72 (br. d,
1H), 6.52 (d, 1H), 7.11 (d, 2H), 7.26 (d, 2H). MS (ESI) m/z 398.24
(M-H).sup.-.
[0338] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous
NaHCO.sub.3 (1 equiv.) with sonication for 10 min. The solvent was
removed by lyophilization to afford the title compound (27).
Example 24
Benzyl
4-[(1-Chloroethoxy)carbonylamino]-(3R)-(4-chlorophenyl)-butanoate
(28)
[0339] Following the procedure of Example 17 and replacing
1-chloro-2-methylpropyl chloroformate with 1-chloroethyl
chloroformate, the title compound (28) was obtained as a pair of
diastereomers in 67% yield. .sup.1H NMR (CDCl.sub.3, 400 MHz):
.delta. 1.71 (d, 3H), 2.63 (dd, 1H), 2.73 (dd, 1H), 3.32 (m, 2H),
3.49 (m, 1H), 5.00 (m, 3H), 6.48 (q, 1H), 7.07 (d, 2H), 7.14-7.28
(m, 7H).
Example 25
Benzyl
4-[(1-Acetoxyethoxy)carbonylamino]-(3R)-(4-chlorophenyl)-butanoate
(29)
[0340] To a stirred solution of compound (28) (183 mg, 0.446 mmol)
in CH.sub.2Cl.sub.2 (5 mL) was added acetic acid (0.26 mL, 4.46
mmol) and N-methylmorpholine (0.25 mL, 2.23 mmol), and the
resulting reaction mixture was stirred at room temperature for 48
h. The mixture was diluted with CH.sub.2Cl.sub.2, washed
successively with water, 10% aqueous NaHCO.sub.3 solution and
brine, then dried over anhydrous Na.sub.2SO.sub.4. After removal of
the solvent in vacuo, the residue was purified by flash
chromatography on silica gel, eluting with a gradient of 10%-20%
ethyl acetate in hexane to afford the title compound (29) as a pair
of diastereomers (110 mg, 57%). .sup.1H NMR (CDCl.sub.3, 400 MHz):
.delta. 1.41 (m, 3H), 2.03 (m, 3H), 2.61 (m, 1H), 2.72 (m, 1H),
3.33 (m, 2H), 3.49 (m, 1H), 4.82 (br. s, 1H), 5.00 (s, 2H), 6.74
(m, 1H), 7.13 (m, 2H), 7.17-7.28 (m, 7H).
Example 26
Sodium
4-[(1-Acetoxyethoxy)carbonylamino]-(3R)-(4-chlorophenyl)-butanoate
(30)
[0341] Following the procedure of Example 6 and replacing compound
(9) with compound (29), the product in its protonated acid form was
obtained as a pair of diastereomers in 57% yield. .sup.1H NMR
(CDCl.sub.3, 400 MHz): .delta. 1.42 (m, 3H), 2.02 (m, 3H), 2.62 (m,
1H), 2.71 (m, 1H), 3.32 (m, 2H), 3.49 (m, 1H), 4.80 (br. s, 1H),
6.74 (m, 1H), 7.13 (m, 2H), 7.27 (m, 2H). MS (ESI) m/z 342.24
(M-H).sup.-.
[0342] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous
NaHCO.sub.3 (1 equiv.) with sonication for 10 min. The solvent was
removed by lyophilization to afford the title compound (30).
Example 27
Benzyl
4-[(1-Butanoyloxyethoxy)carbonylamino]-(3R)-(4-chlorophenyl)-butano-
ate (31)
[0343] Following the procedure of Example 25 and replacing acetic
acid with n-butyric acid, the title compound (31) was obtained as a
pair of diastereomers (109 mg, 68%). .sup.1H NMR (CDCl.sub.3, 400
MHz): .delta. 0.94 (m, 3H), 1.42 (m, 3H), 1.64 (m, 2H), 2.27 (m,
2H), 2.60 (m, 1H), 2.71 (m, 1H), 3.31 (m, 2H), 3.50 (m, 1H), 4.80
(br. s, 1H), 5.00 (s, 2H), 6.75 (m, 1H), 7.11 (d, 2H), 7.15-7.28
(m, 7H).
Example 28
Sodium
4-[(1-Butanoyloxyethoxy)carbonylamino]-(3R)-(4-chlorophenyl)-butano-
ate (32)
[0344] Following the procedure of Example 6 and replacing compound
(9) with compound (31), the product in its protonated acid form was
obtained as a pair of diastereomers in 75% yield. .sup.1H NMR
(CDCl.sub.3, 400 MHz): .delta. 0.94 (m, 3H), 1.42 (m, 3H), 1.64 (m,
2H), 2.27 (m, 2H), 2.60 (m, 1H), 2.71 (m, 1H), 3.31 (m, 2H), 3.50
(m, 1H), 4.82 (br. s, 1H), 6.75 (m, 1H), 7.11 (d, 2H), 7.27 (d,
2H). MS (ESI) m/z 370.27 (M-H).sup.-.
[0345] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous
NaHCO.sub.3 (1 equiv.) with sonication for 10 min. The solvent was
removed by lyophilization to afford the title compound (32).
Example 29
Sodium
4-[(1-Isobutanoyloxyethoxy)carbonylamino]-(3R)-(4-chlorophenyl)-but-
anoate (33)
[0346] To a suspension of R-baclofen hydrochloride (500 mg, 1.47
mmol) in CH.sub.2Cl.sub.2 at 0.degree. C. was added triethylamine
(0.9 mL, 6.4 mmol) and a 1N solution of chlorotrimethylsilane in
CH.sub.2Cl.sub.2 (3.23 mL, 3.23 mmol). The resulting reaction
mixture was stirred at 0.degree. C. for 10 min, then was added
1-isobutanoyloxyethyl-p-nitrophenyl carbonate (577 mg, 1.94 mmol,
prepared as described in Gallop et al., U.S. Patent Appl. Publ.
2003/0176398, in CH.sub.2Cl.sub.2. The reaction mixture was stirred
at room temperature for 3 h (monitoring by LC/MS) and then diluted
with CH.sub.2Cl.sub.2, washed with citric acid solution and brine,
and dried over anhydrous Na.sub.2SO.sub.4. After removal of solvent
in vacuo, the residue was purified by flash chromatography on
silica gel, eluting first with CH.sub.2Cl.sub.2 to remove
p-nitrophenol, then with 20% ethyl acetate in hexane to afford the
product in its protonated acid form as a pair of diastereomers (400
mg, 73%). .sup.1H NMR (CDCl.sub.3, 400 MHz): .delta. 1.13 (m, 6H),
1.40 (m, 3H), 2.51 (m, 1H), 2.57 (dd, 1H), 2.71 (dd, 1H), 3.32 (m,
2H), 3.47 (m, 1H), 4.89 (br. s, 1H), 6.72 (q, 1H), 7.11 (d, 2H),
7.26 (d, 2H). MS (ESI) m/z 370.15 (M-H).sup.-.
[0347] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous
NaHCO.sub.3 (1 equiv.) with sonication for 10 min. The solvent was
removed by lyophilization to afford the title compound (33).
Example 30
Asymmetric Synthesis of Sodium
4-{[(1S)-Isobutanoyloxyethoxy]-carbonylamino}-(3R)-(4-chlorophenyl)-butan-
oate (34)
Step A: Synthesis of
4-{[(1S)-Isobutanoylethoxy]carbonylamino}-(3R)-(4-chlorophenyl)-butanoic
Acid (35)
[0348] To a solution of (4S)-hydroxy-2-methylpentan-3-one (200 mg,
1.67 mmol) in CH.sub.2Cl.sub.2 (10 mL) at 0.degree. C. was added
p-nitrophenyl chloroformate (336 mg 1.67 mmol), pyridine (0.135 mL,
1.67 mmol) and 4-dimethylaminopyridine (61 mg, 0.5 mmol). The
resulting mixture was stirred at 0.degree. C. for 1 h, then allowed
to warm to room temperature overnight. The reaction mixture was
then added to a suspension containing R-baclofen hydrochloride (500
mg, 1.47 mmol), chlorotrimethylsilane (2.94 mmol) and triethylamine
(5.99 mmol) in CH.sub.2Cl.sub.2 at 0.degree. C. The reaction was
stirred at room temperature for 5 h, then diluted with
CH.sub.2Cl.sub.2, washed successively with water, 10% aqueous
NaHCO.sub.3 solution, dilute citric acid solution and brine, then
dried over anhydrous Na.sub.2SO.sub.4. After filtration and removal
of the solvent in vacuo, the crude product was purified by
preparatory LC/MS to afford compound (35) (230 mg, 44%). .sup.1H
NMR (CDCl.sub.3, 400 MHz): .delta. 1.06 (d, 3H), 1.12 (d, 3H), 1.32
(d, 3H), 2.60 (m, 1H), 2.75 (m, 2H), 3.29 (m, 2H), 3.44 (m, 1H),
5.13 (q, 1H), 7.13 (m, 2H), 7.26 (m, 2H). MS (ESI) m/z 354.10
(M-H).sup.-.
Step B: Synthesis of Sodium
4-{[(1S)-Isobutanoyloxyethoxy]carbonylamino}-(3R)-(4-chlorophenyl)-butano-
ate (34)
[0349] To a solution of compound (35) (179 mg, 0.503 mmol) in
CH.sub.2Cl.sub.2 (5 mL) at 0.degree. C. was added NaHCO.sub.3 (42
mg, 0.503 mmol) and m-chloroperbenzoic acid (174 mg, 1.00 mmol).
The resulting suspension was stirred at 0.degree. C. to room
temperature for 24 h, then an additional aliquot of
m-chloroperbenzoic acid (174 mg, 1.00 mmol) was added to the
reaction. The mixture was allowed to stir at room temperature for a
further 24 h, then diluted with CH.sub.2Cl.sub.2, filtered through
a pad of Celite, and the filtrate washed with water and brine, then
dried over anhydrous Na.sub.2SO.sub.4. After filtration and removal
of the solvent in vacuo, the crude product was purified by
preparatory LC/MS to afford the product in its protonated acid form
as a single diastereomer (24 mg, 14%). .sup.1H NMR (CDCl.sub.3, 400
MHz): .delta. 1.15 (d, 6H), 1.40 (d, 3H), 2.51 (hept, 1H), 2.59
(dd, 1H), 2.70 (dd, 1H), 3.30 (m, 2H), 3.50 (m, 1H), 4.94 (br. s,
1H), 6.72 (q, 1H), 7.12 (d, 2H), 7.26 (d, 2H). MS (ESI) m/z 370.15
(M-H).sup.-.
[0350] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous
NaHCO.sub.3 (1 equiv.) with sonication for 10 min. TIhe solvent was
removed by lyophilization to afford the title compound (34).
Example 31
Benzyl
4-[(1-Pivaloylethoxy)carbonylamino]-(3R)-(4-chlorophenyl)-butanoate
(35)
[0351] To a stirred solution of compound (28) (500 mg, 1.22 mmol)
in THF (5 mL) was added pivalic acid (1.24 g, 12.1 mmol) and
N-methylmorpholine (0.7 mL, 6.05 mmol), and the resulting reaction
mixture was stirred at 50.degree. C. for 48 hours. The reaction
mixture was diluted with ethyl acetate, washed successively with
water, 10% aqueous NaHCO.sub.3 solution and brine, then dried over
anhydrous Na.sub.2SO.sub.4. After removal of solvent in vacuo, the
residue was purified by flash chromatography on silica gel, eluting
with a gradient of 5-10% ethyl acetate in hexane to afford the
title compound (35) as a pair of diastereomers (252 mg, 44%).
.sup.1H NMR (CDCl.sub.3, 400 MHz): .delta. 1.15 (s, 3H), 1.17 (s,
6H), 1.40 (q, 3H), 2.62 (dd, 1H), 2.74 (dd, 1H), 3.25 (m, 2H), 3.46
(m, 1H), 4.82 (br.t, 1H), 4.99 (s, 2H), 6.71 (m, 1H), 7.29-7.07 (m.
9H).
Example 32
Sodium
4-[(1-Pivaloylethoxy)carbonylamino]-(3R)-(4-chlorophenyl)-butanoate
(36)
[0352] Following the procedure of Example 6 and replacing compound
(9) with compound (35), the product in its protonated acid form was
obtained as a pair of diasteromers in 76% yield. .sup.1H NMR
(CDCl.sub.3, 400 MHz): .delta. 1.16 (s, 3H), 1.18 (s, 6H), 1.40 (d,
3H), 2.59 (dd, 1H), 3.31 (m, 2H), 3.48 (m, 1H), 3.70 (dd, 1H), 4.82
(m, 1H), 6.70 (m, 1H), 7.12 (d, 2H), 7.26 (d, 2H). MS (ESI) m/z
384.18 (M-H).sup.-.
[0353] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous
NaHCO.sub.3 (1 eq.) with sonication for 10 min. The solvent was
removed by lyophilization to afford the title compound (36).
Example 33
Benzyl
4-[(1-Cyclohexylcarbonyloxyethoxy)carbonylamino]-(3R)-(4-chlorophen-
yl)-butanoate (37)
[0354] To a stirred solution of compound (28) (500 mg, 1.22 mmol)
in THF (5 mL) was added cyclohexanecarboxylic acid (1.56 g, 12.14
mmol) and N-methylmorpholine (0.7 mL, 6.05 mmol), and the resulting
reaction mixture was stirred at 45.degree. C. for 48 hours. The
reaction mixture was diluted with ethyl acetate, washed
successively with water, 10% aqueous NaHCO.sub.3 solution and
brine, then dried over anhydrous Na.sub.2SO.sub.4. After removal of
solvent in vacuo, the residue was purified by flash chromatography
on silica gel, eluting with a gradient of 5-10% ethyl acetate in
hexane to afford the title compound (37) as a pair of diastereomers
(348 mg, 57%). .sup.1H NMR (CDCl.sub.3, 400 MHz): .delta. 1.22 (m,
3H), 1.39 (m, 5H), 1.61 (m, 1H), 1.72 (m, 2H), 1.85 (m, 2H), 2.24
(m, 1H), 2.62 (dd, 1H), 2.73 (dd, 1H), 3.30 (m, 2H), 3.46 (m, 1H),
4.90 (br. m, 1H), 4.98 (s, 2H), 6.73 (m, 1H), 7.07-7.28 (m,
9H).
Example 34
Sodium
4-[(1-Cyclohexylcarbonyloxyethoxy)carbonylamino]-(3R)-(4-chlorophen-
yl)-butanoate (38)
[0355] Following the procedure of Example 6 and replacing compound
(9) with compound (37), the product in its protonated acid form was
obtained as a pair of diasteromers in 38% yield. .sup.1H NMR
(CDCl.sub.3, 400 MHz): .delta. 1.24 (m, 3H), 1.40 (m, 5H), 1.63 (m,
1H), 1.74 (m, 2H), 1.86 (m, 2H), 2.27 (m, 1H), 2.59 (dd, 1H), 2.70
(dd, 1H), 3.31 (m, 2H), 3.48 (m, 1H), 4.79 (br. d, 1H), 6.72 (q,
1H), 7.11 (d, 2H), 7.25 (d, 2H). MS (ESI) m/z 410.21
(M-H).sup.-.
[0356] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous NaHCO3 (1
eq.) with sonication for 10 min. The solvent was removed by
lyophilization to afford the title compound (38).
Example 35
Benzyl
4-[(1-Benzoyloxyethoxy)carbonylamino]-(3R)-(4-chlorophenyl)-butanoa-
te (39)
[0357] Following the synthesis procedure for compound (37) and
replacing cyclohexanecarboxylic acid with benzoic acid, the title
compound (39) was obtained as a pair of diastereomers in 69% yield.
.sup.1H NMR (CDCl.sub.3, 400 MHz): .delta. 1.54 (q, 3H), 2.62 (m,
1H), 2.74 (dd, 1H), 3.31 (m, 2H), 3.48 (m, 1H), 4.92 (br. s, 1H),
4.97 (s, 2H), 7.01 (q, 1H), 7.27-7.05 (m, 10H), 7.39 (m, 2H), 7.52
(m, 1H), 7.98 (m, 2H).
Example 36
Sodium
4-[(1-Benzoyloxyethoxy)carbonylamino]-(3R)-(4-chlorophenyl)-butanoa-
te (40)
[0358] Following the procedure of Example 6 and replacing compound
(9) with compound (39), the product in its protonated acid form was
obtained as a pair of diasteromers in 74% yield. .sup.1H NMR
(CDCl.sub.3, 400 MHz): .delta. 1.56 (t, 3H), 2.59 (m, 1H), 2.71 (m,
1H), 3.33 (m, 2H), 3.49 (m, 1H), 7.01 (q, 1H), 7.10 (d, 2H), 7.25
(dd, 2H), 7.42 (t, 2H), 7.55 (t, 1H), 8.02 (t, 2H). MS (ESI) m/z
404.17 (M-H).sup.-.
[0359] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous NaHCO3 (1
eq.) with sonication for 10 min. The solvent was removed by
lyophilization to afford the title compound (40).
Example 37
Benzyl
4-[(1-Benzoyloxyisobutoxy)carbonylamino]-(3R)-(4-chlorophenyl)-buta-
noate (41)
[0360] To a stirred solution of compound (21) (0.634 g, 1.45 mmol)
in THF (5 mL) was added benzoic acid (1.76 g, 14.5 mmol) and
N-methylmorpholine (0.73 g, 7.23 mmol), and the resulting reaction
mixture was stirred at 50.degree. C. for 48 hours. The reaction
mixture was diluted with ethyl acetate, washed successively with
water, 10% aqueous NaHCO.sub.3 solution and brine, then dried over
anhydrous Na.sub.2SO.sub.4. After removal of solvent in vacuo, the
residue was purified by flash chromatography on silica gel, eluting
with a gradient of 5%-10 ethyl acetate in hexane to afford the
title compound (41) as a pair of diastereomers (0.59 g, 45%).
.sup.1H NMR (CDCl.sub.3, 400 MHz): .delta. 1.02 (m, 6H), 2.10 (m,
1H), 2.63 (m, 1H), 2.74 (m, 1H), 3.32 (m, 2H), 3.49 (m, 1H), 4.79
(t, 1H), 4.98 (d, 2H), 6.78 (t, 1H), 7.07 (d, 2H), 7.18 (m, 4H),
7.27 (m, 3H), 7.40 (m, 2H), 7.56 (m, 1H), 8.01 (t, 2H).
Example 38
Sodium
4-[(1-Benzoyloxyisobutoxy)carbonylamino]-(3R)-(4-chlorophenyl)-buta-
noate (42)
[0361] Following the procedure of Example 6 and replacing compound
(9) with compound (41), the product in its protonated acid form was
obtained as a pair of diasteromers in 59% yield. .sup.1H NMR
(CDCl.sub.3, 400 MHz): .delta. 8.02 (d, 2H), 7.56 (t, 1H), 7.43 (t,
3H), 7.21 (d, 2H), 7.11 (d, 2H), 6.77 (d, 1H), 4.71 (m, 1H), 3.54
(m, 1H), 3.31 (m. 2H), 2.72 (m, 1H), 2.60 (m, 1H), 2.11 (m, 1H),
1.00 (m, 6H). MS (ESI) m/z 432.25 (M-H).sup.-.
[0362] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous
NaHCO.sub.3 (1 eq.) with sonication for 10 min. The solvent was
removed by lyophilization to afford the title compound (42).
Example 39
Sodium
4-[(1-Pivaloyloxyisobutoxy)carbonylamino]-(3R)-(4-chlorophenyl)-but-
anoate (43)
Step A: O-(1-Chloroisobutoxy) S-Ethyl Thiocarbonate (44)
[0363] To a stirred solution of ethanethiol (1.23 mL, 16.7 mmol)
and triethylamine (2.93 mL, 21.1 mmol) in CH.sub.2Cl.sub.2 at
0.degree. C. was added 1-chloro-2-methylpropyl chloroformate (3.0
g, 17.5 mmol). The resulting mixture was stirred for 10 min. at
0.degree. C., and then the reaction mixture was diluted with
CH.sub.2Cl.sub.2, washed successively with dilute HCl and brine,
then dried over anhydrous Na.sub.2SO.sub.4. After concentration in
vacuo the crude O-(1-chloroisobutoxy) S-ethyl thiocarbonate (44)
was obtained, and used directly in the next step without further
purification. .sup.1H NMR (CDCl.sub.3, 400 MHz): .delta. 1.05 (t,
6H), 1.35 (t, 3H), 2.17 (m, 1H), 2.90 (q, 2H), 6.33 (d, 1H).
Step B: O-(1-Pivaloyloxyisobutoxy) S-Ethyl Thiocarbonate (45)
[0364] A mixture of (44) (936 mg, 4.76 mmol), pivalic acid (2.43 g,
23.8 mmol) and N,N-diisopropylethylamine (2.40 g, 23.8 mmol) was
stirred at 75.degree. C. for four days, and the reaction was judged
complete by .sup.1H-NMR. The reaction mixture was cooled to room
temperature and portioned between water and ether, the ether phase
was washed successively with water, aqueous NaHCO.sub.3, and brine,
then dried over anhydrous Na.sub.2SO.sub.4. After rotary
evaporation, the crude O-(1-pivaloyloxyisobutoxy) S-ethyl
thiocarbonate (45) was obtained in quantitative yield, and used in
the next step without further purification. .sup.1H NMR
(CDCl.sub.3, 400 MHz): .delta. 0.96 (d, 6H), 1.21 (d, 9H), 1.30 (t,
3H), 2.03 (m, 1H), 6.65 (d, 1H).
Step C: (1-Pivaloyloxyisobutoxy)Chloroformate (46)
[0365] A solution of (45) (4.76 mmol) in CH.sub.2Cl.sub.2 at
0.degree. C. was treated with sulfuryl chloride (1.1 mmol) under
N.sub.2 for 10 min, then the reaction mixture was concentrated to
dryness in vacuo to afford the crude chloroformate (46) in
quantitative yield, which used in the next step without further
purification. .sup.1H NMR (CDCl.sub.3, 400 MHz): .delta. 1.00 (d,
6H), 1.20 (d, 9H), 2.143 (m, 1H), 6.54 (d, 1H).
Step D: [(1-Pivaloyloxyisobutoxy)carbonyloxy]Succinimide (47)
[0366] To a solution of N-hydroxysuccinimide (1.2 eq.) and pyridine
(2.4 eq.) in CH.sub.2Cl.sub.2 at 0.degree. C. was added an
equimolar solution of the above chloroformate (46) in
CH.sub.2Cl.sub.2. The resulting reaction mixture was stirred at
0.degree. C. for 1 h, then was washed successively with water,
dilute HCl and brine, then dried over Na.sub.2SO.sub.4. After
removal of the solvent in vacuo, the crude N-hydroxysuccinimidyl
carbonate (47) was obtained in quantitative yield, and was used in
the next step without further purification.
Step E: Sodium
4-[(1-Pivaloyloxyisobutoxy)carbonylamino]-(3R)-(4-chlorophenyl)-butanoate
(43)
[0367] To a stirred solution of R-baclofen (1 g, 4.69 mmol) and
NaHCO.sub.3 (394 mg, 4.69 mmol) in water was added a solution of
(47) (4.69 mmol) in acetonitrile. The resulting reaction mixture
was stirred at room temperature for 1 h, then acidified to pH 5
with 10% HCl, extracted with ethyl acetate, washed with brine, and
dried over anhydrous Na.sub.2SO.sub.4. The solvent was removed in
vacuo to afford the crude product, which was purified by
preparative LC/MS to afford 146 mg of the product in its acid form.
.sup.1H NMR (CDCl.sub.3, 400 MHz): .delta. 0.88 (m, 6H), 1.15 (d,
9H), 1.92 (m, 1H), 2.54 (m, 1H), 2.67 (m, 1H), 3.27 (m, 2H), 3.42
(m, 1H), 4.83 (t, 1H), 7.08 (d, 2H), 7.21 (d, 2H). MS (ESI) m/z
412.30 (M-H).sup.-.
[0368] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous
NaHCO.sub.3 (1 eq.) with sonication for 10 min. The solvent was
removed by lyophilization to afford the title compound (43).
Example 40
Sodium
4-[(1-Propanoyloxyisobutoxy)carbonylamino]-(3R)-(4-chlorophenyl)-bu-
tanoate (48)
[0369] Following the procedures of Example 39 and replacing pivalic
acid with propionic acid in Step B afforded the title compound in
its acid form. .sup.1H NMR (CDCl.sub.3, 400 MHz): .delta. 0.90 (m,
6H), 1.14 (t, 3H), 1.96 (m, 1H), 2.33 (m, 2H), 2.64 (m, 1H), 2.72
(m, 1H), 3.52-3.28 (m, 3H), 4.69 (m, 1H), 6.51 (d, 1H), 7.12 (m,
2H), 7.27 (m, 2H). MS (ESI) m/z 384.10 (M-H).sup.-.
[0370] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous
NaHCO.sub.3 (1 eq.) with sonication for 10 min. The solvent was
removed by lyophilization to afford the title compound (48).
Example 41
Sodium
4-[(1-Cyclopentylcarbonyloxyisobutoxy)carbonylamino]-(3R)-(4-chloro-
phenyl)-butanoate (49)
[0371] Following the procedures of Example 39 and replacing pivalic
acid with cyclopentanecarboxylic acid in Step B afforded the title
compound in its acid form. .sup.1H NMR (CDCl.sub.3, 400 MHz):
.delta. 0.91 (m, 6H), 1.53-1.98 (m, 9H), 2.56-2.74 (m, 3H), 3.31
(m, 2H), 3.45 (m, 1H), 4.71 (m, 1H), 6.49 (d, 1H), 7.10 (q, 2H),
7.24 (m, 2H). MS (ESI) m/z 424.11 (M-H).sup.-.
[0372] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous
NaHCO.sub.3 (1 eq.) with sonication for 10 min. The solvent was
removed by lyophilization to afford the title compound (49).
Example 42
Sodium
4-[(1-Cyclohexylcarbonyloxyisobutoxy)carbonylamino]-(3R)-(4-chlorop-
henyl)-butanoate (50)
[0373] Following the procedures of Example 39 and replacing pivalic
acid with cyclohexanecarboxylic acid in Step B afforded the title
compound in its acid form. .sup.1H NMR (CDCl.sub.3, 400 MHz):
.delta. 0.89 (m, 6H), 1.22 (m, 3H), 1.40 (m, 2H), 1.61 (m, 1H),
1.70 (m, 2H), 1.89 (m, 3H), 2.27 (m, 1H), 2.58 (m, 1H), 2.70 (m,
1H), 3.29 (m, 2H), 3.23 (m, 1H), 4.73 (br.s, 1H), 6.48 (m, 1H),
7.10 (dd, 2H), 7.24 (dd, 2H). MS (ESI) m/z 438.14 (M-H).sup.-.
[0374] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous
NaHCO.sub.3 (1 eq.) with sonication for 10 min. The solvent was
removed by lyophilization to afford the title compound (50).
Example 43
Sodium
4-[(2,2-Diethoxypropanoyloxymethoxy)carbonylamino]-(3R)-(4-chloroph-
enyl)-butanoate (51)
Step A: Benzyl
4-[(2,2-Diethoxypropanoyloxymethoxy)-carbonylamino]-(3R)-(4-chlorophenyl)-
-butanoate (52)
[0375] A suspension of compound (8) (230 mg, 0.528 mmol) and cesium
2,2-diethoxypropionate (233 mg, 0.792 mmol) in DMF was stirred at
40.degree. C. for 1 h then cooled to room temperature. The reaction
mixture was partitioned between ice-water and ethyl acetate, and
the organic phase was washed with brine, dried over anhydrous
Na.sub.2SO.sub.4, and concentrated in vacuo to afford the crude
product, which was purified by chromatography on silica gel,
eluting with a mixture of 20% ethyl acetate in hexane to give the
title compound (52). .sup.1H NMR (CDCl.sub.3, 400 MHz): .delta.
1.18-1.27 (m, 6H), 2.68 (m, 1H), 2.80 (m, 1H), 3.33-3.58 (m, 7H),
4.99 (m, 3H), 5.75 (s, 2H), 7.08-7.29 (m, 9H).
Step B: Sodium
4-[(2,2-Diethoxypropanoyloxymethoxy)-carbonylamino]-(3R)-(4-chlorophenyl)-
-butanoate (51)
[0376] Following the procedure of Example 6 and replacing compound
(9) with (52) afforded the title compound in its acid form. .sup.1H
NMR (CDCl.sub.3, 400 MHz): .delta. 1.20 (t, 6H), 2.59 (dd, 1H),
2.69 (dd, 1H), 3.31-3.61 (m, 7H), 5.15 (m, 1H), 5.76 (s, 2H), 7.11
(d, 2H), 7.26 (d, 2H). MS (ESI) m/z 430.14 (M-H).sup.-.
[0377] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous
NaHCO.sub.3 (1 eq.) with sonication for 10 min. The solvent was
removed by lyophilization to afford the title compound (51).
Example 44
Sodium
4-[(4-Methoxybenzoyloxymethoxy)carbonylamino]-(3R)-(4-chlorophenyl)-
-butanoate (53)
[0378] Following the same procedures of Example 39 but replacing
1-chloro-2-methylpropyl chloroformate with chloromethyl
chloroformate in Step A and replacing pivalic acid with p-anisic
acid in Step B afforded the title compound in its acid form.
.sup.1H NMR (CDCl.sub.3, 400 MHz): .delta. 2.60 (dd, 1H), 2.70 (dd,
1H), 3.33 (m, 2H), 3.50 (m, 1H), 3.83 (s, 3H), 5.24 (m, 1H), 5.87
(s, 2H), 6.88 (d, 2H), 7.09 (d, 2H), 7.20 (d, 2H), 7.96 (d, 2H). MS
(ESI) m/z 420.11 (M-H).sup.-.
[0379] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous
NaHCO.sub.3 (1 eq.) with sonication for 10 min. The solvent was
removed by lyophilization to afford the title compound (53).
Example 45
Sodium
4-[(Nicotinoyloxymethoxy)carbonylamino]-(3R)-(4-chlorophenyl)-butan-
oate (54)
[0380] Following the same procedures of Example 39 but replacing
1-chloro-2-methylpropyl chloroformate with chloromethyl
chloroformate in Step A and replacing pivalic acid with nicotinic
acid in Step B afforded the title compound in its acid form.
.sup.1H NMR (CD.sub.3OD 400 MHz): .delta. 2.55 (dd, 1H), 2.70 (dd,
1H), 3.29 (m, 3H), 5.90 (s, 2H), 7.19 (m, 5H), 7.55 (dd, 1H), 8.35
(d, 1H), 8.74 (dd, 1H), 9.09 (s, 1H). MS (ESI) m/z 393.11
(M+H).sup.+.
[0381] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous
NaHCO.sub.3 (1 eq.) with sonication for 10 min. The solvent was
removed by lyophilization to afford the title compound (54).
Example 46
Sodium
4-[(Cyclopentylcarbonyloxymethoxy)carbonylamino]-(3R)-(4-chlorophen-
yl)-butanoate (55)
[0382] Following the same procedures of Example 39 but replacing
1-chloro-2-methylpropyl chloroformate with chloromethyl
chloroformate in Step A and replacing pivalic acid with
cyclopentanecarboxylic acid in Step B afforded the title compound
in its acid form.
[0383] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous
NaHCO.sub.3 (1 eq.) with sonication for 10 min. The solvent was
removed by lyophilization to afford the title compound (55).
.sup.1H NMR (CD.sub.3OD 400 MHz): .delta. 1.57-1.88 (m. 8H), 2.54
(m, 1H), 2.72 (m, 2H), 3.29 (m, 3H), 5.61 (q, 2H), 7.23 (m, 4H). MS
(ESI) m/z 381.91 (M-H).sup.-.
Example 47
Sodium
4-[(2-Furoyloxymethoxy)carbonylamino]-(3R)-(4-chlorophenyl)-butanoa-
te (56)
[0384] Following the same procedures of Example 39 but replacing
1-chloro-2-methylpropyl chloroformate with chloromethyl
chloroformate in Step A and replacing pivalic acid with 2-furoic
acid in Step B afforded the title compound in its acid form.
[0385] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous
NaHCO.sub.3 (1 eq.) with sonication for 10 min. The solvent was
removed by lyophilization to afford the title compound (56).
.sup.1H NMR (CD.sub.3OD 400 MHz): .delta. 2.37 (dd, 1H), 2.52 (dd,
1H), 3.29 (m, 3H), 5.77 (q, 2H), 6.61 (d, 1H), 7.20 (m, 4H), 7.23
(d, 1H), 7.76 (d, 1H). MS (ESI) m/z 379.99 (M-H).sup.-.
Example 48
Sodium
4-[(2-Thienylcarbonyloxymethoxy)carbonylamino]-(3R)-(4-chlorophenyl-
)-butanoate (57)
[0386] Following the same procedures of Example 39 but replacing
1-chloro-2-methylpropyl chloroformate with chloromethyl
chloroformate in Step A and replacing pivalic acid with
thiophene-2-carboxylic acid in Step B afforded the title compound
in its acid form.
[0387] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous
NaHCO.sub.3 (1 eq.) with sonication for 10 min. The solvent was
removed by lyophilization to afford the title compound (57).
.sup.1H NMR (CD.sub.3OD 400 MHz): .delta. 2.39 (dd, 1H), 2.52 (dd,
1H), 3.30 (m, 3H), 5.80 (AB q, 2H), 7.16 (m, 5H), 7.80 (m, 2H). MS
(ESI) m/z 419.77 (M+Na).sup.+.
Example 49
Sodium
4-[(Phenylacetoxymethoxy)carbonylamino]-(3R)-(4-chlorophenyl)-butan-
oate (58)
[0388] Following the same procedures of Example 39 but replacing
1-chloro-2-methylpropyl chloroformate with chloromethyl
chloroformate in Step A and replacing pivalic acid with
phenylacetic acid in Step B afforded the title compound in its acid
form.
[0389] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous
NaHCO.sub.3 (1 eq.) with sonication for 10 min. The solvent was
removed by lyophilization to afford the title compound (58).
.sup.1H NMR (CD.sub.3OD 400 MHz): .delta. 2.38 (dd, 1H), 2.51 (dd,
1H), 3.29 (m, 3H), 5.61 (AB q, 2H), 7.24 (m, 9H). MS (ESI) m/z
403.91 (M-H).sup.-.
Example 50
Sodium
4-[(3-Methylbutanoyloxymethoxy)carbonylamino]-(3R)-(4-chlorophenyl)-
-butanoate (59)
[0390] Following the same procedures of Example 39 but replacing
1-chloro-2-methylpropyl chloroformate with chloromethyl
chloroformate in Step A and replacing pivalic acid with isovaleric
acid in Step B afforded the title compound in its acid form.
[0391] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous
NaHCO.sub.3 (1 eq.) with sonication for 10 min. The solvent was
removed by lyophilization to afford the title compound (59).
.sup.1H NMR (CD.sub.3OD 400 MHz): .delta. 0.94 (d, 6H), 2.03 (m,
1H), 2.19 (d, 2H), 2.53 (m, 1H), 2.70 (m, 1H), 3.29 (m, 3H), 5.62
(AB q, 2H), 7.23 (m, 4H). MS (ESI) m/z 394.03 (M+Na).sup.+.
Example 51
Sodium
4-[(Pentanoyloxymethoxy)carbonylamino]-(3R)-(4-chlorophenyl)-butano-
ate (60)
[0392] Following the same procedures of Example 39 but replacing
1-chloro-2-methylpropyl chloroformate with chloromethyl
chloroformate in Step A and replacing pivalic acid with valeric
acid in Step B afforded the title compound in its acid form.
[0393] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous
NaHCO.sub.3 (1 eq.) with sonication for 10 min. The solvent was
removed by lyophilization to afford the title compound (60).
.sup.1H NMR (CD.sub.3OD 400 MHz): .delta. 0.91 (t, 3H), 1.33 (m,
2H), 1.56 (p, 2H), 2.31 (t, 2H), 2.42 (m, 1H), 2.56 (m, 1H), 3.30
(m, 3H), 5.59 (AB q, 2H), 7.22 (m, 4H). MS (ESI) m/z 394.15
(M+Na).sup.+.
Example 52
Sodium
4-[(Cinnamoyloxymethoxy)carbonylamino]-(3R)-(4-chlorophenyl)-butano-
ate (61)
[0394] Following the same procedures of Example 39 but replacing
1-chloro-2-methylpropyl chloroformate with chloromethyl
chloroformate in Step A and replacing pivalic acid with cinnamic
acid in Step B afforded the title compound in its acid form.
[0395] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous
NaHCO.sub.3 (1 eq.) with sonication for 10 min. The solvent was
removed by lyophilization to afford the title compound (61).
.sup.1H NMR (CD.sub.3OD 400 MHz): .delta. 2.39 (dd, 1H), 2.53 (d,
1H), 3.29 (m, 3H), 5.72 (AB q, 2H), 6.49 (d, 1H), 7.21 (m, 4H),
7.31 (m, 3H), 7.61 (m, 2H), 7.72 (d, 1H). MS (ESI) m/z 440.14
(M+Na).sup.+.
Example 53
Sodium
4-[(3-Phenylpropionoyloxymethoxy)carbonylamino]-(3R)-(4-chloropheny-
l)-butanoate (62)
[0396] Following the same procedures of Example 39 but replacing
1-chloro-2-methylpropyl chloroformate with chloromethyl
chloroformate in Step A and replacing pivalic acid with
dihydrocinnamic acid in Step B afforded the title compound in its
acid form.
[0397] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous
NaHCO.sub.3 (1 eq.) with sonication for 10 min. The solvent was
removed by lyophilization to afford the title compound (62).
.sup.1H NMR (CD.sub.3OD 400 MHz): .delta. 2.39 (dd, 1H), 2.52 (dd,
1H), 2.61 (t, 2H), 2.88 (t, 2H), 3.29 (m, 3H), 5.58 (s, 2H), 7.21
(m, 9H). MS (ESI) m/z 442.14 (M+Na).sup.+.
Example 54
Sodium
4-[(2-Methylbutanoyloxymethoxy)carbonylamino]-(3R)-(4-chlorophenyl)-
-butanoate (63)
[0398] Following the same procedures of Example 39 but replacing
1-chloro-2-methylpropyl chloroformate with chloromethyl
chloroformate in Step A and replacing pivalic acid with
2-methylbutyric acid in Step B afforded the title compound in its
acid form.
[0399] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous
NaHCO.sub.3 (1 eq.) with sonication for 10 min. The solvent was
removed by lyophilization to afford the title compound (63) as a
pair of diasteromers. .sup.1H NMR (CD.sub.3OD 400 MHz): .delta.
0.87 (dt, 3H), 1.08 (dd, 3H), 1.44 (m, 1H), 1.60 (m, 1H), 2.36 (m,
2H), 2.50 (m, 1H), 3.29 (m, 3H), 5.60 (AB q, 2H), 7.21 (m, 4H). MS
(ESI) m/z 394.04 (M+Na).sup.+.
Example 55
Sodium
4-[(1-Cyclopentanecarbonyloxybutoxy)carbonylamino]-(3R)-(4-chloroph-
enyl)-butanoate (64)
Step A: 1-Chlorobutyl Chloroformate (65)
[0400] To a solution of triphosgene (4.94 g, 16.6 mmol) and
n-butyraldehyde (3.0 g, 41.6 mmol) in anhydrous ether (30 mL) at
0.degree. C. was added pyridine (0.67 mL, 8.32 mmol) dropwise. The
resulting suspension was stirred at 0.degree. C. for 30 min. The
reaction mixture was filtered through a pad of Celite and the
supernatant was concentrated on a rotary evaporator, affording the
title chloroformate (4.38 g, 62%), which was used in the next step
without further purification. .sup.1H NMR (CDCl.sub.3, 400 MHz):
.delta. 0.95 (t, 3H), 1.51 (m, 2H), 2.04 (m, 2H), 6.30 (t, 1H).
Step B: O-(1-Chlorobutoxy) S-Ethyl Thiocarbonate (66)
[0401] To a solution of ethanethiol (1.8 mL, 24.3 mmol) and
triethylamine (4.3 mL, 30.7 mmol) in CH.sub.2Cl.sub.2 at 0.degree.
C. was added chloroformate (65) (4.38 g, 25.6 mmol) in
CH.sub.2Cl.sub.2. The resulting reaction mixture was stirred for 10
min at 0.degree. C., then was washed successively with water,
dilute HCl and brine. The organic phase was dried over anhydrous
Na.sub.2SO.sub.4. After concentration in vacuo the crude
O-(1-chlorobutoxy) S-ethyl thiocarbonate (66) (3.99 g) was
obtained, and used directly in the next step without further
purification. .sup.1H NMR (CDCl.sub.3, 400 MHz): .delta. 0.96 (t,
3H), 1.34 (t, 3H), 1.50 (m, 2H), 2.00 (m, 2H), 2.90 (m, 2H), 6.47
(t, 2H).
Step C: O-(1-Cyclopentanecarbonyloxybutoxy) S-Ethyl Thiocarbonate
(67)
[0402] A mixture of (66) (1.33 g, 6.76 mmol) and
cyclopentancarboxylic acid (1.30 g, 10.1 mmol) was stirred at
75.degree. C. for five days. The reaction was then cooled to room
temperature and partitioned between water and ether. The ether
layer was washed with brine, dried over anhydrous Na.sub.2SO.sub.4.
Filtration then removal of the solvent by rotary evaporation gave
the title thiocarbonate (67) (1.62 g, 86%). .sup.1H NMR
(CDCl.sub.3, 400 MHz): .delta. 0.95 (t, 3H), 1.20-1.85 (m, 15H),
2.68 (m, 1H), 2.82 (m, 2H). 6.84 (t, 1H).
Step D: [(1-Cyclopentanecarbonyloxybutoxy)carbonyloxy]Succinimide
(68)
[0403] A solution of (67) (1.83 g, 6.34 mmol) in CH.sub.2Cl.sub.2
at 0.degree. C. was treated with sulfuryl chloride (0.62 mL, 7.61
mmol) under N.sub.2 for 10 min, then the reaction mixture was
concentrated to dryness in vacuo to afford crude
(1-cyclopentanecarbonyloxy-butoxy)chloroformate in quantitative
yield. The chloroformate was dissolved in CH.sub.2Cl.sub.2, and was
added to a mixture of N-hydroxysuccinimide (1.09 g, 9.51 mmol) and
pyridine (1.28 mL, 15.8 mmol) in CH.sub.2Cl.sub.2 at 0.degree. C.
The reaction mixture was stirred at 0.degree. C. for 1 h, then was
washed with water, dilute HCl and brine and dried over
Na.sub.2SO.sub.4. After removal of solvent in vacuo the title
N-hydroxysuccinimidyl carbonate (68) was obtained in quantitative
yield, and was used in the subsequent step without further
purification.
Step E: Sodium
4-[(1-Cyclopentanecarbonyloxybutoxy)-carbonylamino]-(3R)-(4-chlorophenyl)-
-butanoate (64)
[0404] To a solution of R-baclofen (644 mg, 3.02 mmol) and
NaHCO.sub.3 (323 mg, 3.848 mmol) in water at room temperature was
added a solution of (68) (900 mg, 2.749 mmol) in acetonitrile. The
resulting reaction mixture was stirred for 1 h at that temperature,
then was acidified to pH 4 with 10% HCl, and extracted with ethyl
acetate. The combined organic phase was washed with brine and dried
over anhydrous Na.sub.2SO.sub.4. Filtration and removal of the
solvent in vacuo gave the crude product, which was purified by
preparative LC/MS to afford the acid form of the title compound as
a pair of diastereomers (636 mg, 75%).
[0405] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (1 mL) and then addition of aqueous NaHCO.sub.3
(1 eq.) with sonication for 10 min. The solvent was removed by
lyophilization to afford the title compound (64). .sup.1H NMR
(CD.sub.3OD, 400 MHz): .delta. 0.92 (m, 3H), 1.36 (m, 2H),
1.56-1.87 (m, 10H), 2.41 (m, 1H), 2.52 (m, 1H), 2.70 (m, 1H), 3.29
(m, 3H), 6.59 (q, 1H), 7.22 (m, 4H). MS (ESI) m/z 448.7
(M+Na).sup.+.
Example 56
Sodium
4-[(1-Cyclohexanecarbonyloxybutoxy)carbonylamino]-(3R)-(4-chlorophe-
nyl)-butanoate (69)
[0406] Following the same procedures of Example 55 but replacing
cyclopentanecarboxylic acid with cyclohexanecarboxylic acid
afforded the title compound (69) as a pair of diastereomers (596
mg). .sup.1H NMR (CD.sub.3OD, 400 MHz): .delta. 0.94 (m, 3H), 1.33
(m, 7H), 1.61-1.83 (m, 7H), 2.26 (m, 1H), 2.41 (m, 1H), 2.51 (m,
1H), 3.30 (m, 3H), 6.59 (m, 1H), 7.21 (m, 4H). MS (ESI) m/z 462.76
(M+Na).sup.+.
Example 57
Sodium
4-[(1-Hexanoyloxybutoxy)carbonylamino]-(3R)-(4-chlorophenyl)-butano-
ate (70)
[0407] Following the same procedures of Example 55 but replacing
cyclopentanecarboxylic acid with hexanoic acid afforded the title
compound (70) as a pair of diastereomers (894 mg). .sup.1H NMR
(CD.sub.3OD, 400 MHz): .delta. 0.92 (m, 6H), 1.31 (m, 6H),
1.55-1.70 (m, 4H), 2.64 (m, 2H), 2.40 (m, 1H), 2.53 (m, 1H), 3.30
(m, 3H), 6.61 (m, 1H), 7.22 (s, 4H). MS (ESI) m/z 450.76
(M+Na).sup.+.
Example 58
Sodium
4-[(1-Benzoyloxybutoxy)carbonylamino]-(3R)-(4-chlorophenyl)-butanoa-
te (71)
[0408] Following the same procedures of Example 55 but replacing
cyclopentanecarboxylic acid with benzoic acid afforded the title
compound (71) as a pair of diastereomers (100 mg). .sup.1H NMR
(CDC.sub.3, 400 MHz): .delta. 0.71 (m, 3H), 1.14 (m, 2H), 1.48 (m,
2H), 2.72 (m, 2H), 3.35 (m, 2H), 3.50 (m, 1H), 5.32 (br.m, 1H),
6.80 (m, 5H), 7.22 (m, 2H), 7.40 (m, 1H), 7.75 (m, 2H). MS (ESI)
m/z 456.10 (M+Na).sup.+.
Example 59
Sodium
4-[(1-Isobutanoyloxybutoxy)carbonylamino]-(3R)-(4-chlorophenyl)-but-
anoate (72)
[0409] Following the same procedures of Example 55 but replacing
cyclopentanecarboxylic acid with isobutyric acid afforded the title
compound (72) as a pair of diastereomers (70 mg). .sup.1H NMR
(CDCl.sub.3, 400 MHz): .delta. 0.92 (m, 3H), 1.14 (m, 6H), 1.35 (m,
2H), 1.68 (m, 2H), 2.48-2.72 (m, 3H), 3.25-3.52 (m, 3H), 4.73 (br.
m, 1H), 6.65 (t, 1H), 7.11 (d, 2H), 7.25 (d, 2H). MS (ESI) m/z
422.14 (M+Na).sup.+.
Example 60
Sodium
4-[(1-Butanoyloxybutoxy)carbonylamino]-(3R)-(4-chlorophenyl)-butano-
ate (73)
[0410] Following the same procedures of Example 55 but replacing
cyclopentanecarboxylic acid with n-butyric acid afforded the title
compound (73) as a pair of diastereomers (122 mg). .sup.1H NMR
(CDCl.sub.3, 400 MHz): .delta. 0.85 (m, 6H), 1.24 (m, 2H), 1.52 (m,
4H), 2.14 (m, 2H), 2.35 (m, 2H), 3.03-3.23 (2H), 3.35 (m, 1H), 5.40
(br.s, 1H), 6.61 (m, 1H), 6.98 (d, 2H), 7.08 (m, 2H). MS (ESI) m/z
422.14 (M+Na).sup.+.
Example 61
Sodium
4-[(1-Acetoxybutoxy)carbonylamino]-(3R)-(4-chlorophenyl)-butanoate
(74)
[0411] Following the same procedures of Example 55 but replacing
cyclopentanecarboxylic acid with acetic acid afforded the title
compound (74) as a pair of diastereomers (600 mg). .sup.1H NMR
(CD.sub.3OD, 400 MHz): .delta. 0.92 (m, 3H), 1.35 (m, 2H), 1.67 (m,
2H), 1.99 (2s, 3H), 2.55 (m, 1H), 2.70 (m, 1H), 3.29 (m, 3H), 6.60
(q, 1H), 7.25 (m, 4H). MS (ESI) m/z 394.20 (M+Na).sup.+.
Example 62
Sodium
4-[(1-Propionyloxybutoxy)carbonylamino]-(3R)-(4-chlorophenyl)-butan-
oate (75)
[0412] Following the same procedures of Example 55 but replacing
cyclopentanecarboxylic acid with propionic acid afforded the title
compound (75) as a pair of diastereomers (405 mg). .sup.1H NMR
(CD.sub.3OD, 400 MHz): .delta. 0.93 (m, 3H), 1.08 (m, 3H), 1.33 (m,
2H), 1.64 (m, 2H), 2.22-2.33 (m, 2H), 2.39 (m, 1H), 2.50 (m, 1H),
2.30 (m, 3H), 6.60 (m, 1H), 7.22 (s, 4H). MS (ESI) m/z 408.11
(M+Na).sup.+.
Example 63
Sodium
4-[(1-Cyclohexanecarbonyloxypropoxy)carbonylamino]-(3R)-(4-chlorophenyl)-b-
utanoate (76)
[0413] Following the same procedures of Example 55 but replacing
butyraldehyde with propionaldehyde in Step A and replacing
cyclopentanecarboxylic acid with cyclohexanecarboxylic acid in Step
C afforded the title compound (76) as a pair of diastereomers (700
mg). .sup.1H NMR (CD.sub.3OD, 400 MHz): .delta. 0.87 (m, 3H),
1.25-1.39 (m, 5H), 1.62-1.86 (m, 7H), 2.1-2.54 (m, 3H), 3.29 (m,
3H), 6.51 (m, 1H), 7.21 (m, 4H). MS (ESI) m/z 448.20
(M+Na).sup.+.
Example 64
Sodium
4-[(1-Isobutanoyloxypropoxy)carbonylamino]-(3R)-(4-chlorophenyl)-bu-
tanoate (77)
[0414] Following the same procedures of Example 63 but replacing
cyclohexanecarboxylic acid with isobutyric acid afforded the title
compound (77) as a pair of diastereomers (140 mg). .sup.1H NMR
(CD.sub.3OD, 400 MHz): .delta. 0.86-0.92 (m, 3H), 1.06-1.13 (m,
6H), 1.69 (m, 2H), 2.36-2.55 (m, 3H), 3.30 (m, 3H), 6.51 (m, 1H),
7.22 (s, 4H). MS (ESI) m/z 408.11 (M+Na).sup.+.
Example 65
Sodium
4-[(1-Butanoyloxypropoxy)carbonylamino]-(3R)-(4-chlorophenyl)-butan-
oate (78)
[0415] Following the same procedures of Example 63 but replacing
cyclohexanecarboxylic acid with n-butyric acid afforded the title
compound (78) as a pair of diastereomers (1.09 g). .sup.1H NMR
(CD.sub.3OD, 400 MHz): .delta. 0.91 (m, 6H), 1.59 (m, 2H), 1.69 (m,
2H), 2.23-2.25 (m, 2H), 2.40 (m, 1H), 2.51 (m, 1H), 3.29 (m, 3H),
6.56 (q, 1H), 7.22 (s, 4H). MS (ESI) m/z 408.73 (M+Na).sup.+.
Example 66
Sodium
4-[(1-Propionoyloxypropoxy)carbonylamino]-(3R)-(4-chlorophenyl)-but-
anoate (79)
[0416] Following the same procedures of Example 63 but replacing
cyclohexanecarboxylic acid with propionic acid afforded the title
compound (79) as a pair of diastereomers (100 mg). .sup.1H NMR
(CD.sub.3OD, 400 MHz): .delta. 0.88 (m, 3H), 1.08 (m, 3H), 2.21 (m,
1H), 2.25 (m, 2H), 2.39 (m, 1H), 2.50 (m, 1H), 3.30 (m, 3H), 6.52
(q, 1H), 7.22 (s, 4H). MS (ESI) m/z 394.08 (M+Na).sup.+.
Example 67
Sodium
4-[(1-Pivaloyloxypropoxy)carbonylamino]-(3R)-(4-chlorophenyl)-butan-
oate (80)
[0417] Following the same procedures of Example 63 but replacing
cyclohexanecarboxylic acid with pivalic acid afforded the title
compound (80) as a pair of diastereomers (420 mg). .sup.1H NMR
(CD.sub.3OD, 400 MHz): .delta. 0.90 (m, 3H), 1.10 (s, 4.5H), 1.16
(s, 4.5H), 1.70 (m, 2H), 2.47-2.55 (m, 2H), 3.30 (m, 3H), 6.50 (dt,
1H), 7.22 (s, 4H). (ESI) m/z 422.07 (M+Na).sup.+.
Example 68
Sodium
4-[(1-Benzoyloxypropoxy)carbonylamino]-(3R)-(4-chlorophenyl)-butano-
ate (81)
[0418] Following the same procedures of Example 63 but replacing
cyclohexanecarboxylic acid with benzoic acid afforded the title
compound (81) as a pair of diastereomers (129 mg). .sup.1H NMR
(CD.sub.3OD, 400 MHz): .delta. 0.98 (m, 3H), 1.85 (m, 2H), 2.39 (m,
1H), 2.52 (m, 1H), 3.30 (m, 3H), 6.78 (m, 1H), 7.18 (m, 4H), 7.48
(m, 2H), 7.60 (m, 1H), 7.95 (m, 2H). MS (ESI) m/z 442.07
(M+Na).sup.+.
Example 69
Sodium
4-[(1-Acetoxy-1-cyclohexylmethoxy)carbonylamino]-(3R)-(4-chlorophen-
yl)-butanoate (82)
[0419] Following the same procedures of Example 55 but replacing
butyraldehyde with cyclohexanecarboxaldehyde in Step A and
replacing cyclopentanecarboxylic acid with acetic acid in Step C
afforded the title compound (82) as a pair of diastereomers (759
mg). .sup.1H NMR (CD.sub.3OD, 400 MHz): .delta. 0.94-1.28 (m, 4H),
1.60-1.80 (m, 6H), 1.98 (s, 1.5H), 2.01 (s, 1.5H), 2.39 (m, 1H),
2.51 (m, 1H), 3.30 (m, 3H), 6.40 (M, 1H), 7.22 (s, 4H). MS (ESI)
m/z 434.73 (M+Na).sup.+.
Example 70
Sodium
4-[(1-Propionyloxy-1-cyclohexylmethoxy)carbonylamino]-(3R)-(4-chlorophenyl-
-butanoate (83)
[0420] Following the same procedures of Example 55 but replacing
butyraldehyde with cyclohexanecarboxaldehyde in Step A and
replacing cyclopentanecarboxylic acid with propionic acid in Step C
afforded the title compound (83) as a pair of diastereomers (310
mg). .sup.1H NMR (CD.sub.3OD, 400 MHz): .delta. 0.96-1.30 (m, 7H),
1.58-1.80 (m, 6H), 2.24-2.42 (m, 3H), 2.53 (m, 1H), 3.30 (m, 3H),
6.42 (q, 1H), 7.21 (s, 4H). MS (ESI) m/z 448.10 (M+Na).sup.+.
Example 71
Sodium
4-[(1-Isobutanoyloxy-1-cyclohexylmethoxy)carbonylamino]-(3R)-(4-chl-
orophenyl)-butanoate (84)
[0421] Following the same procedures of Example 55 but replacing
butyraldehyde with cyclohexanecarboxaldehyde in Step A and
replacing cyclopentanecarboxylic acid with isobutyric acid in Step
C afforded the title compound (84) as a pair of diastereomers (800
mg). .sup.1H NMR (CD.sub.3OD, 400 MHz): .delta. 0.96-1.28 (m, 10H),
1.58-1.79 (m, 6H), 2.36-2.54 (m, 3H), 3.30 (m, 3H), 7.21 (s, 4H).
MS (ESI) m/z 462.21 (M+Na).sup.+.
Example 72
Sodium
4-[(1-Butanoyloxy-1-cyclohexylmethoxy)carbonylamino]-(3R)-(4-chlorophenyl)-
-butanoate (85)
[0422] Following the same procedures of Example 55 but replacing
butyraldehyde with cyclohexanecarboxaldehyde in Step A and
replacing cyclopentanecarboxylic acid with n-butyric acid in Step C
afforded the title compound (85) as a pair of diastereomers (520
mg). .sup.1H NMR (CD.sub.3OD, 400 MHz): .delta. 0.92 (m, 3H),
0.98-1.28 (m, 4H), 1.54-1.78 (m, 8H), 2.24 (m, 2H), 2.39 (m, 1H),
2.53 (m, 1H), 3.29 (m, 3H), 6.41 (q, 1H). MS (ESI) m/z 462.06
(M+Na).sup.+.
Example 73
Asymmetric Synthesis of Sodium
4-{[(1S)-Butanoyloxybutoxy]carbonylamino}-(3R)-(4-chlorophenyl)-butanoate
(86)
Step A: Synthesis of
[(1S)-Butanoylbutoxy]-(4-nitrophenyl)-carbonate (87)
[0423] To a solution of (5S)-5-hydroxyoctan-4-one (1.10 g, 7.63
mmol) in CH.sub.2Cl.sub.2 (50 mL) at 0.degree. C. was added
p-nitrophenyl chloroformate (1.90 g, 9.14 mmol), pyridine (0.98 mL,
12.1 mmol) and 4-dimethylaminopyridine (186 mg, 1.52 mmol). The
resulting mixture was stirred at 0.degree. C. for 1 h then at room
temperature overnight. The reaction mixture was diluted in
CH.sub.2Cl.sub.2, washed excessively with water, dilute HCl and
brine, and dried over anhydrous Na.sub.2SO.sub.4. Filtration and
removal of the solvent in vacuo afforded the crude carbonate, which
was purified by chromatography on silica gel, eluting with 5% ether
in hexane to afford the title compound (87) (1.45 g, 65%). .sup.1H
NMR (CDCl.sub.3, 400 MHz): .delta. 0.94 (t, 3H) 0.99 (t, 3H), 1.51
(hex, 2H), 1.66 (hex, 2H), 1.85 (m, 2H), 2.48 (m, 2H), 5.03 (AB q,
1H), 7.03 (d, 2H), 8.26 (d, 2H).
Step B: Synthesis of
4-{[(1S)-Butanoylbutoxy]carbonylamino}-(3R)-(4-chlorophenyl)-butanoic
Acid (88)
[0424] To a stirred suspension of R-baclofen (1.0 g, 4.69 mmol) in
CH.sub.2Cl.sub.2 (50 mL) at 0.degree. C. was added triethylamine
(2.4 mL, 18.76 mmol) and TMSCl (1.19 mL, 9.38 mmol). The resulting
reaction mixture was stirred at 0.degree. C. for 15 min. Then, to
the suspension was added a solution of compound (87) (4.7 mmol) in
CH.sub.2Cl.sub.2 (5 mL) and the resulting reaction mixture stirred
at room temperature for 5 h. The mixture was diluted with
CH.sub.2Cl.sub.2, washed with ice-cold dilute HCl and brine, and
dried over anhydrous Na.sub.2SO.sub.4. The solvent was removed in
vacuo to afford the crude product, which was purified by
chromatography on silica gel, eluting first with pure
CH.sub.2Cl.sub.2 to remove p-nitrophenol, and then with 20% ethyl
acetate in CH.sub.2Cl.sub.2 to afford the carbamate compound (88)
(1.20 g, 67%). .sup.1H NMR (CDCl.sub.3, 400 MHz): .delta. 0.90 (m,
6H), 1.33 (m, 2H), 1.60 (m, 4H), 2.39 (m, 2H), 2.58 (m, 1H), 2.71
(m, 1H), 3.3.25-3.50 (m, 3H), 4.90 (AB q, 1H), 5.06 (t, 1H), 7.13
(d, 2H), 7.26 (d, 2H).
Step C:
4-{[(1S)-Butanoyloxybutoxy]carbonylamino}-(3R)-(4-chlorophenyl)-bu-
tanoic Acid (89)
[0425] To a stirred suspension of urea-hydrogen peroxide (1.43 g,
15.2 mmol) in CH.sub.2Cl.sub.2 (30 mL) at 0.degree. C. was added
carbamate (88) (417 mg, 1.09 mmol) in CH.sub.2Cl.sub.2 (5 mL),
followed by dropwise addition of trifluoroacetic anhydride (1.06
mL, 7.60 mmol). The resulting reaction mixture was stirred at
0.degree. C. and quenched after 5 h. The reaction mixture was
washed with water and brine, then dried over anhydrous
Na.sub.2SO.sub.4 to afford the crude product, which was purified by
preparative LC/MS to afford the title compound (89) (189 mg, 43.5%)
as a single diastereomer (as determined by chiral LC/MS). .sup.1H
NMR (CDCl.sub.3, 400 MHz): .delta. 0.92 (m, 6H), 1.38 (m, 2H), 1.65
(m, 4H), 2.28 (t, 2H), 2.59 (dd, 1H), 2.70 (dd, 1H), 3.29 (m, 2H),
3.50 (m, 1H), 4.78 (br. m, 1H), 6.67 (t, 1H), 7.11 (d, 2H), 7.26
(d, 2H). MS (ESI) m/z 398.14 (M-H).sup.-.
Step D: Sodium
4-{[(1S)-Butanoyloxybutoxy]carbonylamino}-(3R)-(4-chlorophenyl)-butanoate
(86)
[0426] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous
NaHCO.sub.3 (1 eq.) with sonication for 10 min. The solvent was
removed by lyophilization to afford the title compound (86).
Example 74
Asymmetric Synthesis of Sodium
4-{[(1R)-Butanoyloxyisobutoxy]carbonylamino}-(3R)-(4-chlorophenyl)-butano-
ate (90)
[0427] Following the procedures of Example 73 but replacing
(5S)-5-hydroxyoctan-4-one with (3R)-3-hydroxy-2-methylheptan-4-one,
the free acid form of the title compound was obtained as a single
diastereomer (158 mg, 23%). .sup.1H NMR (CDCl.sub.3, 400 MHz):
.delta. 0.91 (m, 9H) 1.63 (hept, 2H), 1.94 (m, 2H), 2.29 (t, 2H),
2.60 (dd, 1H), 2.71 (dd, 1H), 3.30 (m, 2H), 3.51 (m, 1H), 4.70 (t,
1H), 6.51 (d, 1H), 7.12 (d, 2H), 7.26 (d, 2H). MS (ESI) m/z 398.14
(M-H).sup.-.
[0428] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous
NaHCO.sub.3 (1 eq.) with sonication for 10 min. The solvent was
removed by lyophilization to afford the title compound (90).
Example 75
Asymmetric Synthesis of Sodium
4-{[(1S)-Isobutanoyloxybutoxy]carbonylamino}-(3R)-(4-chlorophenyl)-butano-
ate (91)
[0429] Following the procedures of Example 73 but replacing
(5S)-5-hydroxyoctan-4-one with (4S)-4-hydroxy-2-methylheptan-3-one,
the free acid form of the title compound was obtained as a single
diastereomer (20 mg, 7%). .sup.1H NMR (CDCl.sub.3, 400 Mhz):
.delta. 0.93 (t, 3H), 1.16 (m, 6H), 1.34 (m, 2H), 1.68 (m, 2H),
2.52 (m, 1H), 2.58 (dd, 1H), 2.71 (dd, 1H), 3.30 (m, 2H), 3.52 (m,
1H), 4.70 (t, 1H), 6.67 (t, 1H), 7.12 (d, 2H), 7.26 (d, 2H). MS
(ESI) m/z 398.14 (M-H).sup.-.
[0430] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous
NaHCO.sub.3 (1 eq.) with sonication for 10 min. The solvent was
removed by lyophilization to afford the title compound (91).
Example 76
Asymmetric Synthesis of Sodium
4-{[(1S)-Isobutanoyloxyisobutoxy]carbonylamino}-(3R)-(4-chlorophenyl)-but-
anoate (92)
[0431] Following the procedures of Example 73 but replacing
(5S)-5-hydroxyoctan-4-one with
(4S)-2,5-dimethyl-4-hydroxyhexan-3-one, the free acid form of the
title compound was obtained as a single diastereomer (8.0 mg, 2%).
.sup.1H NMR (CDCl.sub.3, 400 MHz): .delta. 0.89 (m, 6H), 1.15 (m,
6H), 1.94 (m, 1H), 2.52 (m, 1H), 2.58 (dd, 1H), 2.78 (dd, 1H), 3.28
(m, 2H), 3.49 (m, 1H), 4.68 (t, 1H), 6.48 (d, 1H), 7.10 (d, 2H),
7.24 (d, 2H). MS (ESI) m/z 398.14 (M-H).sup.-.
[0432] The carboxylic acid was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous
NaHCO.sub.3 (1 eq.) with sonication for 10 min. The solvent was
removed by lyophilization to afford the title compound (92).
Example 77
Synthesis of O-(1-Isobutanoyloxyisobutoxy) S-Methyl Thiocarbonate
(93)
Step A: O-(1-Chloroisobutoxy) S-Methyl Thiocarbonate (94)
[0433] A solution of 1-chloro-2-methylpropyl chloroformate (1026 g,
6.0 mol) and tetrabutylammonium hydrogensulfate (20 g, 60 mmol) in
dichloromethane (1500 mL) in a jacketed 10 L reactor equipped with
a mechanical stirrer, temperature probe, and addition funnel was
cooled to 10.degree. C. To the reaction mixture was gradually added
a 15% aqueous solution of sodium methylthiolate (3 L, 6.4 mol) over
4 h. The reaction was moderately exothermic and the internal
temperature was maintained between 10 and 20.degree. C. during the
addition. The aqueous phase was separated and the organic phase was
washed with brine (2.times.2 L) and water (2 L). The organic layer
was dried over anhydrous Na.sub.2SO.sub.4, filtered, and
concentrated under reduced pressure to afford the title compound
(94) (1050 g, 5.76 mol, 96%) as a colorless liquid. .sup.1H NMR
(CDCl.sub.3, 400 MHz): .delta. 1.1 (dd, 6H), 2.2 (m, 1H), 2.4 (s,
3H), 6.35 (d, 1H).
Step B: Tetramethylammonium Isobutyrate (95)
[0434] To a 20 L round bottom flask was added isobutyric acid (1300
mL, 14 mol), and an aqueous solution of 25% tetramethylammonium
hydroxide (5 L, 14 mol). The water was removed under reduced
pressure, and azeotroped with toluene (2.times.2 L) to leave the
product (95) as an amber liquid, which was used without further
purification.
Step C: O-(1-Isobutanoyloxyisobutoxy) S-Methyl Thiocarbonate
(93)
[0435] To a 3 L three neck round bottom flask equipped with a
mechanical stirrer and teflon-coated thermocouple was added (95)
(1672 g, 9 mol), isobutyric acid (264 g, 1.5 mol), and (94) (1050
g, 5.76 mol). The reaction mixture was heated to 80.degree. C. for
12 h, monitoring the reaction progress by .sup.1H NMR. The reaction
mixture was cooled to 20.degree. C., diluted with EtOAc (1 L) and
washed with water (2.times.1 L), saturated NaHCO.sub.3 (1.times.2
L) and water (1 L). The organic phase was separated and
concentrated under reduced pressure to afford the product (93) (905
g, 3.9 mol, 65%) as a colorless liquid. .sup.1H NMR (CDCl.sub.3,
400 MHz): .delta. 1.0 (d, 6H), 1.2 (dd, 6H), 2.05 (m, 1H), 2.35 (s,
3H), 2.6 (m, 1H), 6.7 (d, 1H).
Example 78
Synthesis of
(1R)-1-[((3S,4S)-2,5-Dioxo-3,4-dibenzoyloxypyrrolidinyl)-oxycarbonyloxy]--
2-methylpropyl 2-methylpropanoate (96)
Step A: (3S,4S)-2,5-Dioxo-3,4-dibenzoyloxy-3,4-dihydrofuran
(97)
[0436] A suspension of 2,3-dibenzoyl-D-tartaric acid (100 g, 279
mmol) in acetic anhydride (300 mL) was stirred at 85.degree. C. for
2 h then the reaction mixture allowed to cool to room temperature.
The crystalline product was collected by filtration, washed with a
mixture of ether and hexane (1:1) and dried under vacuum to afford
the title compound (97) (80 g, 84%). .sup.1H NMR (CDCl.sub.3, 400
MHz): .delta. 5.99 (s, 2H), 7.50 (m, 4H), 7.66 (m, 2H), 8.07 (m,
4H).
Step B: 1-Hydroxy-(3S,4S)-2,5-Dioxo-3,4-dibenzoyloxypyrrolidine
(98)
[0437] To a suspension of (97) (60 g, 176 mmol) in a mixture of
acetonitrile and water (8:1, 400 mL) at 0.degree. C. was added a
50% aqueous solution of hydroxylamine (13.0 mL, 211 mmol). The
resulting suspension was stirred overnight at room temperature to
obtain a clear solution. The bulk of the acetonitrile was removed
by rotary evaporation and the residue was portioned between ethyl
acetate and water. The organic phase was washed successively with
water and brine, dried over anhydrous Na.sub.2SO.sub.4 and
concentrated in vacuo to afford the intermediate, 2,3-dibenzoyloxy
D-tartaric acid mono-hydroxamate. This compound was suspended in
toluene heated under reflux for 2 h, then cooled to room
temperature to form a crystalline solid. The product was collected
by filtration, washed with a mixture of ether and hexane (1:1), and
dried under vacuum to afford the title compound (98) (58 g, 93%).
.sup.1H NMR (CDCl.sub.3, 400 MHz): .delta. 6.06 (s, 2H), 7.50 (t,
4H), 7.65 (dt, 2H), 8.06 (m, 4H). MS (ESI) m/z 354.00
(M-H).sup.-.
Step C:
(1R)-1-[((3S,4S)-2,5-Dioxo-3,4-dibenzoyloxypyrrolidinyl)-oxycarbon-
yloxy]-2-methylpropyl 2-methylpropanoate (96)
[0438] To a stirred solution of compound (98) (35 g, 98.6 mmol) and
thiocarbonate (93) (34.6 g, 148 mmol) in dichloromethane at
0.degree. C. was dropwise added a 32% solution of peracetic acid
(300 mmol) in acetic acid over 2 h. The reaction temperature was
kept below 35.degree. C. during the addition of peracetic acid.
After the addition was complete, the reaction mixture was stirred
overnight at room temperature. The resulting white precipitate was
filtered and washed successively with water, and a mixture of ether
and hexane (1:2), then dried under vacuum to afford the crude title
compound. This product was crystallized once from a mixture of
ethyl acetate and hexane (1:1) to afford the title compound (96)
(13.7 g, 25%). The diastereomeric purity of the product was
determined to be 98.4% d.e. by HPLC using a chiral column. .sup.1H
NMR (CDCl.sub.3, 400 MHz): .delta. 1.06 (d, 6H), 1.22 (d, 3H), 1.22
(d, 3H), 2.20 (m, 1H), 2.64 (hept. 1H), 6.01 (br. s, 2H), 6.64 (d,
1H), 7.47 (m, 4H), 7.63 (m, 2H), 8.07 (m, 4H).
Example 79
Synthesis of
4-{[(1R)-Isobutanoyloxyisobutoxy]carbonylamino}-(3R)-(4-chlorophenyl)-but-
anoic Acid (99)
[0439] To a stirred suspension of (96) (11.7 g, 21.7 mmol) in a
mixture of THF and water (10:1) (220 mL) at room temperature was
added R-baclofen (4.78 g, 22.5 mmol). The resulting reaction
mixture was stirred until the suspension became a clear solution
(ca. 2 h) then was concentrated in vacuo to remove most of the
solvent. The residue was partitioned between ether and water, the
ether layer was washed with water and brine, and dried over
anhydrous Na.sub.2SO.sub.4. After filtration and concentration in
vacuo, the crude product was obtained and then purified by
flash-chromatography on silica gel, eluting with a gradient of
10-20% acetone in hexane. Crystallization from an acetone/hexane
mixture afforded the title compound (99) (8.22 g, 95% yield). The
diastereomeric purity of the product was determined to be 99.9%
d.e. by HPLC using a chiral column. .sup.1H NMR (CDCl.sub.3, 400
MHz): .delta. 0.95 (d, 6H), 1.17 (d, 3H), 1.18 (d, 3H), 1.99 (m,
1H), 2.55 (hept. 1H), 2.64 (dd, 1H), 2.76 (dd, 1H), 3.40 (m, 3H),
4.73 (br. t, 1H), 6.51 (d, 1H), 7.13 (d, 2H), 7.27 (m, 2H). MS
(ESI) m/z 398.50 (M-H).sup.-.
Example 80
Synthesis of Sodium
4-{[(1R)-Isobutanoyloxyisobutoxy]carbonylamino}-(3R)-(4-chlorophenyl)-but-
anoate (100)
[0440] The carboxylic acid (99) was converted to the sodium salt by
dissolution in MeCN (0.5 mL) and then addition of aqueous
NaHCO.sub.3 (1 eq.) with sonication for 15 min. The solvent was
removed by lyophilization to afford the title compound (100).
.sup.1H NMR (CD.sub.3OD, 400 MHz): .delta. 0.93 (d, 3H), 0.94 (d,
3H), 1.08 (d, 3H), 1.10 (d, 3H), 1.94 (m, 1H), 2.37-2.54 (m, 3H),
3.31 (m, 3H), 6.43 (d, 1H), 7.23 (s, 4H). MS (ESI) m/z 398.57
(M-Na).sup.-.
Example 81
Synthesis of
(1S)-1-[((3R,4R)-2,5-Dioxo-3,4-dibenzoyloxypyrrolidinyl)-oxycarbonyloxy]--
2-methylpropyl 2-methylpropanoate (101)
Step A: (3R,4R)-2,5-Dioxo-3,4-dibenzoyloxy-3,4-dihydrofuran
(102)
[0441] To a 3-necked 5 L round bottom flask fitted with a
mechanical stirrer and a teflon coated thermocouple was added
(-)-2,3-dibenzoyl-L-tartaric acid (1000 g, 2.79 mol) followed by
acetic anhydride (2 L). The suspension was stirred and heated to
85.degree. C. for 2 h during which time the starting material
gradually dissolved. A short time thereafter, the product began to
crystallize in the reaction mixture and the suspension was then
cooled to 25.degree. C. The product was collected by filtration,
washed with 10% acetone in hexane (2.times.1 L), and dried in a
vacuum oven at 50.degree. C. overnight to afford the title compound
(102) as a white solid. .sup.1H NMR (CDCl.sub.3, 400 MHz): .delta.
6.0 (s, 2H), 7.45 (app. t, 4H), 7.65 (app. t, 2H), 8.05 (d,
4H).
Step B: 1-Hydroxy-(3R,4R)-2,5-Dioxo-3,4-dibenzoyloxypyrrolidine
(103)
[0442] To a 3-neck 5 L round bottom flask fitted with a mechanical
stirrer and a teflon coated temperature probe was added (102) (2.79
mol) followed by acetonitrile (2 L). The suspension was cooled in
an ice bath to 4.degree. C., followed by the addition of 50%
aqueous hydroxylamine (180 mL, 2.93 mol) over 1 h. The starting
material gradually dissolved during the addition and the reaction
mixture was warmed to 20.degree. C. and stirred for 1 h. The
reaction mixture was concentrated in vacuo, diluted with EtOAc (1
L) and washed with 1 N HCl (2.times.1 L). The organic phase was
separated and concentrated in vacuo to afford a viscous red syrup.
The syrup was then heated for two hours in toluene (2.5 L) at
100.degree. C. with azeotropic removal of water. The syrup
gradually dissolved and then the product crystallized. After
cooling to room temperature the solid was collected by filtration,
washed with 10% acetone in hexane (2.times.1 L) and dried in a
vacuum oven to afford the title compound (103) (862 g, 2.43 mol,
87%) as a white solid. .sup.1H NMR (CDCl.sub.3, 400 MHz): .delta.
5.85 (s, 2H), 7.45 (app. t, 4H), 7.65 (app t, 2H), 8.05 (m,
4H).
Step C: (1S)-1-[((3R,4R)-2,5-Dioxo-3,4-dibenzoyloxy
pyrrolidinyl)-oxycarbonyloxy]-2-methylpropyl 2-methylpropanoate
(101)
[0443] A 3 L three necked round bottom flask fitted with a
mechanical stirrer, teflon coated temperature probe and an addition
funnel was charged with (93) (234 g, 1 mol), (103) (330 g, 0.95
mol), and 1,2-dichloroethane (2200 mL). The reaction mixture was
cooled under a nitrogen atmosphere in an ice water bath to
15.degree. C. To the stirred reaction mixture was added a 39%
solution of peracetic acid in dilute acetic acid (500 mL, 2.94 mol)
over 2 h, maintaining the temperature between 15 and 22.degree. C.
This temperature was maintained for an additional 12 h during which
time a white precipitate was formed. The reaction mixture was
further cooled to 3-4.degree. C., the product collected by
filtration, and washed with hexane (2.times.1 L). The product was
dried in vacuo, yielding the title compound (101) (128 g, 0.24 mol,
25%). The diastereomeric purity of the product was determined to be
>99% d.e. by HPLC using a chiral column. .sup.1H NMR
(CDCl.sub.3, 400 MHz): .delta. 1.0 (d, 6H), 1.2 (dd, 6H), 2.1 (m,
1H), 2.65 (m, 1H), 6.0 (br. s, 2H), 6.6 (d, 1H), 7.45 (app. t, 4H),
7.65 (app. t, 2H), 8.05 (d, 4H).
Example 82
Synthesis of
4-{[(1S)-Isobutanoyloxyisobutoxy]carbonylamino}-(3R)-(4-chlorophenyl)-but-
anoic Acid (104)
[0444] To a 3 L three necked round bottom flask fitted with a
mechanical stirrer, temperature probe, and nitrogen inlet was added
(101) (75 g, 139 mmol), R-baclofen (31.2 g, 146 mmol), THF (1000
mL), and water (100 mL). The suspension was stirred under a
nitrogen atmosphere at 18-20.degree. C. for 4 h. The reaction
became homogenous in 30 min. The THF was removed in vacuo and the
reaction mixture was diluted with methyl tert-butyl ether (250 mL)
and washed with 1N HCl (1.times.500 mL) and water (2.times.200 mL).
The organic phase was separated and concentrated in vacuo to leave
a white solid. The solid was purified by flash chromatography (800
g silica gel; eluting with 20% acetone in hexane) to afford the
product (50 g, 125 mmol, 90% yield) as a white solid.
Crystallization from either an acetone/hexane mixture or ethyl
acetate/heptane mixture afforded the title compound (104) (50 g,
125 mmol, 90% yield) as a white solid. The diastereomeric purity of
the product was determined to be >99% d.e. by HPLC using a
chiral column. .sup.1H NMR (CDCl.sub.3, 400 MHz): .delta. 0.89 (m,
6H), 1.15 (m, 6H), 1.94 (m, 1H), 2.52 (m, 1H), 2.58 (dd, 1H), 2.78
(dd, 1H), 3.28 (m, 2H), 3.49 (m, 1H), 4.68 (t, 1H), 6.48 (d, 1H),
7.10 (d, 2H), 7.24 (d, 2H). MS (ESI) m/z 398.14 (M-H).sup.-.
Example 83
Synthesis of Sodium
4-{[(1S)-Isobutanoyloxyisobutoxy]carbonylamino}-(3R)-(4-chlorophenyl)-but-
anoate (92)
[0445] The carboxylic acid (101) was converted to the sodium salt
by dissolution in MeCN and then addition of aqueous NaHCO.sub.3 (1
eq.) with sonication for 15 min. The solvent was removed by
lyophilization. Crystallization from either mixtures of
acetone/hexane, ethyl acetate/heptane, THF/heptane or
1,2-dimethoxyethane/hexane afforded the title compound (92) as a
white crystalline solid. .sup.1H NMR (CD.sub.3OD, 400 MHz): .delta.
0.90 (d, 6H), 1.14 (d, 3H), 1.15 (d, 3H), 1.91 (m, 1H), 2.40 (m,
1H), 2.52 (m, 2H), 3.30 (m, 3H), 6.41 (d, 1H), 7.22 (s, 4H). MS
(ESI) m/z 398.08 (M-Na).sup.-.
Example 84
Standard Methods for Determination of Enzymatic Cleavage of
Prodrugs In Vitro
[0446] The stabilities of prodrugs were evaluated in one or more in
vitro systems using a variety of tissue preparations following
methods known in the art. The chemical stability of prodrugs in
aqueous buffers at pH's of 2.0, 7.4 and 8.0 were also measured.
Tissues were obtained from commercial sources (e.g., Pel-Freez
Biologicals, Rogers, AR, or GenTest Corporation, Woburn, Mass.).
Experimental conditions used for the in vitro studies are described
in Table 1 below. Each preparation was incubated with test compound
at 37.degree. C. for one hour. Aliquots (50 .mu.L) were removed at
0, 30, and 60 min and quenched with 0.1% trifluoroacetic acid in
acetonitrile. Samples were then centrifuged and analyzed by
LC/MS/MS (see Example 86 below for method details). Stability of
prodrugs towards specific enzymes (e.g., peptidases, etc.) were
also assessed in vitro by incubation with the purified enzyme:
[0447] Pancreatin Stability: Stability studies were conducted by
incubating prodrug (5 .mu.M) with 1% (w/v) pancreatin (Sigma,
P-1625, from porcine pancreas) in 0.025 M Tris buffer containing
0.5 M NaCl (pH 7.5) at 37.degree. C. for 60 min. The reaction was
stopped by addition of 2 volumes of methanol. After centrifugation
at 14,000 rpm for 10 min, the supernatant was removed and analyzed
by LC/MS/MS.
[0448] Caco-2 Homogenate S9 Stability. Caco-2 cells were grown for
21 days prior to harvesting. Culture medium was removed and cell
monolayers were rinsed and scraped off into ice-cold 10 mM sodium
phosphate/0.15 M potassium chloride, pH 7.4. Cells were lysed by
sonication at 4.degree. C. using a probe sonicator. Lysed cells
were then transferred into 1.5 mL centrifuge vials and centrifuged
at 9000 g for 20 min at 4.degree. C. The resulting supernatant
(Caco-2 cell homogenate S9 fraction) was aliquoted into 0.5 mL
vials and stored at -80.degree. C. until used.
[0449] For stability studies, prodrug (5 .mu.M) was incubated in
Caco-2 homogenate S9 fraction (0.5 mg protein per mL) for 60 min at
37.degree. C. Concentrations of intact prodrug and released
baclofen were determined at zero time and 60 minutes using
LC/MS/MS. Data from these studies is summarized in Table 2.
TABLE-US-00001 TABLE 1 Standard Conditions for Prodrug In Vitro
Metabolism Studies Substrate Preparation Concentration Cofactors
Rat Plasma 2.0 .mu.M None Human Plasma 2.0 .mu.M None Rat Liver S9
2.0 .mu.M NADPH* (0.5 mg/mL) Human Liver S9 2.0 .mu.M NADPH* (0.5
mg/mL) Human Intestine 2.0 .mu.M NADPH* S9 (0.5 mg/mL)
Carboxypeptidase 2.0 .mu.M None A (10 units/mL) Caco-2 5.0 .mu.M
None Homogenate Pancreatin 5.0 .mu.M None *NADPH generating system,
e.g., 1.3 mM NADP+, 3.3 mM glucose-6-phosphate, 0.4 U/mL
glucose-6-phosphate dehydrogenase, 3.3 mM magnesium chloride and
0.95 mg/mL potassium phosphate, pH 7.4.
TABLE-US-00002 TABLE 2 % of Prodrug Remaining/% of Baclofen
Released from Baclofen Prodrugs after 60 min. in Various Tissue
Preparations (10) (12) (14) (16) (18) (20) (23) pH 2.0 100/1 100/0
100/1 100/0 105/0 100/0 107/0 pH 7.4 101/3 100/0 103/1 100/0 95/0
100/0 89/1 pH 8.0 98/9 105/0 102/2 100/0 102/0 103/0 90/2 Rat
Plasma 85/15 72/14 55/48 54/40 39/60 92/8 11/93 Human Plasma 64/26
95/5 90/10 62/20 61/27 82/9 96/3 Rat Liver S9 0/78 3/100 2/99 1/100
1/100 25/75 3/107 (0.5 mg/mL) Human Liver S9 1/80 1/100 2/102 1/100
2/100 1/100 4/105 (0.5 mg/mL) Caco-2 S9 2/96 2/100 2/97 1/100 1/100
1/100 15/87 Pancreatin 75/21 15/77 2/101 1/84 2/91 58/36 82/24 (25)
(27) (30) (33) (34) (40) (43) pH 2.0 101/0 102/0 100/0 100/0 100/0
103/0 95/0 pH 7.4 100/0 100/0 87/1 72/0 100/0 100/0 87/0 pH 8.0
100/0 101/1 81/3 101/0 100/0 107/2 92/0 Rat Plasma 5/96 12/88 58/42
73/30 78/18 72/17 71/29 Human Plasma 93/4 82/12 85/8 96/4 90/2
101/2 100/2 Rat Liver S9 1/98 0/89 1/85 4/101 1/100 8/96 3/97 (0.5
mg/mL) Human Liver S9 4/91 8/79 7/87 3/101 3/100 1/105 61/39 (0.5
mg/mL) Caco-2 S9 2/95 27/67 24/70 3/95 2/100 15/85 51/49 Pancreatin
22/84 71/9 90/9 46/52 81/18 43/58 82/4 (51) (57) (59) (62) (84)
(85) (86) pH 2.0 100/0 100/0 103/0 105/0 85/0 82/0 101/0 pH 7.4
97/2 100/0 103/1 94/2 84/0 92/0 99/1 pH 8.0 91/9 100/0 97/2 88/8
94/1 93/0 94/2 Rat Plasma 31/72 82/10 2/85 5/95 91/11 82/12 1/83
Human Plasma 53/50 73/14 77/11 84/2 89/4 95/4 73/13 Rat Liver S9
2/103 2/78 2/85 2/80 4/91 2/91 2/92 (0.5 mg/mL) Human Liver S9 6/91
1/86 1/82 0/69 2/82 2/84 2/87 (0.5 mg/mL) Caco-2 S9 3/100 2/104
3/104 1/89 13/76 4/82 2/95 Pancreatin 44/50 12/75 46/50 1/79 47/40
15/64 4/76 (90) (91) (92) (100) (104) pH 2.0 97/0 100/0 97/0 101/0
100/0 pH 7.4 93/0 97/0 95/0 98/0 100/0 pH 8.0 93/1 94/1 96/1 95/0
100/0 Rat Plasma 5/77 80/10 12/73 9/64 14/85 Human Plasma 81/2 83/2
86/1 89/3 98/2 Rat Liver S9 3/85 22/70 6/88 3/85 3/97 (0.5 mg/mL)
Human Liver S9 1/78 1/78 4/80 1/83 3/97 (0.5 mg/mL) Caco-2 S9 5/90
6/107 55/53 7/90 17/83 Pancreatin 9/68 11/78 85/7 68/27 90/6
Example 85
In Vitro Determination of Caco-2 Cellular Permeability of
Prodrugs
[0450] The trans-epithelial cellular permeability of prodrugs of
baclofen and baclofen analogs may be assessed in vitro using
standard methods well known in the art (see, e.g., Stewart, et al.,
Pharm. Res., 1995, 12, 693). For example, cellular permeability may
be evaluated by examining the flux of a prodrug across a cultured
polarized cell monolayer (e.g., Caco-2 cells). Caco-2 cells
obtained from continuous culture (passage less than 28) were seeded
at high density onto Transwell polycarbonate filters. Cells were
maintained with DMEM/10% fetal calf serum+0.1 mM nonessential amino
acids+2 mM L-Gln, 5% CO.sub.2/95% O.sub.2, 37.degree. C. until the
day of the experiment. Permeability studies were conducted at pH
6.5 atypically (in 50 mM MES buffer containing 1 mM CaCl.sub.2, 1
mM MgCl.sub.2, 150 mM NaCl, 3 mM KCl, 1 mM NaH.sub.2PO.sub.4, 5 mM
glucose) and pH 7.4 basolaterally (in Hanks' balanced salt solution
containing 10 mM HEPES) in the presence of efflux pump inhibitors
(250 .mu.M MK-571, 250 .mu.M Verapamil, 1 mM Ofloxacin). Inserts
were placed in 12 or 24 well plates containing buffer and incubated
for 30 min at 37 C..degree.. Prodrug (200 .mu.M) was added to the
apical or basolateral compartment (donor) and concentrations of
prodrug and/or released parent drug in the opposite compartment
(receiver) were determined at intervals over 1 hour using LC/MS/MS.
Values of apparent permeability (P.sub.app) were calculated using
the equation:
P.sub.app=V.sub.r(dC/dt)//(AC.sub.o)
[0451] Here V.sub.r is the volume of the receiver compartment in
mL; dC/dt is the total flux of prodrug and parent drug (.mu.M/s),
determined from the slope of the plot of concentration in the
receiver compartment versus time; C.sub.o is the initial
concentration of prodrug in .mu.M; A is the surface area of the
membrane in cm.sup.2. Preferably, prodrugs with significant
transcellular permeability demonstrate a value of P.sub.app of
.gtoreq.1.times.10.sup.-6 cm/s and more preferably, a value of
P.sub.app of .gtoreq.1.times.10.sup.-5 cm/s, and still more
preferably a value of P.sub.app of .gtoreq.5.times.10.sup.-5 cm/s.
Typical values of P.sub.app obtained for baclofen prodrugs are
shown in the following table:
TABLE-US-00003 P.sub.app (apical to P.sub.app (basolateral to Ratio
Compound basolateral) (cm/s) apical) (cm/s) A - B/B - A (10) 1.1
.times. 10.sup.-6 9.2 .times. 10.sup.-7 1.2 (12) 1.0 .times.
10.sup.-4 1.7 .times. 10.sup.-5 5.9 (14) 2.2 .times. 10.sup.-5 5.3
.times. 10.sup.-6 4.1 (16) 6.1 .times. 10.sup.-6 1.2 .times.
10.sup.-6 5.1 (18) 6.4 .times. 10.sup.-6 5.6 .times. 10.sup.-6 1.1
(20) 9.1 .times. 10.sup.-5 7.7 .times. 10.sup.-6 11.8 (25) 5.8
.times. 10.sup.-5 1.4 .times. 10.sup.-5 4.1 (27) 6.5 .times.
10.sup.-5 9.4 .times. 10.sup.-6 6.9 (30) 8.7 .times. 10.sup.-6 2.3
.times. 10.sup.-6 3.8 (32) 3.7 .times. 10.sup.-5 4.9 .times.
10.sup.-6 7.6 (36) 2.9 .times. 10.sup.-5 1.9 .times. 10.sup.-5 1.5
(38) 1.5 .times. 10.sup.-5 1.4 .times. 10.sup.-5 1.1 (40) 6.9
.times. 10.sup.-5 3.0 .times. 10.sup.-5 2.3 (43) 4.2 .times.
10.sup.-5 1.8 .times. 10.sup.-5 2.3 (48) 1.1 .times. 10.sup.-5 1.7
.times. 10.sup.-6 6.5 (50) 2.5 .times. 10.sup.-5 1.4 .times.
10.sup.-5 1.8 (51) 2.9 .times. 10.sup.-5 9.6 .times. 10.sup.-6 3.0
(53) 8.5 .times. 10.sup.-5 3.6 .times. 10.sup.-5 2.4 (71) 9.2
.times. 10.sup.-5 1.3 .times. 10.sup.-5 7.1 (72) 2.8 .times.
10.sup.-5 8.0 .times. 10.sup.-6 3.5 (73) 2.2 .times. 10.sup.-5 6.8
.times. 10.sup.-6 3.2 (74) 1.0 .times. 10.sup.-5 8.9 .times.
10.sup.-7 11.2 (78) 1.5 .times. 10.sup.-5 1.9 .times. 10.sup.-6
7.9
[0452] The data in this table shows that several of the prodrugs
disclosed herein have high cellular permeability and should be well
absorbed from the intestine. With the exception of compound (10),
the apical-to-basolateral permeabilities of these prodrugs
significantly exceed their basolateral-to-apical permeabilities,
suggesting that these compounds may be substrates for active
transport mechanisms present in the apical membrane of Caco cells
(though some component of this transcellular permeability may also
be mediated by passive diffusion).
Example 86
Uptake of R-Baclofen Following Administration of R-Baclofen or
R-Baclofen Prodrugs Intracolonically in Rats
[0453] Sustained release oral dosage forms, which release drug
slowly over periods of 6-24 hours, generally release a significant
proportion of the dose within the colon. Thus, drugs suitable for
use in such dosage forms preferably exhibit good colonic
absorption. This experiment was conducted to assess the suitability
of baclofen prodrugs for use in an oral sustained release dosage
form.
Step A: Administration Protocol
[0454] Rats were obtained commercially and were pre-cannulated in
the both the ascending colon and the jugular vein. Animals were
conscious at the time of the experiment. All animals were fasted
overnight and until 4 hours post-dosing. R-Baclofen or baclofen
prodrugs (10), (12), (23), (25), (27), (32), (33), (40), (51),
(92), (100) and (104) were administered as a solution (in water or
PEG 400) directly into the colon via the cannula at a dose
equivalent to 10 mg of baclofen equivalents per kg body weight.
Blood samples (0.5 mL) were obtained from the jugular cannula at
intervals over 8 hours and were quenched immediately by addition of
methanol to prevent further conversion of the prodrug. Blood
samples were analyzed as described below.
Step B: Sample Preparation for Colonic Absorbed Drug
[0455] 1. Rat blood was collected at different time points and 100
.mu.L of blood was added into an eppendorf tube containing 300
.mu.L of methanol and vortexed to mix immediately. [0456] 2. 20
.mu.L of p-chlorophenylalanine was added as an internal standard.
[0457] 3. 300 .mu.L of methanol was added into each tube followed
by 20 .mu.L of p-chlorophenylalanine. 90 .mu.L of blank rat blood
was added to each tube and mix. Then 10 .mu.L of a baclofen
standard solution (0.04, 0.2, 1, 5, 25, 100 .mu.g/mL) was added to
make up a final calibration standard (0.004, 0.02, 0.1, 0.5, 2.5,
10 .mu.g/mL). [0458] 4. Samples were vortexed and centrifuged at
14,000 rpm for 10 min. [0459] 5. Supernatant was taken for LC/MS/MS
analysis.
Step C: LC/MS/MS Analysis
[0460] An API 2000 LC/MS/MS spectrometer equipped with Shidmadzu
10ADVp binary pumps and a CTC HTS-PAL autosampler were used in the
analysis. A Phenomenex hydro-RP 4.6.times.50 mm column was used
during the analysis. The mobile phase was water with 0.1% formic
acid (A) and acetonitrile with 0.1% formic acid (B). The gradient
condition was: 10% B for 0.5 min, then to 95% B in 2.5 min, then
maintained at 95% B for 1.5 min. The mobile phase was returned to
10% B for 2 min. A TurbolonSpray source was used on the API 2000.
The analysis was done in positive ion mode and an MRM transition of
m/z 214/151 was used in the analysis of baclofen (MRM transitions
m/z 330/240 for (10), m/z 392/240 for (12), m/z 372/240 for (23),
m/z 400/240 for (25), m/z 400/240 for (27), m/z 372/240 for (32),
m/z 372/240 for (33), 406/240 for (40), 454/61 for (51), 400/240
for (92), 400/240 for (100) and 400/240 for (104) were used). 10
.mu.L of the samples were injected. The peaks were integrated using
Analyst 1.2 quantitation software. Following colonic administration
of prodrugs (12), (23), (25), (27), (32), (33), (40), (51), (92),
(100) and (104) the maximum plasma concentrations of R-baclofen
(C.sub.max), as well as the area under the baclofen plasma
concentration vs. time curves (AUC) were significantly greater
(>2-fold) than that produced from colonic administration of
R-baclofen itself. This data demonstrates that these compounds may
be formulated as compositions suitable for enhanced absorption
and/or effective sustained release of baclofen analogs to minimize
dosing frequency due to rapid systemic clearance of these baclofen
analogs.
Example 87
Pharmacokinetics of R-Baclofen Following Intravenous Administration
to Cynomolgus Monkeys
[0461] R-Baclofen hydrochloride salt was administered to four male
cynomolgus monkeys as an aqueous solution by intravenous bolus
injection into the saphenous vein at a dose of 1.2 mg/kg. Blood
samples were obtained from all animals at intervals over 24 hours
post-dosing. Blood was processed immediately for plasma at
4.degree. C. All plasma samples were subsequently analyzed for
R-baclofen using the LC/MS/MS assay described above. The mean
R-baclofen exposure AUC.sub.inf=3.6 h..mu.g/mL.
Example 88
Uptake of R-Baclofen Following Administration of R-Baclofen or
R-Baclofen Prodrugs Intracolonically in Cynomolgus Monkeys
[0462] R-Baclofen hydrochloride salt and R-baclofen prodrugs (5 mg
baclofen-eq/kg) were administered to groups of four male cynomolgus
monkeys as either aqueous solutions or suspensions in 0.5% methyl
cellulose/0.1% Tween-80 via bolus injection directly into the colon
via an indwelling cannula. For colonic delivery a flexible French
catheter was inserted into the rectum of each monkey and extended
to the proximal colon (approx. 16 inches) using fluoroscopy.
Monkeys were lightly sedated by administration of Telazol/ketamine
during dosing. A washout period of at least 5 to 7 days was allowed
between treatments. Following dosing, blood samples were obtained
at intervals over 24 hours and were immediately quenched and
processed for plasma at 4.degree. C. All plasma samples were
subsequently analyzed for R-baclofen and intact prodrug using the
LC/MS/MS assay described above. Following colonic administration of
prodrugs (12), (22), (25), (40) and (51), the maximum plasma
concentrations of baclofen (C.sub.max), as well as the area under
the baclofen plasma concentration vs. time curves (AUC) were
significantly greater (>2-fold) than that produced from colonic
administration of R-baclofen itself, while colonic administration
of (92), (100) and (104) produced R-baclofen exposures that were
greater than 10-fold that produced from colonic administration of
R-baclofen itself. This data demonstrates that these compounds may
be formulated as compositions suitable for enhanced absorption
and/or effective sustained release of baclofen analogs to minimize
dosing frequency due to rapid systemic clearance of these baclofen
analogs.
Example 89
Uptake of R-Baclofen Following Oral Administration of R-Baclofen
Prodrugs to Cynomolgus Monkeys
[0463] The R-baclofen prodrugs (92) and (104) (5 mg baclofen-eq/kg)
were administered by oral gavage to groups of four male cynomolgus
monkeys as either an aqueous solution or suspension in 0.5% methyl
cellulose/0.1% Tween-80 respectively. Following dosing, blood
samples were obtained at intervals over 24 hours and were
immediately quenched and processed for plasma at 4.degree. C. All
plasma samples were subsequently analyzed for R-baclofen and intact
prodrug using the LC/MS/MS assay described above. The oral
bioavailability of both prodrugs (92) and (104) as R-baclofen was
determined to be greater than 80%.
[0464] Finally, it should be noted that there are alternative ways
of implementing the disclosures contained herein. Accordingly, the
present embodiments are to be considered as illustrative and not
restrictive, and the claims are not to be limited to the details
given herein, but may be modified within the scope and equivalents
thereof. All publications and patents disclosed herein are
incorporated herein by reference in their entirety.
* * * * *